{
  "responseHeader":{
    "status":0,
    "QTime":6,
    "params":{
      "q":"(Background: head and neck squamous cell carcinoma OR Doc_title: head and neck squamous cell carcinoma) AND (Background: CDKN2A OR Doc_title: CDKN2A)"}},
  "response":{"numFound":350,"start":0,"docs":[
      {
        "Meeting_name":" CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis",
        "Background":"['Background', ' HPV infection is associated with high p16 expression and relatively good prognosis in head and neck cancers. Analysis of CDKN2A, the gene that encodes the p16 tumor suppressor protein, may further elucidate the association between HPV status and prognosis in head and neck squamous cell carcinomas (HNSCCs). We aimed to identify whether CDKN2A copy number loss was associated with poor survival in HNSCCs stratified by HPV status. Methods', ' We analyzed The Cancer Genome Atlas (TCGA) head and neck cancer data, integrating genomic measurements with clinical metadata. Patients 85 years old or younger with a primary tumor in the oral cavity, oropharynx, hypopharynx, or larynx were included. Defining CDKN2A copy number loss as a relative log2 copy number ratio <0.6, CDKN2A mRNA and p16 protein expression levels were compared to confirm significant differences in gene transcription and translation between the copy number loss and non-copy number loss patient groups. Overall survival (OS) and disease-free survival (DFS) were evaluated to characterize prognostic differences between genomic groups. Results', ' 397 patients negative for HPV (HPV) and 91 patients positive for HPV (HPV+) HNSCC were identified. 139 HPV patients and 9 HPV+ patients demonstrated CDKN2A copy number loss. The CDKN2A copy number loss group expressed significantly lower levels of CDKN2A mRNA and p16 protein than did the non-copy number loss group in both HPV+ and HPV disease. Median OS for HPV patients with and without CDKN2A copy number loss was 21.8 months and 46.0 months (P = 0.02). Median DFS was 12.0 and 19.4 months respectively (P < 0.05). Median OS for HPV+ patients with and without CDKN2A copy number loss was 12.7 months and 57.4 months (P = 0.004) and median DFS was 7.0 and 36.6 months respectively (P = 0.02). Conclusions', ' CDKN2A copy number loss was associated with low CDKN2A mRNA and p16 protein expression, with poor prognosis in terms of disease-free and overall survival.']",
        "Doc_id":"ASCO_187826-199",
        "Doc_title":" CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis",
        "_version_":1606189000282865665},
      {
        "Meeting_name":" Characterization of the differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas and correlation with patient outcome.",
        "Background":"['Background. CDKN2A inactivation has been reported to be a frequent event in head and neck squamous cell carcinomas that correlates with worse patient outcome. The differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas (OTSCC) have been poorly characterised. We sought to determine the frequency of potential mechanisms of CDKN2A inactivation in OTSCC and explore their impact on patient outcome.Material and methods. We investigated a cohort of 134 OTSCC patients treated between 2002 to 2008 with combinations of surgery, radiotherapy and chemotherapy, who have been comprehensively annotated for patient/tumour characteristics and outcome. 134 formalin fixed paraffin embedded blocks representative of primary tumours prior to treatment were collected. DNA was extracted from 115 patient blocks and a tissue microarray was made representing 123 patient samples. We assessed p16/CDKN2A expression by immunohistochemistry (IHC), promoter methylation status by methylation-sensitive high resolution melting, mutation status by Sanger sequencing, gene copy number variation by fluorescence in-situ hybridisation and correlated each of these with patient outcome.Results. The majority of OTSCC demonstrated loss of p16 expression (107/118, 90.7%), assessed by IHC. The frequency of CDKN2A inactivating mutations was 20.3% (21/103), homozygous CDKN2A loss was 4.1% (7/98), hemizygous CDKN2A loss 30.6% (30/98), and CDKN2A promoter methylation >10% was 17.7% (20/113). 34/107(31.8%) p16 IHC negative tumours had no evidence of CDKN2A mutation, copy number variation or promoter methylation identified. Of eleven p16 IHC positive patients, only two demonstrated evidence of HPV type 16 and 33 on PCR. No correlation was identified between any of the mechanisms of CDKN2A inactivation and clinicopathological features. Smoking status and age did not influence the frequency of any mechanism of CDKN2A inactivation or patient outcome. There was a non-significant trend for worse outcome for p16 IHC negative patients versus IHC positive patients (HR=0.65, 95% CI=0.23-1.79, p=0.40). No significant relationship between mechanisms of p16 inactivation and patient outcome were found.Conclusion. Loss of p16 is a frequent event in oral tongue squamous cell carcinomas that can occur through gene copy number variation, mutation, promoter methylation or through other unidentified mechanisms. We identified no correlation between mechanisms of p16 loss and clinicopathological characteristics or patient outcome.']",
        "Doc_id":"AACR_2013-4693",
        "Doc_title":" Characterization of the differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas and correlation with patient outcome.",
        "_version_":1606189008473292800},
      {
        "Meeting_name":" Concurrent mutation of CDKN2A and TP53 loci in primary keratinocytes.",
        "Background":"['Concurrent inactivation of the p16Ink4a and p53 tumor suppressors, often through mutation of CDKN2A and TP53, is frequent in early development of head and neck squamous cell carcinoma (HNSCC) and other cancers. The role of this early combined inactivation, and the oncogenic drivers that subsequently lead to tumor development, are poorly defined. To characterize the precancerous role of concurrently mutated CDKN2A and TP53, we combined a number of recent advances to disrupt both loci in primary cells. First, we grew primary keratinocytes in medium conditioned by irradiated J2-3T3 cells and containing an inhibitor of ROCK kinases, conditions that greatly extend their normally limited proliferative potential. Second, we transfected primary keratinocytes with plasmid vectors expressing both Cas9 and sets of guide RNAs targeting specific regions of CDKN2A and TP53. We targeted either or both of the p14Arf and p16Ink4a protein products of CDKN2A for knockout (KO), together with either TP53 KO or a TP53 point mutation (R248Q protein product), two major categories of genetic alterations of p53 in HNSCC. Third, we evaluated use of nutlin-3, an inhibitor of p53-MDM2 interaction, to try to select against cells that still contained wild-type p53. We assessed KO efficiency by PCR of genomic DNA; the TP53 point mutation introduced a SauA3i site into TP53. Two weeks of nutlin-3 treatment led to a 3 fold increase in p53 KO efficiency versus untreated cells (50% versus 14%). p16Ink4a KO efficiencies were enhanced 2 to 14 fold after nutlin-3 treatment, depending on the specific Cas9/guide-RNA constructs used. In cells transfected to produce p53 R248Q, 14% of PCR products amplifying the mutated region after nutlin-3 exposure showed Sau3Ai digestion, whereas no Sau3Ai digestion was detected in untreated cells. This result suggests that up to 14% of nutlin-3 treated keratinocytes had integrated the mutated donor oligo sequence. We similarly enrich for mutated keratinocytes having p14Arf-specific or combined CDKN2A KO along with TP53 KO or mutation. Combined transfection to generate concurrent CDKN2A and TP53 mutations under conditions that allow extended proliferation in culture, followed by selection for successful TP53 mutation with nutlin-3, will facilitate identification of keratinocyte clones with bi-allelic knockout genotypes. This panel of keratinocytes with concurrent CDKN2A and TP53 mutations will help delineate the roles of these genes in early cancer development and will allow screening for the oncogenic drivers required for tumor development and metastasis, with emphasis on discovering more effective and specific druggable targets for improving treatment.']",
        "Doc_id":"AACR_2017-2575",
        "Doc_title":" Concurrent mutation of CDKN2A and TP53 loci in primary keratinocytes.",
        "_version_":1606189033885532160},
      {
        "Meeting_name":" The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC) is a rare lethal human malignancy with no effective therapy. It is critical to identify new therapeutic strategies for NHSCC. Deregulation of CDKN2A (p16) or CCND1 (cyclin D1) occurs commonly in HNSCC and induces sustained cyclin-dependent kinase (CDK) 4/6 activation. The selective CDK4/6 inhibitor, LY2835219 inhibited CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induced cell cycle arrest and growth inhibition. In an animal xenograft model of HNSCC, LY2835219 treatment led to reduced tumor growth. However, because single-agent treatment with LY2835219 showed a limited effect in HNSCC, a combinational strategy is necessary for effective therapy. At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR. The combination of LY2835219 with mTOR inhibitor was found to be more effective than either drug alone in vitro and in vivo. Taken together, our findings suggest that a combination treatment with LY2835219 and mTOR inhibitor is a promising therapeutic approach for HNSCC.']",
        "Doc_id":"AACR_2016-2837",
        "Doc_title":" The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma",
        "_version_":1606189022343856128},
      {
        "Meeting_name":" Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.",
        "Background":"['Background', ' Despite recent improved understanding of cancer, the 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) remains relatively unchanged. It is critical to identify new therapeutic strategies for NHSCC. Deregulation of CDKN2A (p16) or CCND1 (cyclin D1) occurs commonly in HNSCC and induces sustained cyclin-dependent kinase (CDK) 4/6 activation. In addition, HNSCC is characterized by persistent activation of the AKT/mTOR pathway that triggers a signaling cascade of cell proliferation and survival. Methods', ' HNSCC cell lines were tested for the CDK4/6 inhibitor LY2835219, alone and in combination with mTOR inhibitor, both in vitro and in vivo. Results', ' The selective CDK4/6 inhibitor, LY2835219 inhibited CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induced cell cycle arrest and growth inhibition. In an animal xenograft model of HNSCC, LY2835219 treatment led to reduced tumor growth. However, because single-agent treatment with LY2835219 showed a limited effect in HNSCC, a combinational strategy is necessary for effective therapy. At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR. The combination of LY2835219 with mTOR inhibitor was found to be more effective than either drug alone in vitro and in vivo. Conclusions', ' Taken together, our findings suggest that a combinational treatment with LY2835219 and mTOR inhibitor is a promising therapeutic approach for HNSCC.']",
        "Doc_id":"ASCO_164735-176",
        "Doc_title":" Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.",
        "_version_":1606189013374337024},
      {
        "Meeting_name":" Risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.",
        "Background":"['Background', '   Germline mutations in the tumor suppressor gene CDKN2A occur in 5-20% of familial melanoma cases. A single founder mutation, p.Arg112dup, accounts for the majority of CDKN2A mutations in Swedish carriers. This mutation alters the peptide sequences of tumor suppressors p16-INK4A and p14-ARF. The aim of this study was to assess cancer risks in CDKN2A p.Arg112dup carriers and their first (FDRs) and second degree relatives (SDRS).  Methods', '  In this prospective cohort study, cancer diagnoses in CDKN2A p.Arg112dup mutation carriers (n=120), non-carriers (n=111), carriers FDRs (n=275) and SDRs (n=321) and controls (n=3976) were obtained from the Swedish Cancer Registry. Relative risks (RR) for cancers were calculated (number of cancers/person years). Due to the finding of high risks in mutation carriers of cancers that are normally associated with tobacco smoking, data was retrospectively collected on smoking history in carriers.  Odds ratios were calculated to compare smoking (ever-smoker/never-smoker) in carriers with or without a diagnosis of non-melanoma cancer. Two-sided 95% confidence intervals (95% CI) were calculated for all RRs.  Results', '  In carriers prospective RR for non-melanoma cancers was 5.0 (95% CI=3.7-7.3), for pancreatic cancer 43.8 (95% CI=13.8-139.0), for cancers in upper digestive tissues 17.1 (95% CI=6.3-46.5), and in respiratory tissues 15.6 (5.4-46.0). In FDRs and SDRs, RRs were significantly elevated for cancers in pancreas, respiratory and upper digestive tissues. In ever-smoking carriers compared with never-smoking carriers, the odds ratio of cancers in pancreas, respiratory or upper digestive tissues was 9.3 (95% CI= 1.9-44.7).   Conclusions', '  CDKN2A p.Arg112dup mutation carriers from melanoma-prone families and their FDRs and SDRs have elevated risk for pancreatic, lung, head and neck and gastro-esophageal carcinomas. These cancers were mainly seen in ever-smoking carriers. This is the first study that shows association between smoking history and cancer diagnoses in CDKN2A mutation carriers. Germline CDKN2A mutations may confer an increased sensitivity to carcinogens in tobacco smoke. CDKN2A mutation carriers should be counseled to abstain from smoking.']",
        "Doc_id":"ASCO_125956-144",
        "Doc_title":" Risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.",
        "_version_":1606189039338127360},
      {
        "Meeting_name":" Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas.",
        "Background":"['Background', ' Head and neck squamous cell carcinoma (HNSCC) is one of the leading causes of cancer death in the United States and Worldwide. Most cancers are tobacco-related, although an increasing number of tumors are found in nonsmokers in association with the human papilloma virus (HPV).Methods', ' The Cancer Genome Atlas (TCGA) is conducting DNA, RNA and miRNA sequencing along with DNA copy number profiling, quantification of mRNA expression, promoter methylation, and reverse-phase protein arrays on surgically resected samples from previously untreated patients with HNSCC. We report for the first time the results for 279 HNSCC samples for whom complete data are available.Results', ' The demographics of 279 patients enrolled in the study documented a median age of 61 years (range', ' 19-90); 27% female, and history of tobacco smoking in 80%. Over 30 sites of significant somatic copy number alteration (SCNA) were identified, most of which were shared with recently reported alterations in lung squamous cell carcinoma. However, some notable SCNA were absent in HNSCC', ' PDGFRA amplification and deletion of FOXP. Similarly, SCNA were compared between HPV + and HPV - tumors identifying numerous differences, including a paucity of receptor tyrosine kinase alterations in HPV + tumors and novel deletions in chromosome 11q and 14q. Exome sequencing revealed at least 15 significantly mutated genes at the False Discovery Rate (FDR) of <0.01, including', ' CDKN2A, TP53, PIK3CA, FAT1, MLL2, TGFBR2, HLA-A, NOTCH1, HRAS, NFE2L2, and CASP8. Consideration of differences between HPV + and HPV - tumors suggested differences which included nearly universal alteration of TP53 and frequent p16 mutations in HPV - tumors. By contrast, few TP53 or CDKN2A mutations were observed in HPV + samples. Strikingly, a large number of co-occurring genomic alterations were observed. For example, mutations of HRAS were observed nearly universally in combination with either CASP8 or FAT1. All three of these mutations were absent in HPV + patients. mRNA expression profiling revealed four distinct expression subtypes, each one enriched with distinct SCNA and mutational profiles', ' classical, basal, mesenchymal, and atypical. Deep sequencing by multiple platforms allowed for a detailed accounting of the role of HPV in alterations of the cancer genomes of HNSCC patients, including integration sites, disruption of tumor suppressor genes, and more complex rearrangements. Potential therapeutic targets for clinical trials with currently available drugs will be discussed.Conclusions', ' HNSCC is a heterogeneous tumor which displays distinctive patterns of somatic alteration potentially amenable to molecularly targeted therapies. We document for the first time using TCGA data, the role of an oncogenic virus in the human cancer genome. Results presented on behalf of TCGA.']",
        "Doc_id":"AACR_2013-1117",
        "Doc_title":" Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas.",
        "_version_":1606189017363120128},
      {
        "Meeting_name":" Actionable somatic mutations in head and neck cancer prognosis",
        "Background":"['Head and neck squamous cell carcinoma (HNSCC) is a devastating illness with racial/ethnic disparities in survival. Using a retrospective study design, we evaluated 210 somatic mutation sties of 10 cancer genes (i.e., CDKN2A, EGFR, FGFR3, HRAS, KRAS, MET, NOTCH1, PIK3CA, STK11, and TP53) in 214 HNSCC patients', ' 98 Non-Hispanic Whites (NHW; 46%), 72 Hispanic Whites (HW; 34%), and 44 African Americans (AA; 20%). HW and AA had significantly higher mutation rates for EGFR, HRAS, KRAS, and TP53 compared to that in NHW. Significantly higher proportions of HW (30%) and AA (18%) had at least 3 mutations compared to that in NHW (p<0.001). In logistic regression models using 2-year as the cut-off for early death, we evaluated the overall and racial/ethnic-specific somatic mutations that are associated with early death. Although there was no significant association between somatic mutation and early death in the total population, NOTCH1 mutations were significantly associated with early death in NHW (odds ratio [OR] = 5.51, 95% confidence internal [CI] = 1.22, 24.83). More importantly, the NOTCH1 mutation C6814T (P2272S) within the PEST domain was associated with early death (OR = 13.13 (95%CI = 1.61, 107.36). TP53 mutations were significantly associated with early death in HW (OR = 3.84; 95%CI = 1.08, 13.68) in multivariate analysis after adjustment for age, gender, tumor site, and tumor stage. With limited sample size, no association was observed in AA. This is the first pilot study evaluating the association between somatic mutations and HNSCC early death in a tri-racial/ethnic population. Our data suggest that HW and AA have higher EGFR mutations and these patients may benefit from mutation-targeted precision medicine to improve survival.']",
        "Doc_id":"AACR_2015-3876",
        "Doc_title":" Actionable somatic mutations in head and neck cancer prognosis",
        "_version_":1606189006839611392},
      {
        "Meeting_name":" Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level",
        "Background":"['Spontaneous canine head and neck squamous cell carcinoma (HNSCC) represents an excellent model of human HNSCC but is greatly understudied. To better utilize this valuable resource, we performed its first genome-wide characterization by investigating 12 canine HNSCC cases, of which 9 are oral, via high density array comparative genomic hybridization and RNA-seq. The analyses reveal that these canine cancers faithfully recapitulate many key molecular features of human HNSCC. These include similar genomic copy number abnormality landscapes, analogous sequence mutation patterns, and recurrent alteration of known HNSCC genes (e.g., MYC, CDKN2A) and pathways (e.g., cell cycle, mitogenic signaling, TGF signaling). Amplification or overexpression of protein kinase genes, matrix metalloproteinase genes, and epithelial-mesenchymal transition genes TWIST1 and SNAI are also prominent in these canine tumors.The strong dog-human molecular homology fundamentally justifies the use of our novel dog-human comparison strategy for driver-passenger discrimination for HNSCC. This cross-species comparison will significantly advance beyond the current findings with the massive genomic data of the cancer genome atlas (TCGA), as exemplified by our pilot study on human 8q, a recurrently amplified site in human HNSCC.HNSCC represents the sixth leading cancer by incidence in humans; thus developing effective therapeutic interventions is important. While our understanding of the biology of HNSCC has been greatly advanced over past decades, translating these findings into clinical success has been frustratingly slow. A significant obstacle is the lack of translational model that can bridge the gap between preclinical research and human clinical trials. Our study indicates that spontaneous canine HSCC can effectively bridge this gap, significantly accelerating anti-HNSCC drug discovery.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-5147",
        "Doc_title":" Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level",
        "_version_":1606189040606904321},
      {
        "Meeting_name":" Squamousness",
        "Background":"['Background', '  In order to gain a better understanding of the underlying biology of squamous cell carcinoma (SCC), we tested the hypothesis that SCC originating from different organs may possess common molecular alterations.  Methods', '  SCC samples (N = 361) were examined using clinical-grade targeted next-generation sequencing (NGS) (182 or 236 cancer-related genes).   Results', '  The most frequent SCC tumor types were head and neck, lung, cutaneous, gastrointestinal and genitourinary. The most common gene alterations were TP53 (64.5% of patients), PIK3CA (28.5%), CDKN2A (24.4%), SOX2 (17.7%), and CCND1 (15.8%). By comparing NGS results of our SCC cohort to a non-SCC cohort (N = 277), we found that CDKN2A, SOX2, NOTCH1, TP53, PIK3CA, CCND1, and FBXW7 were significantly more frequently altered, unlike KRAS, which was less frequently altered in SCC specimens (all P < 0.05; multivariable analysis). Therefore, we identified squamousness gene signatures (TP53, PIK3CA, CCND1, CDKN2A, SOX2, NOTCH 1, and FBXW7 aberrations, and absence of KRAS alterations) that were significantly more frequent in SCC versus non-SCC histologies. A multivariable co-alteration analysis established two SCC subgroups', ' (i) patients in whom TP53 and cyclin pathway (CDKN2A and CCND1) alterations strongly correlated but in whom PIK3CA aberrations were less frequent; and (ii) patients with PIK3CA alterations in whom TP53 mutations were less frequent (all P  0.001, multivariable analysis).  Conclusions', '  We identified a set of eight genes altered with significantly different frequencies when SCC and non-SCC were compared, suggesting the existence of patterns for squamousness. Targeting the PI3K-AKT-mTOR and/or cyclin pathway components in SCC may be warranted.']",
        "Doc_id":"ASCO_147471-156",
        "Doc_title":" Squamousness",
        "_version_":1606189001345073152},
      {
        "Meeting_name":" Recurrent mutations of CDKN2A genes characterize worse prognosis of HPV positive and negative oropharyngeal squamous cell carcinoma",
        "Background":"['Background', ' Oropharyngeal squamous cell carcinoma (OSCC) exhibits unique clinical and molecular characteristics, depending on its association with high-risk human papillomavirus (HPV) or other carcinogen like smoking1. Considering significant subset of patients with OSCC still exhibits poor response to contemporary treatments2, which frequently cause significant toxicity, a more detailed understanding of these poor responders, especially adopting current precision genomic technology, could provide a clue for developing better treatment.Methods', ' In this study, we gathered the somatic point mutations and mRNA expression data of 520 OSCC patients from The Cancer Genome Atlas (TCGA) and then investigated recurrent somatic point mutations. To genes having the recurrent and same type point mutations, in addition, we check out the mRNA expression and analyzed a survival analysis.Results', ' We found 7 somatic point mutations of CDKN2A gene, which having recurrent patients and only nonsense SNVs. Out of these mutation, 6 recurrent point mutations of CDKN2A gene have highly expressed on PIK3CA, FGFR2 and FGFR3 genes, as well as showed a significant deterioration on survival outcome.Conclusion', ' Recurrent nonsense mutations of CDKN2A mostly (6/7, 85.7%) derived an abnormal regulation of other genes, such as PI3KA, FGFR2, and FGFR3. Moreover, this pattern of mutations significantly characterizes ominous prognosis in HPV positive and negative OSCC. Our result might provide better insights for characterizing the subgroup of OSCC and eventual development of precision strategy for this disease subset.References1. Licitra, L. et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24, 5630-6 (2006).2. Ang, K.K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363, 24-35 (2010).']",
        "Doc_id":"AACR_2016-111",
        "Doc_title":" Recurrent mutations of CDKN2A genes characterize worse prognosis of HPV positive and negative oropharyngeal squamous cell carcinoma",
        "_version_":1606189022274650112},
      {
        "Meeting_name":" Analysis of genetic aberrations in squamous cell carcinoma of the oral tongue.",
        "Background":"['Squamous cell carcinoma of the oral tongue (SCCOT) is a common form of head and neck squamous cell carcinoma (HNSCC). In the last few decades, a steady increase in incidence rates of SCCOT has been reported across the world including India. SCCOT is known to be an age related disease and tobacco consumption is implicated as the main etiological agent, like other HNSCC subtypes. Recent reports have indicated an increase in incidence of SCCOT in the young and in nonsmokers. Among HNSCC, SCCOT appears to be more aggressive with respect to its clinical and biological behavior. Molecular genetic studies on SCCOT are scarce and most studies have been conducted on a small cohort of patients and/or restricted to a single/few molecular marker(s). We have conducted a multipronged molecular genetic study of SCCOT and analyzed the status of known tumorigenesis pathways including TP53, epidermal growth factor receptor (EGFR), microsatellite instability (MSI), CDKN2A, FHIT and human papilloma virus (HPV) infection in surgically resected primary tumor samples and correlated with clinocopathological variables. 67% (67/100) of SCCOT samples exhibited p53 nuclear stabilization whereas a greater proportion (87/100; 87%) exhibited elevated EGFR expression, in accordance with existing literature. Interestingly, p53 nuclear stabilization was found to be more common in young (31/39; 79.5%) than in older (35/59; 59.3%) patients (p = 0.0481). As expected, patients with p53 nuclear stabilization exhibited poorer survival. Further, PCR based mutation screening of exons 5-8 of TP53 (encoding the DNA binding domain) revealed mutations in 50% of samples exhibiting nuclear stabilization. HPV infection was observed in 11/82 (13.4%) tumors while the frequencies of MSI (12/86; 14%) and loss of heterozygosity (LoH) in CDKN2A (32.6%) and FHIT (28.4%) loci were significantly higher than previous studies. In addition, LoH at FHIT locus was significantly associated with p53 nuclear stabilization (p=0.047). Analysis of genome-wide DNA copy number alterations (CNA) using array based comparative genomic hybridization revealed unique copy number alterations validated by quantitative PCR. Exome sequencing and transcriptome profiling are currently underway to understand the pathways/genes deregulated in SCCOT, especially in samples not exhibiting p53 nuclear stabilization.']",
        "Doc_id":"AACR_2013-1216",
        "Doc_title":" Analysis of genetic aberrations in squamous cell carcinoma of the oral tongue.",
        "_version_":1606189023185862657},
      {
        "Meeting_name":" Genomic profiling of squamous malignancies across anatomic sites.",
        "Background":"['Background', ' Primary squamous cell carcinomas (SCCs) have diverse etiologies, but can share genomic features. We reviewed the genomic profiles of a series of SCC cases of differing anatomic origin. Methods', ' Hybrid-capture based genomic profiling of 182 or 236 or 315 genes was performed on 4783 squamous malignancies in the course of clinical care, with baits for HPV6, 11, 16, and 18, and assessment of tumor mutation burden (TMB; mutations/Mb) and microsatellite instability. Results', ' Sites of origin were head and neck (HNSCC, n = 1300), cervical (cSCC; n = 318), anal (aSCC, n = 248), esophageal (n = 242), lung (lSCC, n = 2386), and cutaneous (sSCC, n = 289) SCC cases. For HNSCC, cSCC, and aSCC (collectively termed HCA SCC), 395 (30%), 215 (68%), and 211 (83%) were HPV positive, respectively. For HCA SCC, the most common GA were in TP53 (45%), CDKN2A (29%), PIK3CA (24%), TERT (21%), and FAT1 (14%). The most frequent GA differentially associated with HPV status were in PIK3CA (34.9% versus 16.0%), CYLD (11.4% versus 1.4%) and PTEN (14.8% versus 6.1%) for HPV+ cases, and TP53 (3.8% versus 76.5%), CDKN2A ()1.4% versus 49.8%), and TERT (4.3% versus 33.0%) for HPV- cases. Mean TMB for HPV+ and HPV- cases were 6.6 (STDEV 7.3) and 13.7 (STDEV 29.7), respectively. TMB of all SCC cases was significantly different (p < 10-12) when stratified by HPV status. For lSCC and eSCC, the most common GA were found in TP53 (86%) CDKN2A (40%), and PIK3CA (26%) and mean TMB was 11.6 with HPV found in 3.1% of cases. In sSCC, the most common GA were in TP53 (85.5%), CDKN2A (54.3%), and TERT(44.0%), and mean TMB was 59.5 with HPV in 3.1% of cases. Subsets of SCC cases had defining and targetable GA including bi-allelic deletion of SMARCB1 ( < 0.3%), amplification of PD-L1 (~2%), and various kinase fusions. Cases demonstrating radiologic response to immunotherapy and matched targeted therapies, as well as subsequent development of multiple mechanisms of acquired resistance, will be presented. Conclusions', ' HPV driven SCC have similar genomic profiles regardless of of site origin, and have a significantly lower median TMB than HPV negative SCC. Early consistency of responses of SCC to matched therapies may strengthen the case for site independent genomic predictors of therapy response.']",
        "Doc_id":"ASCO_195000-199",
        "Doc_title":" Genomic profiling of squamous malignancies across anatomic sites.",
        "_version_":1606189027154722816},
      {
        "Meeting_name":" Clinical and molecular genetic analysis of squamous cell carcinoma of the oral tongue",
        "Background":"['Squamous cell carcinoma of tongue (SCCT) is a common form of head and neck squamous cell carcinoma (HNSCC) in developing countries, mainly in India. In the last few decades, a steady increase in incidence rate of SCCT has been reported across the world. More importantly, though SCCT is considered to be a tobacco-related late-onset cancer, recent reports indicate an increase in incidence of SCCT in the young and in non-smokers. We analyzed the status of known tumorigenic pathways/genes including TP53, epidermal growth factor receptor (EGFR), microsatellite instability (MSI), CDKN2A, FHIT and human papilloma virus (HPV) infection in 120 surgically resected primary oral SCCT (SCCOT) samples and correlated with clinico-pathological variables and disease specific survival. 78 of 121 (65%) samples exhibited p53 nuclear stabilization confirming earlier reports. Interestingly, p53 nuclear stabilization was more common in young (36/46; 78%) than in older (44/75; 56%) patients (p = 0.0184). Further, PCR based mutation screening of exons 5-8 (encoding the DNA binding domain of p53) revealed mutations in ten of nineteen samples (52.6%) that exhibited p53 nuclear stabilization and in three of fifteen tumors (20%) that did not. We identified a novel 33bp deletion, c.616-648del33, located in exon 5 in a p53 positive tumor from a chronic tobacco chewer. Case control analysis revealed that Proline at TP53 codon 72 increased the risk of SCCOT. Majority of samples (97/121; 80%) exhibited significant EGFR expression though HPV infection was rare (14/106; 13%). MSI was observed in 14/106 (13%) samples, a frequency higher than reported for other populations. Loss of Heterozygosity (LOH) was more frequently observed in CDKN2A (28%) and FHIT (26%). In addition, LOH at FHIT locus was significantly associated with p53 nuclear stabilization (p = 0.0508), especially in non-smokers. A significant difference in survival rate between p53 positive and negative group (p = 0.0056) (Hazard ratio 2.5595) was observed. Though associated with p53 stabilization, FHIT loss did not exhibit significant effect on patient survival. Interestingly, patients exhibiting p53 nuclear stabilization as well as FHIT loss exhibited worse survival. We performed genome-wide DNA copy number and transcript profiling in several SCCOT samples. Interestingly, there was no significant difference in extent and profile of chromosomal instability in p53 positive and negative tumors. Amplifications were detected at chromosomal regions 3q26.1 (PIK3CA), 5p, 8q22 (MYC, RUNX1T1), 11q13 (CCND1) and 20q13 (HNF). Genome-wide transcript profiling identified novel pathways that appear to drive tumorigenesis in tumors not exhibiting p53 inactivation. Our comprehensive analysis has therefore revealed important insights into the molecular basis for SCCOT and identified prognostic indicators in patients not associated with tobacco use.']",
        "Doc_id":"AACR_2014-1883",
        "Doc_title":" Clinical and molecular genetic analysis of squamous cell carcinoma of the oral tongue",
        "_version_":1606188989944954880},
      {
        "Meeting_name":" Landscape of genetic alterations in oropharyngeal squamous cell carcinoma (OPSCC) based on RNA-seq and WES analysis of FFPE samples and correlation with data from TCGA.",
        "Background":"['Background', ' Whole human exome sequencing (WES) has identified well characterized somatic mutations (such as TP53, CDKN2A, PIK3CA and HRAS) in patients with squamous cell carcinoma of the head and neck (SCCHN). We sought to optimize a combined RNA-seq and WES approach for identifying actionable mutations and gene expression signatures in p16 + versus - OPSCC. Methods', ' Relying on formalin fixed and paraffin embedded (FFPE) samples we applied a minimal mutation and copy number content (151 genes) on DNA and an extensive RNA panel on a total of 27 OPSCC (22 p16 +, and 5 p16 -). SAMSeq was used to identify the differentially expressed genes. Unsupervised hierarchical clustering of the TCGA OPSCC samples with available p16 status (n = 31) was performed for external validation of the results. Statistical significance was further tested by Fishers exact test. Results', ' We identified a gene signature differentially expressed in p16+ and p16- OPSCC. External validation showed a significant association between gene expression and p16 status (P = 0.00033). We did not however find an association with mutation burden and smoking history. A number of pathways associated with this gene signature such as NCAM1 may have relevant biologic implications in OPSCC. Conclusions', ' Our results underscore the reliability of integrating data from FFPE samples in distinguishing gene signatures characteristic of p16 + versus p16- OPSCC; these signatures need to be further explored for their biologic relevance in OPSCC (This research was supported by a grant NCI R21 CA182661-01A1to NFS and GZC).']",
        "Doc_id":"ASCO_184446-199",
        "Doc_title":" Landscape of genetic alterations in oropharyngeal squamous cell carcinoma (OPSCC) based on RNA-seq and WES analysis of FFPE samples and correlation with data from TCGA.",
        "_version_":1606188989583196160},
      {
        "Meeting_name":" Ultra-deep targeted sequencing to identify HRAS, TP53, and CDKN2A somatic mutations as molecular prognostic markers in patients with advanced oral squamous cell carcinoma.",
        "Background":"['Background', ' Ultra-deep targeted sequencing (UDT-Seq) was used to identify somatic mutations predicting disease-specific survival (DSS) in patients with advanced oral squamous cell carcinoma (OSCC).  Methods', ' Formalin-fixed paraffin-embedded primary tumor specimens were collected from 249 node-positive OSCC patients, including 147 patients with (ECS+) and 102 without (ECS-) extracapsular spread. Mutational hotspots of 45 cancer-related genes were examined with UDT-Seq at an average depth of 1000. Kaplan-Meier plots and Cox regression analyses were used to investigate the association between the mutation status and DSS. Results', ' Non-synonymous variants were identified in 179 (71.9%) specimens. TP53, CDKN2A, HRAS and PI3KCA were the most frequently mutated genes. The presence of ECS did not statistically significantly influence the mutation spectrum. HRAS mutations were strongly associated with poor DSS independent of ECS. Mutations in TP53 (especially located in the DNA-binding domain) and CDKN2A predicted poor DSS in ECS- and ECS+ patients, respectively. No association between PI3KCA mutations and prognosis was detected.   Conclusions', ' Our findings demonstrate that HRAS, TP53 and CDKN2A mutations identified by UDT-Seq predict DSS in advanced OSCC, potentially serving as molecular markers for individualized patient care through risk-adapted therapy.']",
        "Doc_id":"ASCO_143098-156",
        "Doc_title":" Ultra-deep targeted sequencing to identify HRAS, TP53, and CDKN2A somatic mutations as molecular prognostic markers in patients with advanced oral squamous cell carcinoma.",
        "_version_":1606188971188027392},
      {
        "Meeting_name":" Genetic and epidemiology characterization of head and neck cancers by targeted sequencing",
        "Background":"['Oral and pharyngeal cancer, grouped together, is the sixth most common cancer in the world. The annual estimated incidence is around 275,000 for oral and 130,300 for pharyngeal cancers excluding nasopharynx, two-thirds of these cases occurring in developing countries.The principal objective of this work was to investigate the somatic genetic changes that influence the risk of head and neck cancer occurrence and outcome, and how they interact with environmental and host factors', ' HPV infection, alcohol and Smoking.We selected 205 paired samples diagnosed as head and neck SCC included in two multicenter studies in Europe and Brazil', ' ARCAGE, a multi center case- control study, conducted between 2002-2005 involving 10 countries across Europe and the Gencapo case- control study in the state of Sao Paulo from 2001 to 2010.Targeted sequencing was performed independently on both germline DNA and the tumor material using the PGM System at an average depth of 250X.Sequencing included the entire coding region of 5 of the most frequently mutated genes in Head and Neck cancer', ' TP53, NOTCH1, CDKN2A, CASP8, and PTEN. HPV status was achieved by capsid protein serology and DNA genotyping. Statistical tests were carried out in the R statistical programming environment or using STATA statistic software. Kaplan-Meier analysis was used to determine overall survival.Statistically significant differences in exposure status were found between both series of patients with more prevalent cases of former and current both smokers and alcohol drinkers in Brazil(p=0.001). 76% and 63% of the patients in each series had at least 1 mutation and there were no significant differences in the percentage of mutations found. Most of the mutations were found in TP53 (60%) and NOTCH1 (18%). Smoking status was significantly associated to TP53 mutations (p=0.015). Positive serology for HPV16 E6 oncoprotein was associated to Oropharyngeal tumors all of which lack TP53 mutations.When comparing the survival of patients according to the mutational profile we found a reduction in overall survival for those patients carrying mutations in TP53 (p=0.002) and CDKN2A (p=0.001).Combined molecular profiling and exposure data can be a resource to assess the role of lifestyle habits on prognosis, and will help to identify early markers of survival for head and neck cancer patients.']",
        "Doc_id":"AACR_2014-4144",
        "Doc_title":" Genetic and epidemiology characterization of head and neck cancers by targeted sequencing",
        "_version_":1606189028712906752},
      {
        "Meeting_name":" Mutational landscapes of oral tongue squamous cell carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance",
        "Background":"['Carcinoma of the oral tongue (OTSCC) is the most common malignancy of the oral cavity, characterized by frequent recurrence and poor survival. The last three decades has witnessed a change in the OTSCC epidemiological profile, with increasing incidence in younger patients, females and never-smokers. This study aims to characterize the OTSCC genomic landscape and to determine factors that may delineate the genetic basis of this disease, inform prognosis and identify targets for therapeutic intervention. Seventy-eight Asian OTSCC cases were subjected to whole-exome and targeted deep sequencing. While the most common mutation seen was in TP53, the OTSCC genetic landscape differed from previously described cohorts of patients with head and neck squamous cell cancers', ' OTSCCs demonstrated frequent mutations in DST, FSIP2 and RNF213 while alterations in CDKN2A and NOTCH1 were significantly less frequent than previously reported. Despite a lack of previously-known NOTCH1 mutations, integrated analysis showed enrichments of alterations affecting Notch signaling, more commonly seen in women. Importantly, Notch pathway alterations were prognostic on uni- and multivariate analyses. Furthermore, a high proportion of OTSCCs presented with alterations in drug targetable genes and chromatin remodeling genes. Mutations in these groups were also prognostic, where patients harboring mutations in these actionable pathways more likely to succumb from recurrent disease compared to those who did not, suggesting that these patients should indeed be considered for treatment with targeted compounds in future trial designs. In conclusion, these findings define the mutational landscape of OTSCC, highlight the key role of the Notch signaling pathway in oral tongue tumorigenesis and uncover somatic mutations in therapeutically relevant genes which may represent candidate drug targets.']",
        "Doc_id":"AACR_2015-3874",
        "Doc_title":" Mutational landscapes of oral tongue squamous cell carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance",
        "_version_":1606189022374264832},
      {
        "Meeting_name":" Comprehensive characterization of urothelial bladder cancer",
        "Background":"['Urothelial carcinoma (UC) is a major cause of morbidity and mortality for which there are no approved molecularly targeted agents and few good treatment options beyond cisplatin-based chemotherapy. As part of The Cancer Genome Atlas (TCGA) Project, we analyzed 131 chemotherapy-naive, muscle-invasive UC tumors for somatic mutations, DNA copy number variants (CNVs), mRNA and microRNA expression, protein expression and phosphorylation, DNA methylation, transcript splicing, gene fusion, viral integration, pathway perturbation, clinical correlates, and histopathology (TCGA Research Network, Nature, in press). Whole-exome sequencing showed 29 recurrently mutated genes. Potential therapeutic targets include altered PIK3CA, ERBB2, FGFR3, TSC1, and ERBB3, plus mutated chromatin-regulating genes MLL, MLL2, MLL3, CREBBP, CHD7, SRCAP, ARID1A, KDM6A (UTX), and EP300. There were 22 arm-level CNVs and 27 focally amplified or deleted regions. CDKN2A was deleted in 47%. Low-pass whole genome sequencing identified FGFR3-TACC3 fusions. Viral DNA was identified in 6% (CMV, HHV6B, HPV16, BK polyoma), and viral transcripts were identified in 4% (CMV, BK polyoma, HPV16).. mRNA-seq identified 4 tumor clusters. Cluster I shows papillary morphology and FGFR3 dysregulation. Clusters I and II express high HER2 (ERBB2) and estrogen receptor beta signaling signature, sharing features with Luminal A breast cancer. Cluster III shows similarities to Basal-like breast and squamous cell head and neck carcinomas.. Integrated analyses confirm alteration of multiple pathways, including cell cycle regulation (93%), kinase and PI3-K signaling (72%), and epigenetic regulation (histone-modifiers', ' 89%; SWI/SNF nucleosome remodeling complex', ' 64%). Recurrent alterations in the PI3-kinase/AKT/mTOR pathway (42%) and RTK/RAS pathway (44%) are potentially actionable.. Overall, this study and others have identified multiple druggable targets in UC. FGFR3 is activated by mutation, gene fusion, and overexpression, suggesting clinical trials of FGFR3 inhibitors. PI3-kinase/mTOR/AKT/TSC1 pathway alterations are frequent, and mutation in TSC1 has been associated with response to mTOR inhibitors. ERBB2 amplifications and activating mutations may be targetable with agents such as trastuzumab, trastuzumab-DM1, lapatinib, and neratinib. The frequent alterations in epigenetic regulatory pathways suggest trials of agents such as the bromodomain inhibitors. The project is now being updated on the basis of data on 117 additional tumors.']",
        "Doc_id":"AACR_2014-987",
        "Doc_title":" Comprehensive characterization of urothelial bladder cancer",
        "_version_":1606188983386112000},
      {
        "Meeting_name":" Integrated analysis of squamous tumors identifies novel targets and dissects gene regulation",
        "Background":"['Background', ' Studies by The Cancer Genome Atlas (TCGA) and others have identified regions of somatic copy number alteration (SCNA) in head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC). Both tumor types exhibit frequent SCNAs in chromosomes 3q, 9p, and 11q. Although CDKN2A is the putative target of 9p deletions, numerous targets have been proposed in the 3q amplicon, including SOX2, PIK3CA, and TP63. Because expression levels are affected by underlying genomic events, we hypothesized that an integrated analysis of multiple genomic data types would provide increased ability to identify target genes in SCNA regions when compared to methods based on copy number alone while providing insight into mechanisms regulating expression. Findings may be subsequently validated by examining multiple tumor types or performing training/testing analyses.Techniques', ' Gene expression (GE), DNA copy number (CN), DNA methylation (ME), and microRNA expression (miR) data were obtained from the TCGA studies of HNSCC and LUSC. Linear models were constructed for each gene to investigate the effect of changes in CN, ME, and miR on GE. Analysis of model output provided an approach to identify target genes in SCNA regions and assess the effect of genomic alterations on expression.Results', ' Genome-wide GE, CN, ME, and miR data were available for n = 279 (HNSCC) and n = 159 (LUSC) tumor samples. Univariate modeling detected a strong overall association between GE and CN, as measured by the coefficient of determination (model R2). Although some genes found in SCNA studies produced large model R2 e.g. SOX2 a number of genes with large model R2 are relatively unknown. Notable examples include DVL3, and SENP2, which were implicated as driver genes in the 3q amplicon by a recent study of LUSC but not identified in the TCGA report. Remarkably, the model R2 for DVL3 and SENP2 was also high in HNSCC, and such a finding in a distinct tumor type provides validation and merits additional study. Output from models additionally including ME and miR as covariates contributes insight into the diversity of regulation of gene expression, but the strength of the association between GE and CN could mask other effects. Thus we constructed linear models in which the response variable was the residuals from the GE/CN model and the covariates were ME or miR. The TCGA study of glioblastoma noted frequent methylation of MGMT. When modeling MGMT we detected a highly significant association between ME and the GE/CN residuals in both HNSCC and LUSC. These results illustrate a pronounced effect of ME on GE conditional on CN.Conclusion', ' Linear modeling techniques provide a flexible and powerful basis for performing integrated analysis of genomic data. Our approach produces predicted results when analyzing known cancer genes, highlights lesser known genes for future study, provides insight into gene regulation, and draws attention to genes relevant in multiple tumor types.']",
        "Doc_id":"AACR_2014-5334",
        "Doc_title":" Integrated analysis of squamous tumors identifies novel targets and dissects gene regulation",
        "_version_":1606189025601781760},
      {
        "Meeting_name":" Semiconductor-based next-generation sequencing analysis of 409 cancer-related genes for mutations and copy-number variations in oral squamous cell carcinoma",
        "Background":"['Somatic mutation analysis is standard of practice for human cancers in order to identify therapeutic sensitizing and resistance mutations. To better understand the molecular pathogenesis of oral squamous cell carcinoma (OSCC) patients, we performed comprehensive genomic analyses that use PCR target enrichment and next-generation sequencing on the Ion Torrent semiconductor sequencers (PGM and Proton). DNA (40 ng) was extracted from 45 human OSCC specimens and their corresponding non-cancerous tissues including FFPE samples. Using the Ion Ampliseq Comprehensive Cancer Panel, we sequenced 15992 loci from 409 tumor suppressor genes and oncogenes frequently cited and frequently mutated in human cancers (covered regions = 95.4% of total, 1.5 megabases of target sequence). We also detected copy number variations (CNVs) in which segments of the genome can be duplicated or deleted from sequencing data.Each sample underwent on average 5.9 million sequencing reads after quality filtering. The mean read depths were 367.8 x, and >95% of targeted bases were represented .The number of somatic mutations (SNVs and indels) in 45 patients with OSCC ranged from 1 to 36 with a median of 7.33 (6.40/Mb). The most frequent mutations were detected on TP53 (28 of 45; 62.2%). Many of the mutations on TP53 were detected in the DNA-binding domain (23 of 28; 82.1%). NOTCH1 mutations were identified in 10 cases (8 missense, 1 coding frameshift, and 1 essential splice site mutations). CDKN2A mutations were observed in 8 cases; and PIK3CA were mutated 3 cases. Although the most common mutations in OSCC were C/G>T/A transitions, which are consistent with previous reports on head and neck, lung and oesophageal SCCs, the second most frequent mutations were C/G>A/T transversions. We also identified a median of 100 significant CNVs (range of 0-481) per sample. Pathway assessment has shown that somatic aberrations within OSCC genomes are mainly involved in several important pathways, including cell cycle regulation (p53 pathway, 84.4%) and RTK-MAPK-PI3K (62.2%). This targeted next generation sequencing using low amounts of FFPE DNA is a valuable tool for high-throughput genetic testing in research and clinical settings.']",
        "Doc_id":"AACR_2016-3707",
        "Doc_title":" Semiconductor-based next-generation sequencing analysis of 409 cancer-related genes for mutations and copy-number variations in oral squamous cell carcinoma",
        "_version_":1606189010220220416},
      {
        "Meeting_name":" Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy.",
        "Background":"['Background', '  Recent advances in genomic technology and sequencing have allowed the near comprehensive characterization of genetic abnormalities in HNC, but their correlation with clinical outcome remains to be determined. We analysed a clinically annotated cohort of locoregionally advanced HNC for copy number changes and mutations and correlated with outcome in an exploratory fashion.  Methods', '  120 head and neck cancers (frozen tissue) and matching normal tissues/blood from patients with locoregionally advanced HNC treated with definitive chemoradiation +/- induction at the University of Chicago were obtained from our tissue bank. DNA, RNA, protein were extracted. Barcoded, multiplexed sequencing libraries for 500 head and neck cancer associated genes (Agilent capture) were built and sequenced on Illumina HiSeq next generation sequencers. 150 commonly copy number altered and HNC relevant genes were analysed for copy number alterations (CNA) using the Nanostring nCounter platform. Respective genetic aberrations in curated pathways were allocated to tumor subgroups.  Exploratory analysis correlated data with induction response and progression free survival. Confirmatory HPV testing was performed using an E6, nested, multiplex PCR. Results', '  80% of targeted sequences were successfully captured and sequenced. Commonly mutated genes included', ' TP53, CDKN2A, PIK3CA, NOTCH1. Of note PIK3CA mutations were enriched in HPV(+) tumors. Commonly copy number altered genes included amplifications of VEGF1, CCND1, MYC, EGFR, MDM4, CTTN, as well as PIK3CA, and deletions of CDKN2A, SUCLG2, FHIT, TGFBR2, PTPRD, IKBKG, TRAF6, and RASSF1. CCND1, and MYC were commonly co-amplified and correlated with poor progression free survival, representing a distinct HNC phenotype. Analysis for additional genes and influence on induction response will be presented.  Conclusions', '  Targeted, medium throughput genomic profiling is feasible, and provides the majority of HNC specific genetic aberrations at a comparably low cost. Impact on outcome (CCND1/MYC amplification) and potential treatment targets (PIK3CA mutations in HPV(+) tumors) were identified.']",
        "Doc_id":"ASCO_101453-114",
        "Doc_title":" Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy.",
        "_version_":1606189030219710464},
      {
        "Meeting_name":" Novel molecular targets for chemoprevention of squamous cell carcinoma",
        "Background":"['INTRODUCTION', ' It is estimated that cancer prevention efforts can reduce cancer incidence by over 50%. Unlike for advanced disease, effective molecularly-driven interventions and risk assessment are not available for clinically normal tissues that may be have been exposed to carcinogens or for precancerous lesions. Cutaneous squamous cell carcinoma (cuSCC) comprises 15-20% of all skin cancers and has the most accessible and clinically well-characterized progression sequence of any human cancer, from a distinct precancerous lesion, the actinic keratosis (AK), to invasive carcinoma. Thus, it is an ideal model for establishing a paradigm of molecularly targeted cancer chemoprevention.METHODS', ' Here, we performed next-generation sequencing of total RNA and miRNA (Illumina HiSeq) on matched isogenic samples of human cuSCC, surrounding normal (chronically irradiated) skin (NS), and AK. In parallel, we profiled matched samples from a UV-driven Hairless mouse model of cuSCC for cross-species analysis, to identify the most important drivers of progression from NS to AK to cuSCC.RESULTS', ' Unsupervised clustering of both mRNA and miRNA expression changes showed that preneoplastic AKs span a continuum indistinguishable from cuSCC or surrounding NS, whereas cuSCC and NS were easily distinguished. Through cross-species computational analysis of mRNA-miRNA functional pairs, we identified miR-21, miR-205, miR-31, let-7B, and miR-497 and their mRNA targets as core drivers of cuSCC development through the AK intermediate. We show that several of these miRNAs are modulated by UV exposure, regulate susceptibility to apoptosis, and regulate cell motility. Several miRNAs are being inhibited in our mouse model to validate them as chemoprevention targets. TRANSFAC analysis identified E2F, SP1, AP1, and TCF3 as key transcriptional regulators of SCC development. We tested the global mRNA and miRNA expression similarities to other tumor types profiled by the NIH TCGA effort, showing that cuSCC is most closely related to head & neck SCC, lung SCC, and basal subtype of breast cancer. Exome analysis confirmed a high frequency of TP53, NOTCH1/2, and CDKN2A mutations in cuSCC, with mutational loads of >30/Mb that are strongly dominated by UVB signature lesions. Surprisingly, NS contains evidence of numerous mutations reflecting UV-induced somatic mosaicism.CONCLUSIONS', ' We report the first integrated transcriptomic characterization of the development of cuSCC through the preneoplastic AK. AKs are indistinguishable from cuSCC, suggesting that chemoprevention efforts should be directed at UV-exposed skin prior to the emergence of lesions. Key transcriptional responses in miRNAs and transcription factor networks were identified in our cross-species analysis, which have been functionally validated. Finally, SCCs of diverse anatomic sites share deep genomic commonalities suggesting that there may be common chemoprevention strategies applicable to multiple SCC types.']",
        "Doc_id":"AACR_2015-1920",
        "Doc_title":" Novel molecular targets for chemoprevention of squamous cell carcinoma",
        "_version_":1606189006465269760},
      {
        "Meeting_name":" Genomic analyses define molecular subtype of lung squamous cell carcinoma.",
        "Background":"['Lung squamous cell carcinoma, which account for 25 percent of all lung cancers, have not been well characterized owing to a lack of systematic understanding of molecular pathogenesis. We performed the whole-exome and transcriptome sequencing from 101 tumors and matched normal samples from Korean patients. Somatic mutations and gene expression defined two intrinsic subtypes', ' (1) classical subtype; (2) immunogenic subtype. Classical subtype displayed upregulation of cell cycle related genes and enriched for gene mutations (TP53, NAV3, NFE2L2, CDKN2A, PIK2CA, KEAP1 and RB1) involved in cell proliferation, squamous differentiation and oxidative stress. Immunogenic subtype had more tumor-infiltrating immune cells than classical type. More proportion of adaptive immune cells was also detected in immunogenic subtype. Immune genes, involved in adaptive immune response, were also upregulated in immunogenic subtype. Taken together, our finding revealed that each subtype has different immune mechanisms in lung squamous cell carcinoma and provides potential opportunities for therapeutic development.']",
        "Doc_id":"AACR_2017-3258",
        "Doc_title":" Genomic analyses define molecular subtype of lung squamous cell carcinoma.",
        "_version_":1606189003426496512},
      {
        "Meeting_name":" Comprehensive genomic profiling identifies clinically relevant genomic alterations in relapsed and metastatic penile squamous cell carcinoma.",
        "Background":"['Background', '  Penile squamous cell carcinoma (PSCC) is difficult to manage due to the physiological and psychological implications of local treatment with surgery and radiation but minimal evidence is available to guide systemic therapy. We performed comprehensive genomic profiling (CGP) on 20 patients with relapsed/metastatic PSCC in the course of clinical care to identify clinically relevant genomic alterations (CRGA).  Methods', '  DNA was extracted from 40 microns of FFPE sections of advanced PSCC cases. CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 692X for 3,769 exons of 236 cancer-related genes plus 47 introns from 19 genes frequently rearranged in cancer. All classes of genomic alterations (GA) were identified. Clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials.  Results', '  There were 20 male patients with a mean age of 60 years (range 46-87). Three cases (15%) were grade III and 17 (85%) were grade IV. CGP revealed 109 GA (5.45 per tumor), 44 of which were CRGA (2.2 per tumor). TP53 was mutated in 13 (65%) of cases and was the most common GA. At least one CRGA was detected in 19 (95%) cases and the most common CRGA were CDKN2A (40%), NOTCH1 (25%), PIK3CA (25%), and CCND1 (20%). HPV-16 was detected in 2 cases, HPV-6 in 1 case and HPV18 was not detected in any cases. Of the three HPV+ cases, only the HPV6+ case harbored TP53 alterations.  Conclusions', '  The low frequency of HPV 16/18 positivity was unexpected in this PSCC series given the high frequency of HPV 16/18 positivity in cervical squamous cell carcinoma (66%) and anal squamous cell carcinoma (87%) as identified by CGP on the same platform. The low frequency of HPV positivity precluded definitively identifying mutual exclusivity of HPV positivity and TP53 alterations as observed in oral pharyngeal squamous cell carcinoma however, these data suggest that penile SCC may be evolving via HPV non-16/non-18 infection and these cases may harbor TP53 alterations. CGP identified CRGA that may lead to routes of benefit from targeted therapy for these patients.']",
        "Doc_id":"ASCO_153569-156",
        "Doc_title":" Comprehensive genomic profiling identifies clinically relevant genomic alterations in relapsed and metastatic penile squamous cell carcinoma.",
        "_version_":1606189030996705281},
      {
        "Meeting_name":" Circulating tumor DNA as a liquid biopsy in head and neck cancer",
        "Background":"['In cancer patients, a larger fraction of cell-free DNA is of tumor origin, released in circulating blood as a consequence of cell death and tissue trauma, ctDNA carries information on tumor-related genetic and epigenetic changes. Given the utility as a noninvasive marker ctDNA is commonly referred to as liquid biopsy. Some studies have correlated the abundance of ctDNA with tumor size and stage, with as much as 10% of ctDNA in advanced-stage cancers but as low as 0.1-1% in premalignant or early stage disease. Only one published study has explored the detection of ctDNA in Head and neck tumors in advanced cancers detecting mutations in 60% of the cases.Our primary goal was to provide a comprehensive evaluation of the presence of ctDNA in circulating blood fractions from a series of HNSCC cases at early and late stages. We also evaluated the extent to which measures of ctDNA in blood samples correlate with similar findings from paired tumor tissue and correlate with outcome. 48 cases (including plasma, tumor and germline samples) diagnosed as head and neck SCC were selected from a multi center case- control study (ARCAGE), conducted between 2002-2005 involving 10 countries across Europe. Stage distribution was as following', ' 40% stage IV, 23% stage II, 19% stage III, 15% stage I, 3% no Info. Additionally, 65 controls matched by center, age, sex, smoking and alcohol status were included to assess a threshold of the background noise after sequencing.Targeted sequencing was performed independently on both germline DNA and the tumor material using the Ion Proton System at an average depth of 250X. Sequencing included the entire coding region of 14 of the most frequently mutated genes in HNSCC', ' TP53, NOTCH1, CDKN2A, CASP8, PIK3CA, HRAS, FAT1, MLL2, NSD1, FBXW7, RB1, TP63, IRF6 and PTEN. Plasma samples were sequenced using an amplicon based approach. All 65 controls were also sequenced for all mutations detected. Plasma samples were sequenced at an average depth of 10000X. Mutation calls were based on a poisson distribution to distinguish true variants from background noise. Indels were manually inspected using IGV. Statistical tests were carried out in R statistical programming environment. 80% of tumor samples sequenced harboured a somatic mutation in at least one of the 14 genes, for a total 54 somatic mutations. 50% of these mutations including 2 indels were also detected in the corresponding plasma samples, allelic frequencies ranged from 0.005 to 0.30; cases were mostly stage IV although mutations were also detected in four early stage cases. Overall survival was lower for cases harboring TP53 mutations in both tumor and plasma.It is feasible to detect frequent mutations in circulating free DNA in both early and late stage HNSCC. Mutations detected in both tumor and plasma correlated with poor survival especially in oropharyngeal cases demonstrating that ctDNA might be included as a potential biomarker for patient monitoring and outcome prediction.']",
        "Doc_id":"AACR_2015-5230",
        "Doc_title":" Circulating tumor DNA as a liquid biopsy in head and neck cancer",
        "_version_":1606188994918350848},
      {
        "Meeting_name":" Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).",
        "Background":"['Background', ' HNC encompass a group of highly heterogeneous diseases, including oral, oropharyngeal and laryngeal squamous cell carcinomas (SCC), nasopharyngeal (NP), nasosinusal (NS) and salivary gland (SG) tumors. Chemotherapy has shown limited efficacy in recurrent (rec)/metastatic (met) disease. Genomic studies have increased our understanding of HNC biology, identifying potential targetable mutations (mut). We evaluated the impact of precision medicine efforts in HNC at Vall dHebron Institute of Oncology (VHIO). Methods', ' From 10/2010 to 10/2015, 49 patients (pts) with metastatic HNC underwent tumor molecular profiling at VHIO. Mut detection was performed using multiplex mass-spectrometry (Sequenom, n = 21) or NGS (AmpliconSeq, n = 28).Profiling was performed on metastatic (n = 21) or primary sites (n = 19), with missing information in remaining cases (n = 9). Results', ' Most frequent tumor type was SCC (n = 20), followed by SG (n = 18), NP (n = 9) and NS (n = 2). Median age at diagnosis was 51 years, 55% stage IV. Rec/met disease to nodes or lungs was seen in 95% of SCC, while liver met was detected in 33% NP and 39% SG. PIK3CA (5/49) and CDKN2A mut (5/28) were found across all subtypes. TP53 mut were enriched in SCC (8/9, p < 0.001). SG had PTEN (1/10), NF1 (1/3), HRAS (3/18), ERBB3 (1/10) and NRAS (1/18) mut. One NP harbored NRAS mut (1/9). The prevalence of targetable mut varied according to tumor type (44% SG, 15% SCC, 36% N/NS; p = 0.03). In total, 18/49 pts were enrolled into 26 phase 1 trials (ph1), 37% accrual rate. Median prior treatment lines were 2 (0-5). 9/26 ph1 were matched therapies (mTher)', ' 6 in SG (PIK3CA, PTEN or ERBB3 mut), 2 in SCC (CDKN2A or PTEN mut) and 1 in NP (NRAS mut). Stable disease was observed in 5 SG treated with PI3K pathway inhibitors (inh), and 1 partial response in the NP treated with PI3K plus MEK inh. Considering pts as their own controls, median time to treatment failure (TTF) during mTher (9 months, range 3-23) was similar to TTF while on prior first / second treatment line (6.9 months, range 4-110; p = 0.68). Conclusions', ' Genomic characterization of HNC identifies pts likely to benefit from a mTher in ph1, with promising targets being PI3K pathway mut in SG and NRAS mut in NP.']",
        "Doc_id":"ASCO_166827-176",
        "Doc_title":" Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).",
        "_version_":1606188991815614464},
      {
        "Meeting_name":" Mutations and gene copy number variations landscape of metastases of various cancer types from patients enrolled in the SHIVA trial",
        "Background":"['BackgroundThe molecular landscape of primary tumors of several cancer types is available and tissue-independent classification of tumors on the basis of genetic and epigenetic alterations is emerging1. The molecular profile of metastatic cancers remains to be unraveled. Here we present mutations and gene copy number variations (CNV) of metastases across tumor types from patients enrolled in the SHIVA trial2.Patients and methodsThe SHIVA trial is a multicentric randomized proof-of-concept phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with any type of refractory cancer. Mutations using targeted NGS (AmpliSeq cancer panel on Ion Torrent / PGM (Life)), and CNV using Cytoscan HD (Affymetrix) were assessed on a mandatory biopsy from a metastatic site with 30% of tumor cell content. Sequencing data were processed in order to detect actionable somatic mutations. Detected variants were filtered according to their frequency (4% for SNVs and 5% for indels), strand ratio (0.2), and reads coverage (30X for SNVs and 100X for indels). Non polymorphic deleterious mutations were reported. Copy number and allele difference profiles were processed taking into account% of tumor cells and ploidy of the sample. Homozygous and heterozygous deletions and focal amplifications were reported for tumor suppressor genes and oncogenes. Between October 2012 and July 2014, 741 patients with any type of solid cancer were enrolled in the SHIVA trial. Among these, 507 and 496 patients had high quality NGS and CNV profiling, respectively.ResultsMajor cancer types for which molecular analyses were possible on a metastatic biopsy were', ' breast (14%), colorectal (11%), lung (11%), ovarian (11%), pancreatic (8%), sarcoma (6%), head and neck (4%), cervical (4%), urothelial (4%), endometrial (3%), oesogastric (3%) cancers, adenoid cystic carcinoma (3%) and others (18%). TP53 mutations were present in 44% of metastatic patients. Major mutated oncogenes were KRAS (20%), PIK3CA (12%), MET (6%), FGFR3 (5%), EGFR (2%) and BRAF (2%). Tumor suppressor genes PTEN, FBXW7 and CDKN2A were mutated in 3% of patients. Alternatively, homozygous and heterozygous deletions of PTEN, FBXW7 and CDKN2A were observed in around half of the patients analyzed (40%, 40% and 54%, respectively).ConclusionsMutations and CNV analyses on metastatic tumors from patients enrolled in the SHIVA trial showed similar results in terms of frequency of previously reported genetic alterations1,3. The frequency of KRAS mutations (20%) was however higher than the frequency (7%) reported in the pan cancer cohort of the tumors portal3. This result needs to be interpreted in accordance with tumor types before suggesting potential resistance mechanisms in heavily pretreated patients. Clustering of these alterations in specific signaling pathways is currently ongoing.']",
        "Doc_id":"AACR_2016-1524",
        "Doc_title":" Mutations and gene copy number variations landscape of metastases of various cancer types from patients enrolled in the SHIVA trial",
        "_version_":1606189007243313152},
      {
        "Meeting_name":" Cell cycle regulators p16INK4a in metaplasia, dysplasia, and adenocarcinoma of Barrett's esophagus.",
        "Background":"['Background', ' p16INK4a is a cyclin-dependent kinase inhibitor, together with p21, p53 and p63 playing an important role in the regulation of the cell cycle and histomorphology in embryology, regeneration and in tumours. The variety of neoplastic and non-neoplastic types of epithelia and their architecture in Barrett esophagus may be associated with structural and functional proteins such as cell-cycle regulators. Loss of heterozygosity in p16INK4a/CDKN2A occurs in 75% of Barrett-carcinomas and is a amrker of better prognosis. Methods', ' Twenty formalin-fixed, paraffine embeded biopsies of Barrett esophagus with epithelia of specialised (colonic) type, twenty cases with metaplastic gastric foveolar type/cardiac type and ten cases of Barrett-associated adenocarcinoma (diffuse, intestinal and exophytic papillary type) were analysed for the expression and distribution of p16INK4a (Antibodies', ' mtm Heidelberg).All cases histologically and endopscopically confirmed (Munic Type C patients). Results', ' Nonneoplastic Barrett', ' Strong,expression of p16INK4a in the stratum spinosum cells of regenerative hyperplastic squamous epithelium', ' mostly coherent cells in columnar or reticulated arrangement. No expression in the foveolar cells of esophageal gastric heterotopia. Crypts and intestinal- metaplastic cardia-glands show slight to moderate nuclear and cytoplasmic expreession. Dysplasia and neoplasia in Barrett', ' Low p16INK4a positivity in colon-type specialized epithelium of low grade dysplasia. Moderarte positivity in high grade dysplasia. Most cases indeterminate for dysplasia are negative. Two different patterns of p16INK4a expression in invasive adenocarcinomas of Barrett epithelia', ' well-differentiated papillary and tubuloglandular cancers highly positive for p16INK4a; carcinomas of macroglandular or diffuse pattern or signet-cell-type no or low expression. Conclusions', ' Inactivation of CDKN2A /p16 and is an early event in Barrett\"s carcinogenesis correlated with abnormal deposition in tumor cells; it is a marker of dysplasia and good diffferentiated carcinomas and is not found in normal and highly malignant carcinoma cells.']",
        "Doc_id":"ASCO_49985-74",
        "Doc_title":" Cell cycle regulators p16INK4a in metaplasia, dysplasia, and adenocarcinoma of Barrett's esophagus.",
        "_version_":1606188985439223808},
      {
        "Meeting_name":" Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).",
        "Background":"['Background', ' Multiple genomic alterations were described in HNC, including squamous cell carcinomas (SCC), salivary gland (SG) and nasopharyngeal (NF) tumors. Tumor molecular profiling (TMP) may increase therapeutic alternatives in early trials for pts with refractory metastatic (met) HNC. We evaluate the impact of matched/unmatched therapy (mT/uT) in HNC with potentially targetable alterations. Methods', ' From 2010-16, 47 met HNC pts were treated in 57 early trials after TMP. Clinical benefit was measured by', ' time to progression (TTP); clinical benefit rate (CBR', ' complete response [CR], partial response [PR] and stable disease [SD] > 4months [m]); progression-free survival [PFS] ratio1.3 (PFS under molecular therapeutics/PFS upon last prior chemotherapy [pT]). Results', ' Median age was 51 years; median number of pT lines was 1 (0-5). In total, 26 SCC, 11 SG, 8 NF and 2 nasosinusal pts (mostly with lymph nodes and lung met) were treated with small kinases (SK) inhibitors (inh) (50%; main targets PI3K/HER/FGFR), immune-oncology (IO) drugs (40%, PD-1/PD-L1), angiogenesis inh (5%) or chaperone, cytidine analog, RNA polymerase (5%). 14/57 trials were mT including CDKinh (1 CDKN2A mutation [mut]), PI3Kinh (5 PIK3CA mut, 2 PTEN mut), PI3K/MEKinh (1 NRAS mut), HERinh (1 ERBB3mut), FGFRinh (2 FGFR1mRNA high, 1 FGF3/4/19 ligand amplified) and porcupine inh (1 ZNFR3mut). Distribution by tumor', ' IO (16 SCC/5 NF), SKmT (8SG/4SCC/2NF) and SKuT (9SCC/4SG). Responses', ' 1CR in SCC (IO), 5 PR in SCC (4 IO, 1 FGFRinh), 3 PR in NF (1 cytidin analog, 1 IO, 1 PI3K/MEKinh). Benefit', ' median TTP 9.33m (CI95% 7-20) with upward trend in NF and SG vs SCC (HR 0.6;p = 0.28), without differences according to target therapies (HR 0.8; p = 0.9); CBR of 58%, without differences by tumor type (p = 0.42) or therapy (SKmT, SKuT, IO; p = 0.5); 60% with PFS ratio1.3, significantly higher in SCC and SG (p = 0.016), particularly with IO drug and SKmT, respectively. Conclusions', ' Considering our preselected fit population as bias selection, individualized treatment selection with novel therapeutics based on TMP, especially in NF and SG irrespective of targets (SKmT, SKuT, IO), and in SCC with IO drugs, seems to confer substantial clinical benefit.']",
        "Doc_id":"ASCO_189499-199",
        "Doc_title":" Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).",
        "_version_":1606188989031645184},
      {
        "Meeting_name":" Association of p53 codon72 polymorphism, BCCIP & CDKN2A with melanoma risk. A p53-dependent mechanism",
        "Background":"['Cancers arise due to accumulation of mutations in genes critical for cell proliferation, differentiation, and cell death. Direct interaction with cell cycle regulators characterizes growth suppression by several tumor suppressor genes. Mutation or polymorphisms that occur in the promoter or coding regions may affect gene expression and may thus have the potential to be of phenotypic or even of pathological significance. In our previous studies, we showed the differential gene expression patterns and gene interactions/ association of of BCCIP and/or CDKN2A gene1, TNF and/or CCR52 with respect to genotypes, melanoma types and family history. We reported a significant interaction between BCCIP and CDKN2A genotypes among melanoma cases and a significant difference between cases and controls for the BCCIP/CDKN2A haplotype, when adjusted with age and sex, possibly confering different levels of susceptibility to melanoma. In the same report we also had a finding of CDKN2A mutant genotype showing significant association with Melanoma type 1 followed by type 2 suggesting this gene to be critical only in cases with family history and /or with other malignancy. Previous reports have shown that BCCIP as an important component in maintaining the tumor suppression function of wild type p53.Without BCCIP, p53 fails to form tetramers, cannot bind with its target promoter sequences, and is defective in transactivation activity. The p53 pathway responds to cellular stresses that threaten the fidelity of DNA replication, genome stability, chromosome separation and cell division. Many of the cellular stresses can be oncogenic in nature and in skin, the most damaging stresses in carcinogenesis is UV radiation. In this follow up study we show a strong association of p53 codon72 polymorphism (p<0.003) with melanoma (N=126) as compared to controls (N=172). Positive correlations of p53 gene with BCCIP polymorphism (p<.013), BCCIP(p<0.010) & CDKN2A(p<0.032) gene expressions from tumor tissues from melanoma patients suggest the possible functional role of these reported gene interactions in causation or in disease progression. A 12 gene panel (TNF, CCR5 and other CDK pathway genes) and their possible interactions showing clinical relevance of these markers in melanoma development and/or progression through p53-dependent mechanism are discussed.']",
        "Doc_id":"AACR_2012-2651",
        "Doc_title":" Association of p53 codon72 polymorphism, BCCIP & CDKN2A with melanoma risk. A p53-dependent mechanism",
        "_version_":1606189000517746688},
      {
        "Meeting_name":" Transcriptional landscape of lung squamous cell carcinoma in Northeast Asian patients",
        "Background":"['Lung Squamous Cell Carcinoma (LSCC), the second most prevalent type of lung cancer, is known to have different genetic and epigenetic characteristics from lung adenocarcinoma. Molecular pathogenesis remains to be elucidated to identify therapeutic targets, especially for patients with no driver mutations identified in previous studies. In this study, we obtained RNAs from fresh tissue of 101 patients of LSCC, and its paired normal site. RNA-seq was performed with paired-end sequencing of HiSeq2000. The average throughput uniquely mapped to the human genome reference was 10Gbp per sample. Differentially expressed genes showed higher expression in HOX families, FOXL2, SOX2, FGFR3, JAK3, and ALK. In contrast, WIF1, RSPO2, ROS1, TAL1, PRDM16 was down regulated in tumor cells. To subgroup patients with their driver mutation, somatic mutation have been detected with comparison to normal paired samples, filtering with MAF<0.01 of Northeast Asian Population, 1KG, and ExAC 65000 exomes. The average number of nonsynonymous somatic mutation was 49.63 per sample. Sixty-seven patients had somatic mutation in TP53, CDKN2A, NFE2L2, and PIK3CA. This was relatively small compared to patients from TCGA, mainly consisting of Western population. After excluding 4 patients identified to be close to normal cells by PCA analysis of expression pattern, and 2 other patients suspected to be false classified from adenocarcinoma presenting mutation in EGFR (L858R) and KRAS (G12D), 28 patients remained to be elucidated. No EGFR, ALK, RET, FGFR3, TACC fusion have been found, suggesting novel isoform of transcripts or other mechanisms driving carcinogenesis.']",
        "Doc_id":"AACR_2015-4802",
        "Doc_title":" Transcriptional landscape of lung squamous cell carcinoma in Northeast Asian patients",
        "_version_":1606189004938543104},
      {
        "Meeting_name":" Exploring a possible relationship of germline CDKN2A mutations with breast cancer in a multigene panel cohort.",
        "Background":"['Background', ' Germline mutations in CDKN2A have been known to increase the risk of melanoma and pancreatic cancer compared to the general population. With the advent of multi-gene panels, individuals who may not have melanoma or pancreatic cancer are undergoing CDKN2A analysis. Previous studies in homogenous populations have suggested that breast cancer risks may also be increased in CDKN2A. This study aims to further evaluate a possible relationship of CDKN2A mutations with breast cancer through a series of case-control comparisons. Methods', ' Clinical histories and molecular results were retrospectively reviewed for patients undergoing CDKN2A analysis as part of two diagnostic pan-cancer panels at a single laboratory to ascertain CDKN2A mutation carriers (n = 104) and patients negative for all genes analyzed (n = 20,280). Patients with a personal and/or family history (1st and 2nd degree relatives) of pancreatic cancer and/or melanoma were excluded from case-control analysis. Results', ' The majority of CDKN2A mutation carriers (82.6%, n = 86/104) had a personal history of cancer documented on the test requisition form. The most common cancers were breast (n = 38, 52.8%), melanoma (n = 37, 43.0%) and pancreatic (n = 6, 7.1%). The average age of breast cancer diagnosis in this cohort was 49.3 years (range 25-84). Family history of breast, melanoma, and/or pancreatic cancer was reported for 54.9%, 46.1%, and 34.3% of CDKN2A mutation carriers, respectively. Females with breast cancer were not more likely to test positive for a CDKN2A mutation than females with cancer other than breast (OR = 0.84, p = 0.79) or unaffected females (OR = 1.02, p = 1). Conclusions', ' Although CDKN2A mutations were not significantly associated with breast cancer in this cohort, these findings do not necessarily rule out an association of CDKN2A mutations with breast cancer, particularly if risks are moderate or if genotype-phenotype correlations exist. Additional studies involving breast cancer cases unselected for age and family history and/or longitudinal studies of CDKN2A carriers are needed to better understand the relationship between CDKN2A and breast cancer risk.']",
        "Doc_id":"ASCO_192371-199",
        "Doc_title":" Exploring a possible relationship of germline CDKN2A mutations with breast cancer in a multigene panel cohort.",
        "_version_":1606189037251461120},
      {
        "Meeting_name":" Detection of SMAD4, MAP2K4, RB1 and CDKN2A gene deletions in human tumor cells by multiplex qPCR",
        "Background":"['Gene duplications and deletions are critical to understanding cancer biology. Deletion in SMAD4, MAP2K4, RB1 and CDKN2A genes are known to play important roles in certain types of cancer or cancer states. Characterization of such mutations in different tumor cells provide insight into the study of novel biomarkers of cancer susceptibility, initiation, progression and metastases and help identify them as risk factors for various types of cancer. We demonstrated a quantitative method to detect multiple gene deletions in human tumor cells by multiplex PCR. We designed four TaqMan Copy Number Assays to interrogate common deletion mutations in SMAD4, MAP2K4, RB1 and CDKN2A genes and performed multiplex PCR alongside with endogenous controls on representative human tumor and normal cells in different tissues. Since the detection of multiple deletion targets were performed in one single reaction, we were able to profile multiple deletion mutations in one single sample. This method can potentially be applied to the study of Copy Number Variations (CNV) on biological samples with limited quantity such as FFPE samples, as well as enables the characterization of multiple targets on samples in exactly the same condition and state.']",
        "Doc_id":"AACR_2014-1517",
        "Doc_title":" Detection of SMAD4, MAP2K4, RB1 and CDKN2A gene deletions in human tumor cells by multiplex qPCR",
        "_version_":1606188996445077504},
      {
        "Meeting_name":" Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.",
        "Background":"['Background', '   The unresponsiveness to anticancer drugs in patients outlines the need to identify novel and robust biomarkers of response to therapy. The recent release of large molecular cell line datasets labeled for drug sensitivity enables the development of such predictors. Cell line based models poorly reflect the extent of molecular heterogeneity existing at the patient level. We aimed to overcome this limitation by combining cell line with patient data to uncover novel molecular traits associated with drug response at the patient level.  Methods', '  We used both patients and cell lines data from the following publicly available datasets', '  CCLE (1057 cell lines, 24 drugs), Sanger (790 cell lines, 130 drugs) and TCGA (patients', ' breast cancer, colorectal cancer, lung squamous carcinoma, lung adenocarcinoma, ovarian cancer, endometrial cancer and melanoma). A two-step Elastic Net approach was used to model the drug sensitivity using gene-expression, copy-number alteration, and somatic mutation data. As validation, we used the dataset of 420 cancer patients prospectively enrolled in the ongoing MOSCATO molecular screening program (Gustave Roussy, France).  Results', '   As positive control, we were able to recover all of the recognized landmark biomarkers across drug - tissue combination (e.g. Erlotinib', ' EGFR mutation in lung adenocarcinoma; Lapatinib', ' ERBB2 amplification in breast cancer; Vemurafenib', ' BRAF mutation in melanoma, etc). We uncovered novel molecular traits (copy, number mutations) associated (FDR<20%) with drug response (e.g. erlotinib', ' CDKN2A deletion in lung adenocarcinoma, lapatinib', ' CDH1 deletion in breast cancer, etc.). The validation of our framework in the MOSCATO patients cohort will be presented.   Conclusions', '   We provide a comprehensive annotation of mutations and copy-number events predicted to be associated with sensitivity and resistance in 142 anti-cancer drugs and across 7 tumor types. This approach is likely to exert a major impact on precision medicine programs in oncology.']",
        "Doc_id":"ASCO_133297-144",
        "Doc_title":" Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.",
        "_version_":1606189032474148864},
      {
        "Meeting_name":" Mutation and immune profiles in early-stage lung squamous cell carcinoma",
        "Background":"['PURPOSE', ' Lung squamous cell carcinoma (LUSC) accounts for 20-30% of non-small cell lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our inadequate understanding of the molecular underpinnings of the disease. We sought to perform whole-exome sequencing (WES), comprehensive immune profiling and clinicopathological analysis of early-stage LUSCs to increase our understanding of the pathobiology of this malignancy.METHODS', ' Matched pairs of surgically resected stage I-III LUSCs and normal lung tissues (n = 108) were analyzed by WES. Immunohistochemistry and image analysis-based profiling of 10 immune markers was done on a subset of LUSCs (n = 91). Associations among mutations, immune markers and clinicopathological variables were statistically examined using ANOVA and Fisher tests. Cox proportional hazards regression models were used for statistical analysis of clinical outcome.RESULTS', ' This early-stage LUSC cohort displayed an average of 209 exonic mutations per tumor. Fourteen genes exhibited significant enrichment for mutation', ' TP53, MLL2, PIK3CA, NFE2L2, CDH8, KEAP1, PTEN, ADCY8, PTPRT, CALCR, GRM8, FBXW7, RB1 and CDKN2A. Among mutated genes associated with poor recurrence-free survival, MLL2 mutations predicted poor prognosis in both TP53 mutant and wild type LUSCs. We also found that in treated patients, FBXW7 and KEAP1 mutations were associated with poor response to adjuvant therapy, particularly in TP53-mutant tumors. Analysis of mutations with immune markers revealed that ADCY8 and PIK3CA mutations were associated with markedly decreased tumoral PD-L1 expression, LUSCs with PIK3CA mutations exhibited elevated CD45ro levels and CDKN2A-mutant tumors displayed an up-regulated immune response.CONCLUSION', ' Our findings pinpoint mutated genes that may impact clinical outcome as well as personalized strategies for targeted immunotherapies in early-stage LUSC.']",
        "Doc_id":"AACR_2016-142",
        "Doc_title":" Mutation and immune profiles in early-stage lung squamous cell carcinoma",
        "_version_":1606189022193909760},
      {
        "Meeting_name":" Assessment of treatment response to immunotherapy in melanoma patients with pathogenic mutations of NRAS, BRAF, CDKN2A and P53.",
        "Background":"['Background', ' BRAF, NRAS, CDKN2A and P53 mutations are commonly observed pathogenic mutations in cutaneous melanoma. The influence of mutations such as BRAF, NRAS, CDKN2A and P53 on treatment response in the PD1 inhibitor era has not been well defined. Methods', ' This study included patients with melanoma with a cutaneous or unknown primary. All patients had genomic profiling with the Mayo Clinic 50-gene solid tumor mutation panel. Treatment response to first line immunotherapy with PD1, CTLA-4, or combination PD1/CTLA-4 inhibitors were assessed by response rate and time-to-progression (TTP) rate at 12 months. Each patient outcome was stratified by non-mutually exclusive gene mutation status into BRAF, NRAS, P53, CDKN2A, or quadruple negative (N4) groups. Results', ' Genomic profiling was performed on 208 patients, of whom 102 received first line immunotherapy. Most patients received a PD1 inhibitor (n = 62), followed by CTLA-4 inhibitor (n = 34), and combination therapy (n = 6). A trend towards improved outcomes was observed in CDKN2A and BRAF mutated patients with worse outcomes noted in P53, N4, and NRAS patients. The percent without progression at 12 months were BRAF 52.2%, CDKN2A 58.2%, NRAS 30.5%, P53 37.7%, and N4 26.7% (see table below). Response rates were BRAF 46.4%, CDKN2A 38.5%, NRAS 22.2%, P53 40.0%, and N4 33.3%. Conclusions', ' There is a trend towards improved outcomes with immunotherapy in BRAF and CDKN2A mutated patients while P53, NRAS and N4 patients have inferior outcomes. Event/TotalMedian TTP KM Months (95% CI)% w/o Progression at 12-Months (95% CI)KMOverall Group (n = 102)BRAF[+]16/36NE (3.0-NE)52.2 (37.3-73.1)CDKN2A[+]8/1614.0 (3.0-NE)58.2 (37.1-91.1)NRAS[+]29/444.0 (3.0-13.0)30.5 (17.9-52.0)P53[+]13/227.0 (3.0-NE)37.7 (20.5-69.2)Quadruple[-]8/123.5 (3.0-NE)26.7 (9.1-78.0)NE', ' Not estimable; TTP', ' Time-to-progression KM', ' Kaplan-Meier estimate']",
        "Doc_id":"ASCO_188184-199",
        "Doc_title":" Assessment of treatment response to immunotherapy in melanoma patients with pathogenic mutations of NRAS, BRAF, CDKN2A and P53.",
        "_version_":1606189018578419712},
      {
        "Meeting_name":" Comparing the mutational landscape of African American and Caucasian lung cancers",
        "Background":"['Background', ' The overall death rate from lung cancer is higher in African-Americans (AA) compared to Caucasians (CAU). Understanding differences in the prevalence and type of somatic alterations between races may illuminate differences in prognosis and lead to the reduction of outcome disparities by more precisely targeting patients treatment.Methods', ' Formalin-fixed paraffin embedded tumor samples were collected from Baptist Cancer Center, Memphis, TN. DNA was extracted and sonicated to 250 bp following Covaris FFPE DNA Extraction & Purification protocol and further purified using Agencourt AMPure XP beads. The OncoPanel_v2 target enrichment panel (Agilent SureSelect) was used for hybrid capture of 502 cancer-related genes. Samples were pooled and sequenced on an Illumina HiSeq2500 to a mean depth of coverage of 210x. Tumors with >30x sequencing depth over >80% of targeted bases were considered for analysis. MuTect and SomaticIndelDetector were used to identify somatic single nucleotide variants (SNVs) and short insertions or deletions (indels), respectively. As matched normal DNA was not available for these samples, analysis was limited to variants previously observed in tumors as described in the Catalogue of Somatic Mutations in Cancer (COSMIC) database, and variants were excluded if found in the germline dataset of the Exome Sequencing Project (ESP).Results', \" 510 tumor specimens from 242 Black and 268 White patients (with self-reported race) were analyzed including 320 adenocarcinomas and 142 squamous cell carcinomas. Pathological classification was independently reviewed and confirmed for 374 of 472 cases for an overall concordance rate of 79%. Using principle component analysis (PCA) on germline SNVs, we observed that the biological ancestry was different than the self-reported race for 1.5% of patients. Mutational frequencies for genes with known roles in adenocarcinoma such as KRAS and EGFR were not significantly different between tumors from Black and White patients (Fisher's exact p-value > 0.05). Amplification rates for NKX2-1, MET, MDM2, and MYC and homozygous deletion rates for CDKN2A were also not significantly different between populations. Translocations involving ALK and ROS1 were detected in tumors from Black patients demonstrating that these events are present in both populations. Similarly, mutational frequencies for genes such as PIK3CA and PTEN were not significantly different across populations in squamous cell carcinomas.Conclusions\", ' These results demonstrate that lung cancers from Black patients are more similar to Whites than East Asians with respect to genes such as EGFR, and suggest that clinical trials of targeted therapies could significantly benefit patients in both populations.']",
        "Doc_id":"AACR_2015-3886",
        "Doc_title":" Comparing the mutational landscape of African American and Caucasian lung cancers",
        "_version_":1606189012059422720},
      {
        "Meeting_name":" Comprehensive genomic analyses of oral squamous cell carcinoma tissues by semiconductor-based next-generation sequencing",
        "Background":"['Somatic mutation analysis is standard of practice for human cancers in order to identify therapeutic sensitizing and resistance mutations. We performed comprehensive genomic analyses that use PCR target enrichment and next-generation sequencing on the Ion Torrent Personal Genome Machine (PGM). We first validated a multigene sequencing screen interrogating 2855 mutational hotspots in 50 cancer-related genes using the Ion Torrent AmpliSeq cancer panel v2. Ten nanogram of DNA was used as template to amplify 207 regions in oral squamous cell carcinoma (OSCC). Approximately 1000 average coverage was obtained with more than 90% of target bases having at least 100 sequence reads. We detected mutations of the TP53 gene in 96% (22 of 23) of OSCC cell lines. Of the 62 OSCC specimens, 42 presented at least one somatic mutation among the 50 investigated genes, and 21 of these showed multiple gene somatic mutations. The most frequent mutations were detected on TP53 (26 of 62; 41.9%). CDKN2A mutations were identified in 9 cases; STK11 mutations were observed in 8 cases; and PIK3CA were mutated 5 cases. In addition, we sequenced 409 cancer-related genes in matched tumor and normal DNA from OSCC patients using the Ion Ampliseq Comprehensive Cancer Panel. This panel targets all exons of 409 tumor suppressor genes and oncogenes frequently cited and frequently mutated (covered regions', ' 95.4% of total), and 15,992 amplicons amplify more than 1.2 megabases of target sequence. We piloted the use of this platform to identify somatic mutations in 37 OSCC specimens including formalin-fixed paraffin-embedded (FFPE) samples. We also detected copy number variations (CNVs) in which segments of the genome can be duplicated or deleted from sequencing data. This targeted next generation sequencing using low amounts of FFPE DNA is a valuable tool for high-throughput genetic testing in research and clinical settings.']",
        "Doc_id":"AACR_2015-4905",
        "Doc_title":" Comprehensive genomic analyses of oral squamous cell carcinoma tissues by semiconductor-based next-generation sequencing",
        "_version_":1606189003664523264},
      {
        "Meeting_name":" Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the Signature program.",
        "Background":"['Background', '  Pts included in the buparlisib (BKM120) module were analyzed by a tissue-agnostic genetic alterationspecific protocol that matches pts to treatments that target tumors harboring PI3K pathwayactivated tumors. The pts are identified via standard of care physician-directed profiling.  Methods', '    Pts with measurable advanced malignancies and no established standard therapy options were eligible. A local CLIA-certified test was sufficient for eligibility, and broad molecular profiling of pt tumors (confirmatory analysis of inclusion genetic alteration) was performed centrally post hoc. The primary objective was to assess clinical benefit (CB; CR + PR + SD at 16 weeks) by local investigator assessment. Buparlisib was given orally (100 mg once daily). Analysis correlating GMP with treatment outcomes will help determine the significance of these mutations.  Results', '    GMP data were available for 76 pts across 19 tumor types (colorectal [14; 18%], sarcoma [11; 15%], ovarian [10; 13%], and head and neck [9; 12%]. Rare tumors included vaginal [1] and appendix [1]]. Median age', ' 60 years (range, 24-80), 49 women (65%), median number of prior therapies', ' 3 (range, 1-16). Baseline actionable alterations (local labs) included 38 PIK3CA mutations (50%), 17 PTEN mutations (22%), 16 PTEN losses (21%; IHC), 7 PIK3CA amplifications (9%), and 2 PIK3R1 mutations (3%). The concordance of baseline actionable alterations between local and central labs was 67%. Overall, 11 pts (15%) achieved CB. DNA from all pts was assayed by NGS, covering a panel of 288 cancer genes. Based on the assay, the tumors had a median of 4 mutations (range, 0-12) and tissue-specific patterns of mutation burden (lowest in cervix and sarcomas', ' 2; highest in colorectal and vaginal', ' 5+). The number of prior therapies did not correlate with the mutation load. Fewer mutations were noted in pts with CB. Most commonly altered genes (8+ pts)', ' PIK3CA, PTEN, KRAS, TP53, APC, CDKN2A, RB1, and ERBB2. Aberrations in APC, BRCA2, CDKN2A, EP300, FBXW7, LRP1B, MLL2, PTEN, RB1, and SMAD4 were enriched in pts with no CB.  Conclusions', '  Buparlisib showed activity in some pts, indicating that specific mutations may correlate with poor outcome. Clinical trial information', ' NCT01833169']",
        "Doc_id":"ASCO_147133-156",
        "Doc_title":" Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the Signature program.",
        "_version_":1606188984671666176},
      {
        "Meeting_name":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "Background":"['Background', '  In the management of metastatic colorectal cancer (mCRC), all RAS (KRAS, NRAS) and BRAF V600E mutation status guides therapeutic options and identify a unique cohort of patients (pts) with a more aggressive clinical course. We hypothesizedthat relapsed/refractory CRC pts develop unique mutational signatures that guide standard and targeted therapy but also predict for therapeutic response, identify novel driver mutations and highlight key signaling pathways for clinical decision making.  Methods', ' Relapsed/refractory mCRC pts (N=31) were molecularly profiled by NGS Caris Molecular Intelligence (IHC, FISH/CISH, NGS) and/or Foundation One (NGS, copy number). Samples were annotated by histology, primary and/or metastatic site, biopsy location, gene mutation, domain, topology, and mutation count. Web-based bioinformatics tools (Enrichr/IntAct) were utilized to analyze mutational profiles, identifying pathway-networks.    Results', '  Pts included progressed on fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab or panitumumab. Most common histology was adenocarcinoma followed by squamous cell carcinoma (colon N=28; rectal N=3). TP53 was the most common mutation followed by APC, KRAS, PIK3CA, BRAF, SMAD4, SPTA1, FAT1, PDGFRA, ATM, ROS1, ALK, CDKN2A, FBXW7, TGFBR2, NOTCH1 and HER3. Pts had on average >5 unique gene mutations. High mutational burden was not predictive for PD-1 (5 pts) or PD-L1 (1 pt) positivity. The most common activated signaling pathways were', ' ERRB2/HER2, FGFR, p38 activation through BRAF-MEK cascade via RIT and RIN, ARMS-mediatedactivation of MAPK cascade, and VEGFR2.     Conclusions', ' Dominant oncogene mutations do not always equate with oncogenic dependence, therefore understanding the pathologic interactome in each patient is important to both identification of clinically relevant targets and choosing the next best therapy. Mutational signatures derived from corresponding pathway-networks represent a meaningful tool to 1). Evaluate functional investigation in the laboratory, 2). Predict response to drug therapy, and 3). Guide rational drug combinations in relapsed/refractory mCRC pts entering targeted and immune checkpoint trials.']",
        "Doc_id":"ASCO_157504-173",
        "Doc_title":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "_version_":1606189028578689024},
      {
        "Meeting_name":" Prospective identification of potentially actionable molecular alterations in cancers of unknown primary.",
        "Background":"['Background', '  Patients with cancers of unknown primary (CUP) represent a heterogeneous population, and the frequency of actionable molecular alterations in their tumors remains unknown. These patients are frequently excluded from most Phase II/III studies as most require a histologic diagnosis with a primary site of disease; consequently, little progress has been made in developing targeted therapies for these patients.  Methods', '  We prospectively identified patients with CUP seen for initial consultation at MSKCC from 01/2013 through 11/2014. We excluded patients with a likely primary disease site based on subsequent pathologic and radiographic tests. Tumors and matched normal samples underwent  testing by MSK-IMPACT, a comprehensive molecular profiling platform performed in a CLIA-compliant laboratory using  targeted deep sequencing of 341 cancer-associated genes to identify sequence mutations, copy number alterations, and select rearrangements. We collected tumor histology and defined potentially actionable molecular alterations as those for which investigational or FDA-approved targeted agents exist.  Results', '  Of 34 patients identified with CUP, pathologic review demonstrated 44% adenocarcinoma (15/34) and others, including carcinoma (Ca), squamous cell Ca, neuroendocrine Ca, and sarcoma. 334 alterations were identified with a median 7 alterations / patient (range 0-41). Alterations were seen most commonly in TP53 (19/34), CDKN2A (7/34), ARID1A (7/34), KRAS (7/34), and SMARCA4 (7/34). Potentially actionable alterations were present in 41% (14/34) of patients and included BRAF V600E, AKT1 E17K, and ERBB2 S310F, among others. Actionable alterations identified in 10 patients made them eligible for inclusion in targeted therapy studies available at our institution. Updated treatment and response information will be presented at the meeting.  Conclusions', '  CUPs harbor potentially actionable mutations. Patients with CUPs might benefit from expanded treatment opportunities and possibly improved outcomes through increased access to clinical trials in which eligibility criteria is based on molecular status rather than histologic diagnosis based on a primary site of disease.']",
        "Doc_id":"ASCO_150927-156",
        "Doc_title":" Prospective identification of potentially actionable molecular alterations in cancers of unknown primary.",
        "_version_":1606188989617799168},
      {
        "Meeting_name":" Next-generation sequencing in metastatic lung cancer patients",
        "Background":"['Background', '  Several patients with lung cancer (LC) maintain good performance status even after disease progression following all standard therapies. More recently, targeted therapies have been improving prognosis of patients with advanced LC. We aim at exploring the role of a next-generation sequencing (NGS) assay in identifying therapeutic targets for refractory LC. Methods', '  Patients diagnosed with metastatic LC with available paraffin-embedded tissue evaluated by the method of NGS (Foundation Medicine, USA) were included. Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to  50 ng of DNA extracted from 12 LC specimens and sequenced to high, uniform coverage. Genomic alterations (GA) were reported for each patient sample. Actionable GA were defined as those identifying anti-cancer targeted therapies available on the market or in registered clinical trials.  Results', '    Twenty-nine patients were included (86.2% adenocarcinoma, 6.9% squamous cell carcinoma). Median age was 59 years (range 30-80); 65.5% were male and 55.2% were smokers or previously smokers. A total of 40 GA were identified', ' 29 patients (72.4%) harbored    1 GA, and 16 patients harbored    1 actionable GA (55.2%). The most frequent actionable GA were detected in EGFR (24.1%), AKT2 (10.3%), STK11 (10.3%), MET (6.8%), HER2 (3.4%), ROS1 (3.4%), and FGFR1 (3.4%). Non-actionable GA were mostly detected in TP53 (48.3%), MCL1 (17.2%), and CDKN2A (13.8%). The use of trastuzumab in a patient with mutated HER-2 yielded a time to progression (TTP) of 8 months. Five patients previously identified as wild-type EGFR were found to actually have EGFR mutation, with a median TTP of 11 months (1-16m) with tyrosine kinase inhibitors. Conclusions', '  Comprehensive NGS may identify novel mutations in LC patients with potential clinical utility and serve as genetic biomarkers for personalized therapeutics.']",
        "Doc_id":"ASCO_152355-156",
        "Doc_title":" Next-generation sequencing in metastatic lung cancer patients",
        "_version_":1606188975860482048},
      {
        "Meeting_name":" CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma",
        "Background":"['The p16-CyclinD1-CDK4-RB pathway regulates G1-S cell cycle transition. This pathway is deregulated in 90% of melanomas, through amplification or increased expression of CDK4 or Cyclin D1 (CCND1), or reduced expression of the CDK inhibitor p16INK4A (CDKN2A).To explore if CDK4 may be a viable target for the treatment of human melanoma we screened a panel of melanoma cell lines with the highly selective CDK4/6 inhibitor PD-0332991 (PD-991). A majority of cell lines were found to be sensitive to PD-991, although there was a distinct population of resistant cell lines. In sensitive melanoma cell lines, treatment with PD-991 resulted in loss of hyperphosphorylated RB and a concomitant G0/G1 cell cycle arrest. Treated cells displayed an enlarged flattened morphology and an increase in SA--galactosidase staining compared to vehicle controls, indicative of cellular senescence. RB-null cell lines were resistant to CDK4/6 inhibition, and did not display cell cycle arrest or senescence. Expression and mutational analysis was performed to identify additional genomic predictors of sensitivity and resistance. Loss of CDKN2A/p16 correlated with sensitivity to PD-991 (p<0.02), and this was confirmed at the level of protein expression. Mutation of p53 and the corresponding low expression of p53 targets p21 and MDM2 correlated with resistance (p<0.0001). There was no increase in p53 transcriptional targets or evidence of apoptosis in response to PD-991 treatment of sensitive cells, and senescence occurs in both p53 WT and mutant cells, indicating that this response does not require functional p53. However, in p53 WT cells, combination treatment with PD-991 and the p53 pathway activator Nutlin3a results in increased sensitivity to PD-991 compared to treatment with PD-991 alone. This additive effect is not observed in p53 mutant cells, suggesting there is a functional role for WT p53 in the response to PD-991.Conclusions', ' These preliminary data identify RB, p16 and p53 as predictors of response to PD-991, and support further evaluation of CDK4/6 inhibitors in melanoma.']",
        "Doc_id":"AACR_2015-3089",
        "Doc_title":" CDKN2A and p53 status predicts response to CDK4/6 inhibition in melanoma",
        "_version_":1606189010637553664},
      {
        "Meeting_name":" Genomic characterization of non-small cell lung cancer by targeted massively parallel sequencing in African Americans.",
        "Background":"['Background', '  Technological advances have enabled the comprehensive analysis of genetic perturbations in non-small cell lung cancer (NSCLC), but African-Americans (AA) have often been underrepresented. This ethnic group presents higher lung cancer incidence and mortality, and some studies have suggested a lower incidence of EGFR mutations. Herein we used a targeted massively parallel sequencing approach to assess NSCLC samples resected from AAs.  Methods', '  We designed and validated a NSCLC-specific panel comprising 80 genes of potential interest for therapy. Libraries were constructed using a custom Agilent Haloplex kit, and sequenced on an Illumina HiSeq 2500. Cell lines and clinical formalin-fixed paraffin-embedded samples with known mutation status were used for validation. NSCLC archival tissues derived from AAs were retrospective collected, and medical charts were reviewed to assess clinical data. ALK translocations were evaluated by fluorescence in situ hybridization (FISH).  Results', '  Targeted capture probes covered 15,473 amplicons comprising 310,720 base pairs, with 99.29% coverage. Our platform successfully identified all known mutations in the validation samples. Ninety-nine AAs were included, with a median age of 61 years (41-76). Sixty-one percent were males, and 94% were current/former smokers. Sixty percent of samples had an adenocarcinoma component, and 31% were squamous cell carcinomas. We detected 1,465 non-silent variants in the coding sequence, after excluding known germline polymorphisms. Classic recurrent mutations were found in KRAS (16%), EGFR (5%), PIK3CA (1%), and NRAS (1%). We also identified known somatic mutations in TP53 (48%), BRAF (4%), KEAP1 (3%), PDGFRA, FBXW7, CDKN2A, and CTNNB1 (1% each). In addition, several variants of unknown significance were found and may deserve further investigation. One case was positive for ALK-FISH. EGFR and ALK-positive cases were adenocarcinomas, and no overlap was identified between major drivers.  Conclusions', '  We demonstrated a relatively low frequency of classic driver mutations in NSCLC among AAs. This group may benefit from the identification of novel drivers through comprehensive genomic approaches.']",
        "Doc_id":"ASCO_131854-144",
        "Doc_title":" Genomic characterization of non-small cell lung cancer by targeted massively parallel sequencing in African Americans.",
        "_version_":1606189006007042048},
      {
        "Meeting_name":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "Background":"['Background', ' In the management of metastatic colorectal cancer (mCRC), all RAS (KRAS, NRAS) and BRAF V600E mutation status guides therapeutic options and identify a unique cohort of patients (pts) with a more aggressive clinical course. We hypothesized that relapsed/refractory CRC pts develop unique mutational signatures that guide standard and targeted therapy but also predict for therapeutic response, identify novel driver mutations and highlight key signaling pathways for clinical decision making. Methods', ' Relapsed/refractory mCRC pts (N = 32) were molecularly profiled by NGS Caris Molecular Intelligence (IHC, FISH/CISH, NGS) and/or Foundation One (NGS, copy number). Samples were annotated by histology, primary and/or metastatic site, biopsy location, gene mutation, domain, topology, and mutation count. Web-based bioinformatics tools (Enrichr) were utilized to analyze mutational profiles, identifying pathway-networks. Results', ' Pts included progressed on fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab and/or panitumumab.Most common histology was adenocarcinoma followed by squamous cell carcinoma (colon N = 29; rectal N = 3).TP53 was the most common mutation followed by APC, KRAS, PIK3CA, BRAF, SMAD4, SPTA1, FAT1, PDGFRA, ATM, ROS1, ALK, CDKN2A, FBXW7, TGFBR2, NOTCH1 and HER3. Pts had on average > 5 unique gene mutations. 5 pts were MSI-H. High mutational burden was not predictive for PD-1 (5 pts) or PD-L1 (1 pt) positivity.The most common activated signaling pathways were', ' ERRB2/HER2, FGFR, p38 activation through BRAF-MEK cascade via RIT and RIN, ARMS-mediated activation of MAPK cascade, and VEGFR2. Conclusions', ' Dominant oncogene mutations do not always equate with oncogenic dependence, therefore understanding the pathologic interactome in each patient is important to both identification of clinically relevant targets and choosing the next best therapy. Mutational signatures derived from corresponding pathway-networks represent a meaningful tool to 1). Evaluate functional investigation in the laboratory, 2). Predict response to drug therapy, and 3). Guide rational drug combinations in relapsed/refractory mCRC pts entering targeted and immune checkpoint trials.']",
        "Doc_id":"ASCO_171220-176",
        "Doc_title":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "_version_":1606188974590656512},
      {
        "Meeting_name":" The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen",
        "Background":"['Background', ' We have conducted the Nationwide Cancer Genome Screening Project in Japan since April 2015 using Next Generation Sequencing in advanced non-colorectal gastrointestinal (GI) cancer (aNon-CRC), called as the SCRUM-Japan GI-SCREEN. The objective is to evaluate the frequency of cancer genome alterations in aNon-CRC and to identify patients who are candidate for clinical trial for corresponding targeting agents. Methods', ' This study is ongoing with the participation of 20 major cancer centers. Patients with aNon-CRC, including advanced esophageal cancer (aEC), who plan to or receive chemotherapy were eligible. DNA and RNA were extracted from FFPE tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect gene mutation, copy number variant (CNV) and fusions across 143 genes in a CLIA certified CAP accredited laboratory. The detected genomic variant data were classified according to genetic drivers of cancer including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. In this presentation, we show the results of aEC cohort. Results', ' As of October 31st in 2016, a total of 180 aEC samples were analyzed. The sequence with the OCP was successfully performed in 121 (67.2%). Out of 157 patients except for the 23 patients in which precise data is not collected, the proportion of sample and histology type is followed; surgical specimen 58.0%, squamous cell carcinoma 92.4%. The frequently detected mutations in 114 samples of which results were available were TP53 (77.2%), NFE2L2 (23.7%), CDKN2A (9.6%), PIK3CA (7.0%), RB1 (6.1%), and CNVs were CCND1 (37.7%), EGFR (7.9%), MYC (7.9%), SOX2 (6.1%), ATP11B (5.3%), NKX2-1 (5.3%). ERBB2 amplification was identified in 3 cases (2.6%) and FGFR3-TACC3fusion was identified in one case (0.9%). Conclusions', ' This nationwide screening system is efficient to detect rare gene alterations in aEC. This novel knowledge provides an intriguing background to investigate new target approaches and represents a progress toward more precision medicine. Clinical trial information', ' UMIN000016344.']",
        "Doc_id":"ASCO_189409-199",
        "Doc_title":" The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen",
        "_version_":1606188984715706368},
      {
        "Meeting_name":" Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma.",
        "Background":"['Background', ' Dysregulations of cell cycle and inhibition of apoptosis are crucial factors in tumorigenesis of multiple malignancies, including urothelial carcinoma (UC). Deletions of TP53 and CDKN2A and amplification of MDM2 have been observed in UC, but their exact frequency and functional consequence is less known. We sought to determine the frequency of copy number alteration (CNA) and mutations of genes that regulate cell cycle or apoptosis in a panel of 96 cases of high-grade UC (HGUC) of bladder. Methods', ' 96 frozen cases of HGUC were studied, including 11 bladder small cell carcinomas. DNA was isolated and analyzed for CNA by comparative genomic hybridization (CGH) using a one million oligonucleotide probe array from Agilent. The targeted genes included TP53, MDM2, CCND1, CCNE1, CDKN2A/B, E2F3 and Rb1. Traditional Sanger sequencing for mutations within TP53, Rb1, and CDKN2A was also performed. Results', ' The frequency of CNA and mutations are listed in the table. Overall, 54 of 96 cases (56%) showed CNA (45) or mutation (13). Deletion of CDKN2A/B and amplification of E2F3 were the most common alterations in cell cycle regulatory genes (13 cases each, 14%), followed by amplification of CCND1 (11 cases, 11%). There was no co-amplification of CCND1 and CCNE1 in any sample. Rb1 deletion was present in five cases. CNA in E2F3 and Rb1 were mutually exclusive in 14 of 16 cases (88%) and were both present in two cases only. Mutations in TP53 were noted in 13 cases and deletions in nine. Amplification of MDM2 was noted in four cases, none of which overlapped with TP53 deletions or mutations. Overexpression of E2F3 was significantly more common in small cell carcinoma (5/11) compared to conventional UC (8/85, p = 0.006). Conclusions', ' Regulators of cell cycle and apoptosis are amplified, deleted or mutated in more than half of cases (56%) of high-grade urothelial carcinoma. The overwhelming majority of these abnormalities are nonoverlapping. Amplification of E2F3 seems to be overrepresented in small cell carcinoma of bladder. Alterations in genes of cell cycle regulation or apoptosis Gene Abnormality (n) [A', ' amplification; D', ' deletion; M', ' mutation] CDKN2A/B D (13), A (1), M (2) E2F3 A (13) TP53 M (12), D (9) MDM2 A (4) CCND1 A (11) CCNE1 A (4) RB1 D (5), M (1)']",
        "Doc_id":"ASCO_72593-104",
        "Doc_title":" Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma.",
        "_version_":1606188975357165569},
      {
        "Meeting_name":" Association of tumor mutational burden in cutaneous squamous cell carcinoma with genomic alterations in Notch family receptors.",
        "Background":"['Background', ' In Cutaneous Squamous Cell Carcinoma (cSqCC), Notch1, Notch2, and Notch3 have been identified as tumor suppressors with a high rate of inactivating mutations early in cSqCC pathogenesis. Despite the high frequency of alterations, the biologic and therapeutic implications of Notch genomic alterations (GAs) in cSqCC are incompletely understood. Methods', ' 232 FFPE samples of cSqCC were evaluated by comprehensive genomic profiling (CGP) of 315 genes and analyzed for all classes of GAs, with diagnoses confirmed by central pathology review. Notch GAs with unknown functional impact were excluded. Tumor mutational burden (TMB) was calculated from 1.11 Mb of sequenced DNA and reported as mutations/Mb. Results', ' The cohort of 232 samples was 78% male and 22% female, aged from 17 to 88, with confirmed metastatic disease in 32% of cases. 115 (50%) samples had a Notch family member GA with a known or predicted functional impact. 96 cases had Notch1 GAs, 43 cases had Notch2 GAs, and 14 cases had Notch3 GAs with 40 cases having GAs in multiple Notch family members. These mutations were 41% missense, 34% nonsense, 15% splice site, 9% frameshift indels, and 1% non-frameshift indels alterations. Patients with Notch GAs were significantly older (median 70 years old vs median 64, p < 0.01). TMB was increased among samples with Notch GAs (median TMB of 63 mutations/mb versus 20 mutations/mb, p < 1x10-6), with similar differences for primary and metastatic samples. Cases with Notch GAs had more total GAs per case (mean 10.4 vs 7.4, p < 1.5x10-10); however, the top co-mutated genes were the same (TP53, CDKN2A, FAT1, MLL2). Both groups had a high proportion of C- > T/G- > A transitions, consistent with UV damage; however, the proportion was higher in cases with Notch GAs (median 83% vs 80%) - a difference seen in primary and metastatic samples. Conclusions', ' 50% of cSqCC cases had a Notch family member loss of function GA, which was associated with increased TMB in the primary and metastatic setting. With pre-clinical models and case studies showing responses to PD-1 inhibitors in cSqCC, further investigations are warranted into the associations of Notch GAs with mutational burden and response to immunotherapy.']",
        "Doc_id":"ASCO_189307-199",
        "Doc_title":" Association of tumor mutational burden in cutaneous squamous cell carcinoma with genomic alterations in Notch family receptors.",
        "_version_":1606189023449055232},
      {
        "Meeting_name":" Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations.",
        "Background":"['Background', '  Renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is found in five percent of all renal cell carcinoma (RCC) cases, and has a significantly worse prognosis relative to matched highgrade RCC with only epithelial elements. The genomic features underpinning sRCC are not well understood, and at present, there are no specific or effective therapies for sRCC.  Methods', ' We conducted comprehensive genomic profiling (CGP) on paired epithelial and sarcomatoid areas of 3 sRCC cases. In the course of routine clinical care, CGP was performed on another 23 sRCC harboring diverse epithelial components. CGP was conducted using a hybrid capture next generation DNA sequencing assay(NGS) of 236 cancer-related genes plus 19 genes frequently rearranged in cancer. Results were compared with 56 similarly sequenced cases of clear cell RCC devoid of sarcomatoid component, and with clear cell TCGA.   Results', '  Two of three sRCC cases that underwent CGP of both their epithelial and the sarcomatoid components demonstrated identical mutational profiles, and a third case demonstrated commonly disrupted genes. Of the 23 sRCC, TP53(43%), CDKN2A(30%), VHL(26%) and NF2(22%) were the most frequently altered genes. NF2 mutations were mutually exclusive with TP53 but not with VHL mutations.  Conclusions', '  Two of three sRCC cases that underwent CGP of both their epithelial and the sarcomatoid components demonstrated identical mutational profiles, and a third case demonstrated commonly disrupted genes. Of the 23 sRCC, TP53(43%), CDKN2A(30%), VHL(26%) and NF2(22%) were the most frequently altered genes. NF2 mutations were mutually exclusive with TP53 but not with VHL mutations.']",
        "Doc_id":"ASCO_157971-172",
        "Doc_title":" Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations.",
        "_version_":1606188996402085888},
      {
        "Meeting_name":" Mutational landscape in the normal-appearing airway cancerization field of early-stage non-small cell lung cancer.",
        "Background":"['Lung cancer, of which non-small cell lung cancer (NSCLC) is the most common form, is the second most prevalent cancer in the U.S. and the leading cause of cancer mortality. Field cancerization phenomenon establishes that normal appearing tissues surrounding a tumor will exhibit a field effect -- particularly in smokers -- with the tissues proximal to the tumor showing more, and even sharing, alterations with the tumor. Previous studies in NSCLC provide evidence for both complex progression trajectories, yet, precise mechanisms remain unknown. To investigate the field cancerization phenomenon, we conducted a genome-wide survey of acquired DNA alterations in normal-appearing tissues including small airways adjacent to NSCLC, mainstem bronchi (large airways), nasal epithelium, distant normal lung and blood, along with multiple samples from their surgically resected paired tumors, for a total of 500 samples from 48 patients with early-stage NSCLC (11 squamous cell carcinomas and 37 adenocarcinomas). Since we expect low mutation burdens and mutant cell fractions in pathologically normal tissues, we assessed somatic point mutations via deep targeted sequencing of 409 genes and paired these data with our recent study of acquired copy number alterations (CNAs) inferred from high-density whole-genome SNP microarrays, thus offering a deep and wide survey of somatic DNA alterations. After aggregating results from multiple mutation callers, we observed somatic mutations (exonic, splicing and UTRs) in 257 samples of which 65 (in 35 patients) were from normal-appearing field (non-tumor, non-blood) samples. Tumor and field samples in smokers showed a higher mutation burden and large proportion of C', 'G>A', 'T changes. We also observed concordance of mutations in the airway and corresponding tumor profiles. Further, a statistically significant field effect was established with mutational burden (measured by the variant allele frequency) increasing with proximity to the tumor. Among the 35 NSCLC cases with field mutations, the small adjacent (to tumor) airways in six patients exhibited mutations in lung cancer drivers such as KRAS, STK11, TP53 and KEAP1. We also identified mutations in the large airway (TP53, SETD2, CDKN2A), distant normal lung parenchyma (RB1, RET) and nasal epithelium (AKT1). We then correlated point mutation and CNA mutation profiles. Of eight cases showing a nonsynonymous or stopgain variants in established lung cancer drivers in the airways, four exhibited putative two-hit progression models, e.g. both KEAP1 and STK11 mutations with 19p loss, overlapping TP53 mutation/17p loss, or KRAS mutation/12p gain. Our findings in normal-appearing tissues of the respiratory epithelium offer insights into the earliest mutational events in their progression to NSCLC and, possibly, in tumor relapse and that may represent suitable targets for early detection and chemoprevention.']",
        "Doc_id":"AACR_2017-1434",
        "Doc_title":" Mutational landscape in the normal-appearing airway cancerization field of early-stage non-small cell lung cancer.",
        "_version_":1606189029874728960},
      {
        "Meeting_name":" Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma.",
        "Background":"['Background', ' Somatic copy-number alterations (SCNAs) are distinct molecular events occurring in muscle-invasive urothelial carcinoma (UC). Defining the biologic role and the timing of SCNAs in UCs evolution is critical for precision therapy. Methods', ' To examine whether distinct SCNAs define specific subtypes of UC and characterize the evolutionary dynamics of SCNA acquisition, we conducted whole-exome sequencing (WES) of a discovery cohort of 44 advanced UC tumors and matching germline samples, including 13 pairs of matched primary and metastatic tumors prospectively collected before and after chemotherapy. We queried WES data from 285 UCs from The Cancer Genome Atlas (TCGA) as a validation cohort. We performed a novel in-depth allele-specific copy-number analysis in 2503 cancer genes using the CLONET computational framework, which accounts for tumor ploidy and cellularity to infer the clonal hierarchy of SCNAs. Results', ' Analysis of SCNAs from tumor pairs within each patient revealed punctuated evolution of SCNAs occurring early in UCs development followed by minor changes (clonal stasis) throughout the tumors lifetime. Two distinct clusters of UCs with strikingly different SCNA profiles in the discovery cohort emerged. Cluster A was defined by diploid copy number background and focal deletions in the 9p21 region (CDKN2A, CDKN2B and MTAP). Cluster B was defined by genome-wide duplications and several enriched amplifications including 1q21.1 (SETDB1 and MLLT11), (P = 0.0002) and 6p22.3 (E2F3), (P = 0.001). TP53 mutations (P = 0.0001) were enriched in the cluster B, consistent with the role of functional p53 as a guardian of the genome preventing chromosomal instability. SCNAs clusters A and B were confirmed in the TCGA validation cohort. Cluster A was enriched with tumors belonging to TCGA bladder cancer cluster III (basal/squamous-like) (P = 0.02). Conclusions', ' Using novel allele-specific SCNAs analysis, we define two distinct clusters of UC presenting a framework for understanding this aspect of UCs biology. In contrast to somatic mutations, SCNAs are clonally static during each tumors evolution. This data has important implications for precision medicine for UC.']",
        "Doc_id":"ASCO_179192-197",
        "Doc_title":" Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma.",
        "_version_":1606189004773916673},
      {
        "Meeting_name":" Identifying actionable targets in advanced cancer patients",
        "Background":"['Background', '  The ProfiLER study was designed to characterize tumor genomic alterations (GAs) in a panel of selected genes in patients (pts) with advanced malignancies. Whether the presence of GAs may guide treatment (trt) decision regardless of histological subtype remains unclear.  Methods', '  Pts with advanced solid and hematologic cancers were offered a genetic profiling of their tumor. DNA extracted from archival or freshly collected tumor samples was analyzed by sequencing of 59 cancer-related genes (NGS, Ion Torrent PGM system) and whole genome CGH array (Agilent platform). A multidisciplinary panel of clinicians and scientists reviewed results to determine the relevance of GAs and recommended molecular targeted therapies (MTT) when relevant.  Results', '  From March to October 2013, 431 pts from a single center were consented and 283 (66%) had their tumor analyzed, either by NGS+CGH (186 pts, 66%), NGS alone (86, 30%) or CGH alone (11, 4%). 137 (48%) had at least one actionable target (AT) with a recommended MTT', ' 20% were breast cancers, 17% head and neck, 15% lung, 9% sarcoma, 8% colon and 31% other tumor types. NGS was conclusive for 132 pts, identifying actionable mutations (hot spot or described in COSMIC database) mainly in PIK3CA (15% of pts), EGFR (9%), MET (4%), MTOR (4%), ALK (4%), PTEN (4%), ERBB2 (3%), BRAF (2%) (median nb of mutations/pt', ' 1 [range', ' 0-11]). Main ATs identified with CGH (n=105 pts) were amplifications of CCND1 (17%), FGFR1 (11%), MDM2 (7%), EGFR (5%), ERBB2 (5%), CDK4 (4%), CDK6 (3%), homozygous deletion of CDKN2A (21%) and PTEN (5%) (median nb of copy number variations/pt', ' 1 [0-6]). 19/137 pts (14%) have so far received an MTT, mainly mTOR inhibitors (7 pts, 37%), ALK/MET inhibitors, anti-HER2, FGFR inhibitors or anti-VEGF (2 pts each, 10%). Best responses were PR (2/19, 10%), SD (6/19, 32 %), PD (9/19, 47%) and not evaluable in 2 pts. Median trt duration was 2.2 months [0.87.5] (Data, censored on December 1st2013, will be updated).  Conclusions', '  Systematic tumor profiling is feasible in routine practice, highly attractive for pts with advanced malignancies and identifies ATs in nearly 50% of the pts. Clinical trial information', ' NCT01774409.']",
        "Doc_id":"ASCO_131685-144",
        "Doc_title":" Identifying actionable targets in advanced cancer patients",
        "_version_":1606189005970341888},
      {
        "Meeting_name":" Analysis of genetic alternations in multiple tissue specimens from each patient",
        "Background":"['Colorectal cancer (CRC) develops through a polyp-to-cancer progression sequence, in which normal colorectal epithelium transforms into an adenoma, which then progresses to cancer via the accumulation of progressive molecular changes, including both genetic and epigenetic alterations. Given that Colon epithelial cells can acquire pro-tumorigenic mutations that are insufficient to cause morphological change, genetic alternations in adjacent tumor tissues are primed to become neoplastic cells. It is known that individuals with a personal history of colon adenomas or cancer are at increased risk for metachronous colon neoplasms. To examine the genetic alternations involving in a polyp-to-cancer progression sequence, whole-transcriptome expression profiling of resected normal tissues (N1 and N3), adenoma (A1 and A2), and colorectal cancer (C1) obtained from individuals was performed. Differentially expressed genes among groups were identified using Subio platform. GATK and haplotypecaller was used to compare the somatic mutations among three different tissues. Tophat, Cufflink, Mev, R was used for determining the expression levels. Splicegrapher and Genomon-fusion was used for identifying the fusion genes. Ordinal regression analysis was performed to characterize site-dependent expression profiles. Gene interaction was examined using String (Open database). All statistical tests were two-sided, except where noted. Expression profile showed that highly expressed genes associated with inflammation were detected in adenoma. Our results indicated that highly expressed genes associated with inflammation were initially found in adenoma tissues and its levels were consistent in carcinoma tissues. Number of somatic mutation was extremely increased in carcinoma tissues when compared to adenoma tissues. The same mutations in KRAS, CDKN2A(p16) and TP53 that were observed in carcinoma tissues. They were also present in normal tissues and adenoma tissues. Disruption of TP53, CDKN2A, and KRAS were all seen as possible initial events in tumorigenesis; the sequence of mutations (the tumor development pathway) differed among lesions. Also, unique somatic mutations were found 17 genes which were not exist in normal tissues. Those somatic mutations were found in carcinoma tissues. The results of fusion gene analysis showed that 9 fusion genes were detected. Four fusion genes (FIIR-RBM2292, ST7-AS1-ST7, MMP11-IGLL5, EXOC4-LOC101928861) was detected in all of tissues. Five fusion genes were found in normal tissues and adenoma tissues. Unique fusion gene in carcinoma tissue was not detected. One explanation for this increased risk could be field cancerization, which is a phenomenon in which the histologically normal tissue in an organ is primed to undergo transformation. Our analysis of genetic alterations in a single patient appears to be promising markers for field cancerization.']",
        "Doc_id":"AACR_2016-539",
        "Doc_title":" Analysis of genetic alternations in multiple tissue specimens from each patient",
        "_version_":1606188988245213184},
      {
        "Meeting_name":" Clinical next generation sequencing of adolescents and young adult (AYA) patients with cancer reveals aggressive biology",
        "Background":"['Introduction', ' The survival of adolescents and young adults (AYA), (age 15-39 years), with cancer are worse when compared to younger (<15 yr) and older (> 45 yr) patients across all cancer registries (USA, UK and Australia). One of the reasons cited for the inferior outcomes is the aggressive biology of cancers (both adult and pediatric type) that arise in this population. Clinical next generation sequencing (NGS) may unravel some of the molecular alterations and diverse biology.Methods', ' A methodical chart review of AYA patients who were referred to the Department of Investigational Cancer Therapeutics (A Phase I Program) from July 2012 to May 2013 was performed. All patients had clinical NGS testing of archival tumor tissue by FoundationOne platform, a CLIA certified testing for identification of targetable molecular alterations.Results', ' Among the 27 patients analyzed (14 F', ' 13 M), eight were adult type cancers, twelve were pediatric type cancers and seven were orphan cancers. Unique aberrations were identified in all types of cancers that have been hitherto unreported in the COSMIC database. Of note, TP53, NKX2-1, KRAS, CDKN2A, MDM4, MCL1, MYC, BCL2L2, and RB1 were the aberrations seen across all tumor types in this population. TP53 aberrations were seen in five patients, three patients harbored MYC, MCL1, and CDKN2A aberrations and two patients had alterations in NKX2-1, KRAS, MDM4, BCL2L2, and RB1. The tumor types included pediatric type tumors like osteosarcoma (N=5), medulloblastoma (N=2), alveolar rhabomyosarcoma (N=3), neuroblastoma (N=1), Wilms tumor (N=1); adult type tumors like non-small cell lung cancer (N=1), colorectal cancer (N=1), nasopharyngeal carcinoma (N=2); triple negative breast cancer (N=1), gastric adenocarcinoma (N=1); orphan cancers like, fibrolamellar hepatocellular carcinoma (N=1), junvenile hyalinized fibromatosis (N=1), renal medullary carcinoma(N=2), MPNST (N=1), neurofibromatosis type 2 ( N=1), small cell sarcoma (N=1), gastrointestinal stromal tumor (GIST)(N=1), and neuroendocrine carcinoma of lung (N=1). Several patients had multiple aberrations viz, the wild type GIST patient harbored 5 alterations (MDM4, MCL1, KIT, AKT3, PDGRFA).Conclusions', ' A preliminary report of NGS sequencing in AYA reveals diverse and unique aberrations. AYA patients have physiological and pharmacological differences in addition to genomic mutations compared to younger and older patients in regards to cancer treatment. Further molecular profiling and deeper understanding of the biology of these unique aberrations are warranted.']",
        "Doc_id":"AACR_2014-5080",
        "Doc_title":" Clinical next generation sequencing of adolescents and young adult (AYA) patients with cancer reveals aggressive biology",
        "_version_":1606189030008946688},
      {
        "Meeting_name":" Distinct copy number alterations in genomes of oral cavity squamous cell carcinomas",
        "Background":"['Oral cavity squamous cell carcinoma (OSCC) is one of the most common cancers in Taiwan and worldwide. Despite recent progress in the diagnosis and therapeutic modalities for OSCC, the 5-year survival rate has not been improved in recent two decades. In order to provide some clues for clinical management of OSCC, 72 advanced-stage OSCCs were analyzed using two microarray platforms (26 cases with Affymetrix 500K and 46 cases with Affymetrix SNP 6.0). Genomic copy number was derived from calculating the intensity ratio between the OSCC and a set of normal DNAs from HapMap project. Segmented copy numbers for each tumor were inferred with the hidden markov model using the Partek GS software and circular binary segmentation using GenePattern pipeline. Genomic Identification of Significant Targets in Cancer (GISTIC) analysis was used to identify significant copy number alterations (CNAs) using a Q-value cutoff of 0.25. With this approach, 41 (2 gain and 39 loss) and 32 (4 gain and 28 loss) significant regions were distinguished from 500K and SNP 6.0 platform, respectively. Among them, 12 (2 gains (7p11.2 and 11q13.3) and 10 losses (2q23.3-q24.2, 3p14.2-p12.1, 4q35.2, 7q33-q34, 9p21.3, 11q22.3-q24.3, 16q23.1, 18q11.2-q22.3, 21q21.1 and 21q22.3)) CNAs were identical in these two platforms. Two gain regions contained the well known oncogene EGFR (7p11.2) and CCND1 (11q13.3) and 10 deletion regions resides several known cancer suppressor genes such as FHIT (3p14.2-p12.1), FAT1 (4q35.1), CDKN2A (9p21.3) and ATM (11q22.3-q24.3). Among them, gain of 11q13.3 was correlated significantly with lymph node metastasis and loss of 4q35.2 was significantly associated with lymph node extracapsular spread (LNECS) and poor disease-free survival. Copy number gains of EGFR and CCND1 were further confirmed by fluorescence in situ hybridization and TaqMan CN assay (Hs01818912_cn and Hs02353610_cn), respectively. We found that the concordance rate was 74.63% for EGFR and 77.78% for CCND1. To further explore the clinical value of copy number gains of EGFR and CCND1 in OSCC, 257 OSCC cases were analyzed. Preliminary results indicated that gains of CCND1 were significantly associated with tumor differentiation, lymph node metastasis and LNECS; while amplification of EGFR gene was significantly associated with tumor stage and lymph node metastasis but not LNECS. Furthermore, gains of CCND1 were significantly associated with poor disease-free and overall survival. On the other hand, amplification of EGFR was not associated with either disease-free or overall survival. Taken together, we have revealed the significant CNAs of OSCCs in Taiwan and confirmed the amplification of two important genes (CCND1 and EGFR) in 257 OSCCs. Thus, current genome-wide CNAs analysis provides clues for future characterization of important oncogenes and tumor suppressor genes associated with the behaviors of the disease.']",
        "Doc_id":"AACR_2014-3412",
        "Doc_title":" Distinct copy number alterations in genomes of oral cavity squamous cell carcinomas",
        "_version_":1606189015125458945},
      {
        "Meeting_name":" Clonal evolution in noncancerous esophageal mucosa in normal and cancer-bearing individuals",
        "Background":"['BackgroundEsophageal squamous cell carcinoma (ESCC) represents the most common form of esophageal cancer worldwide, especially in East Asia, where alcohol drinking and smoking have been implicated in the field carcinogenesis of ESCC. However, the oncogenic process therein has been poorly understood in terms of gene mutations.Patients & MethodsA total of 100 samples, including cancer, dysplastic, and non-dysplastic esophageal tissues, were obtained from 24 individual with (N = 14) or without (N = 10) ESCC (a median of 2.5 samples per case', ' 129) either by endoscopy or surgery and were subjected to whole exome sequencing (WES). An additional paired cancer/non-caner samples from 32 patients was analyzed by targeted sequencing (TS). All samples were analyzed for copy number alterations (CNAs) using SNP array- and/or digital sequencing-based karyotyping.ResultsIn WES, clonal evolution in esophageal epithelia, as determined by the presence of somatic mutations, was detected in 21 of 21 cancer, 12 of 12 dysplastic, and 63 of 67 non-dysplastic samples, where the mean number of mutation per sample showed a significant trend to increase in cancer (65) and dysplastic samples (50) compared to non-dysplastic samples (13) (P = 2.110-11). CNAs, especially those involving CDKN2A, CCND1, YAP1, and EGFR, were frequently affected in cancer samples, but rarely so in non-dysplastic samples. Non-dysplastic samples tended to have smaller allelic burden and therefore, clone size, compared to dysplastic and cancer samples (P = 2.210-16). Mutations had a predominant age-related signature in non-dysplastic samples but increasing APOBEC3A/3B patterns was observed in cancer and dysplastic samples. Shared mutations were found only within cancer tissues but never among dysplastic or non-dysplastic samples, suggesting the latter lesions are clonally independent from each other. In accordance with previous reports, TP53 mutations were found in 21/21 cancer samples and also found in dysplastic (11/12) and non-dysplastic samples at a lower frequency (26/67). Strikingly, non-dysplastic samples harbored a very high frequency of NOTCH1 mutations (51/67), which were also found in cancer (3/21) and non-dysplastic (8/12) samples but at much lower frequencies (P = 6.610-7). TS of validation samples confirmed the trend of higher NOTCH1 (84% vs. 25%) and lower TP53 mutation rates (38% vs. 100%) in non-dysplastic samples compared to cancer samples. The number of mutations in non-dysplastic samples was higher in drinkers than non-drinkers. Multiple NOTCH1 mutations were more common in cancer patients and drinkers than non-drinkers.ConclusionClonal proliferation in non-cancer esophageal epithelia is common even in non-ESCC cases and extensive in ESCC cases. NOTCH1 and TP53 mutations play major roles in clonal evolution in common but may have differential impacts on esophageal carcinogenesis, which is likely to be shaped by APOBEC-induced mutations and CNAs.']",
        "Doc_id":"AACR_2016-164",
        "Doc_title":" Clonal evolution in noncancerous esophageal mucosa in normal and cancer-bearing individuals",
        "_version_":1606188984062443520},
      {
        "Meeting_name":" Beyond RB1",
        "Background":"['Introduction', ' Urothelial carcinoma is characterized by a high incidence of molecular alterations in the CDKN2A-RB-E2F axis. Loss of the cyclin-dependent kinase inhibitor p16 encoded by CDKN2A or amplification of CDK4/6 is associated with sensitivity to CDK4/6 inhibitors in various cancers. Functional RB1 is believed to be canonically required for mediating the effects of CDK4/6 inhibition in this setting. However, muscle-invasive urothelial carcinomas harbor RB mutations and copy-number losses in 21% of patients. To extend the activity spectrum of CDK4/6 inhibitors to these RB1-deficient cancers, we investigated the role of pocket protein p130 encoded by the Retinoblastoma-Like 2 (RBL2) gene, in mediating the downstream effects of CDK4/6 inhibition.']",
        "Doc_id":"AACR_2017-2344",
        "Doc_title":" Beyond RB1",
        "_version_":1606189017355780096},
      {
        "Meeting_name":" Genetic and epigenetic inactivation of miR-31 in EBV-associated nasopharyngeal carcinoma",
        "Background":"['Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignant cancer prevalent in Southern China and South-eastern Asia. In this study, we aim to elucidate the fundamental role of aberrant expressed microRNAs (miRNA) in NPC tumorigenesis. By comparison of miRNA expression profiles in NPC tumor lines with non-malignant nasopharyngeal epithelial cell, 119 differentially expressed miRNAs were identified in EBV-associated NPC. Among the 58 microRNAs downregulated in NPC, transcriptional silencing of miR-31 was consistently found in both NPC tumor lines and primary tumors. Expression of miR-31 was detected in none of 6 EBV-positive tumor lines and 38 microdissected primary tumors, but in all normal nasopharyngeal epithelia. Interestingly, miR-31 is located at 0.5 Mb telomeric to CDKN2A at 9p21.3, which is commonly homozygous deleted in NPC. Homozygous deletion of both miR-31 and CDKN2A locus was confirmed in 2 tumor lines. In the 4 tumor lines with intact miR-31, hypermethylation of 5CpG islands was detected by bisulfate sequencing and MSP analysis. Re-expression of miR-31 was demonstrated in the EBV-positive NPC cell line C666-1 treated with 5-aza-2-deoxycytidine. The findings suggested that homozygous deletion and promoter methylation are the major mechanisms for transcriptional silencing of miR-31 in NPC. By microarray and bioinformatic analysis, we have identified a number of putative targets of miR-31. Among these candidates, we have proven that miR-31 targeted FIH1 and MCM2 expression in NPC. Ectopic expression of miR-31 in NPC cells resulted in repression of FIH1 and MCM2 protein. Finally, we have demonstrated that restoration of miR-31 or knockdown of FIH1 expression significantly suppressed cell proliferation of C666-1. Our findings indicated that miR-31 is a NPC-associated microRNA which negatively regulates cell growth by repressing FIH1 expression.']",
        "Doc_id":"AACR_2012-2288",
        "Doc_title":" Genetic and epigenetic inactivation of miR-31 in EBV-associated nasopharyngeal carcinoma",
        "_version_":1606189035158503424},
      {
        "Meeting_name":" A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.",
        "Background":"['Background', '  The Retinoblastoma pathway is targeted for mutational or epigenetic inactivation in more than 70% of NSCLC.  The most common event is loss of CDKN2A expression (p16 protein), usually by hypermethylation, resulting in deregulated CDK4/6 activity and cell cycle progression. Palbociclib is a highly specific CDK4/6 inhibitor and has been shown to inhibit cell cycle progression and promote cellular senescence.  Methods', '  We conducted a phase II, single arm trial of palbociclib in 19 previously-treated patients with recurrent or metastatic NSCLC. Only patients whose tumors were negative for p16 expression by immunohistochemistry were eligible. The primary endpoint was response rate. A Simons 2-stage design was employed, with 2 or more responses required to proceed to the second stage. Palbociclib at 125 mg daily was given orally on days 1-21 of a 28-day cycle. Tumors were assessed by RECIST every 2 cycles. Secondary endpoints included overall survival, progression-free survival, toxicity and biomarker analysis.  Results', '  Of the 16 evaluable patients who received at least one month of therapy, there were no responses, and the trial was closed to accrual. However, 8 patients with previously progressive NSCLC had stable disease (SD) lasting 16, 17, 20, 24, 35, 38, 41 and 42 weeks. The remaining 8 patients had progressive disease within 8 weeks. The median PFS was 12.5 weeks. There was no correlation between SD and histology or EGFR mutation status. One patient experienced grade 3 and 4 toxicities as a result of transaminitis and rhabdomyolysis (generalized muscle weakness and increased CPK) thought to be due to concomitant use of high-dose (80 mg) simvastatin. Three patients developed grade 3 or 4 neutropenia, and one patient developed  grade 3 thrombocytopenia. All other toxicities were grade 1 or 2.  Conclusions', '  Palbociclib therapy alone was well-tolerated, and stable disease (SD) was achieved in 50% of evaluable patients, suggesting the induction of cellular senescence. PFS was comparable to other second-line chemotherapeutic agents. Molecular predictors of clinical benefit (SD) are currently under investigation. Clinical trial information', ' NCT01291017.']",
        "Doc_id":"ASCO_135087-144",
        "Doc_title":" A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.",
        "_version_":1606189028880678912},
      {
        "Meeting_name":" Implementation of precision oncology in the Veterans Health Administration (VHA).",
        "Background":"['Background', ' VHA is the USs largest integrated healthcare system providing care to over 6 million Veterans (~40% in rural areas). Precision Oncology offers the promise of effective, low-toxicity targeted therapies tailored to individual tumor genomics but is unequally available to patients in the US. As part of the Cancer Moonshot, VHA is implementing a system-wide Precision Oncology Program (POP) including patients in rural areas, where specialty oncology care has historically had limited availability. Methods', ' Patients tested with multigene NGS tumor sequencing through 1 of 2 contracted vendors were identified from POP records and cancer characteristics were extracted from POP and medical records. Drug use data was obtained from the VA Corporate Data Warehouse. NGS testing results and annotations were extracted from POP records. Results', ' A total of 978 tumor samples were sent for NGS testing since program inception in 2015. The most common diagnoses are lung (464', ' adeno 314, squamous 107), GI (87), LN (75), liver (56), H&N (52), and prostate (43). The rate of sample test requests increased rapidly after national implementation in July 2016 (mean 23 samples/month prior to implementation to mean 126 samples/month 3 months later) as did the number of participating facilities (mean 8/month to 27/month). Sequencing success rate increased from 68% to 71% over the same interval while mean turn around time remained similar at 19.7 and 19.1 d, respectively. NGS results are available for a cohort of 344 patients including', ' lung 200 (adeno 138, squamous 51), skin 28, LN 20, liver 19, GI 16. 979 variants were found including TP53 278, KRAS 106, STK11, APC 38, PIK3CA 38, and CDKN2A 37. 228 patients had actionable results (on-label drug 24, off-label drug 165, clinical trial 213). To date, 8 patients received a recommended drug outside a clinical trial between 11 and 288 d after testing (median 82 d); 4 additional patients had received an NGS-recommended drug prior to testing. Conclusions', ' Implementation of tumor NGS testing as part of Precision Oncology Program in a US distributed healthcare system is feasible. Further program implementation and provision of appropriate targeted drugs both on and off study will be necessary to impact patient outcomes.']",
        "Doc_id":"ASCO_194453-199",
        "Doc_title":" Implementation of precision oncology in the Veterans Health Administration (VHA).",
        "_version_":1606189024414793728},
      {
        "Meeting_name":" Normal versus tumor and subtype prediction in renal cell carcinoma TCGA data sets",
        "Background":"['Background', \" In clinical practice it is a common challenge to correctly classify disease against normal cases and to identify disease subtypes. In complex diseases such as cancer where patterns are heterogeneous, highly complex interaction of pathways are involved, and continuous multi-level genomic changes occur, this is a challenging task. Using genomics data, analyzed by un-supervised and supervised machine learning tools, we demonstrate the ability to quantitatively and accurately describe a patient's tumor.Design\", ' We used Level III RNASeq gene expression data from 20531 genes in 889 tumor samples of RCC across three subtypes - clear cell renal cell carcinoma (CCRCC), papillary renal cell carcinoma (PRCC), chromophobe carcinoma (ChRCC) and 129 normal samples from the Cancer Genome Atlas (TCGA). We developed a computational framework for feature (gene/transcript) selection and subtype predictive model construction. This framework relies on a well-known random forest (RF) method with iterative feature selection and 10-fold cross-validation. We performed a series of (1) tumor vs normal tissue experiments for each subtype; (2) pairwise subtype comparison, and finally (3) all three subtypes comparison and predictive genes identification.Results', ' In each computational run our method detected 2054 (10%) top varying genes, and estimated the predictive power of each of the selected genes using RF. On average this method demonstrated 93-97% accuracy. We identified genes known to play a role in renal cell carcinoma for example, CA9, LOX, SFRP1, SLC4A1, CDKN2A, KISS1R, EGF and others. In addition, our analysis uncovered genes that may represent characteristic patterns for subtyping and differentiation from normal renal tissue cells, for example TCF21, IRX1, STC2, UMOD, AQP2, ANGPTL4, BSND and FABP7, genes not previously associated with renal cell carcinoma.In three different experiments we differentiated each of the three subtypes from normal tissue, and performed enrichment analysis for the top most significant genes in each case. We observed that both CCRCC and PRCC have genes involved in the glycosaminoglycan biosynthesis - heparan sulfate (HS6ST2, HS6ST3) and riboflavin metabolism (ACPP) pathways. Whereas ChRCC is more strongly associated with the glycosphingolipid biosynthesis - lacto and neolacto series pathway (B3GNT3, FUT6) and have five genes (B3GNT3, CYP2B6, CYP2J2, FUT6, UGT2A3) involved in other metabolic pathways. Changes in glycosaminoglycan and glycolipid were also previously reported for associations with RCC.Conclusions', ' We demonstrate the effectiveness of a computational framework and predictive power of gene expression data for tumor subtyping in RCC. Our framework is generic and can be applied in combination with other types of data such as different modalities of genomic data (copy number variations, methylation) as well as clinical data.']",
        "Doc_id":"AACR_2016-3651",
        "Doc_title":" Normal versus tumor and subtype prediction in renal cell carcinoma TCGA data sets",
        "_version_":1606188987167277056},
      {
        "Meeting_name":" Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study",
        "Background":"['Background', ' Fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in FGFR1amplified sgNSCLC treated with dose  100mg. To identify underlying mechanisms of resistance, we analyzed tumor tissues of selected patients. Methods', ' Within the phase I BGJ398 study, patients (pts) with FGFR1amplified sqNSCLC were treated orally with escalating dose (5 to 150mg) of BGJ398 once daily (QD) or 50mg twice a day. In the expansion phase, pts received BGJ398 either continuously QD or on a 3-weeks on/1-week off schedule. CT scans for response were performed every 8 weeks. Available tumor tissue of pts treated with BGJ398 at our center was analyzed using hybrid capturebased massively parallel sequencing (CAGE). Results', ' Twenty-one pts with FGFR1 amplified sqNSCLC were treated with  100mg BGJ398 at our site. As best response, 3 pts showed partial response (PR), 7 pts stable disease (SD) and 7 pts progressive disease (PD). Two pts withdrew their consents and 2 pts died ahead of first CT scan', ' one due to infection and one due to sudden death. We performed CAGE covering 256 genes on 9 patients', ' on 3 pts with PR, 2 pts with SD, 2 pts with PD and 2 pts who died before first CT scan. All analyzed patients harbored mutations in TP53. Additionally, we detected two CDKN2A (one patient with PR and one patient who died before first CT) and three MLL2 stop codon and frame shift mutations (two patients with SD and one patient with PD). Of interest, we identified three patients with two canonical (one patient with SD and one patient who died before first CT) and one non-canonical mutations in PIK3CA(one patient with SD). Conclusions', ' In our analysis, MLL2 and PIK3CA mutations seem to have a negative impact on response in FGFR1 amplified pts treated with BGJ398. Further analysis with higher patient number is needed to identify the role of MLL2 and PIK3CA mutations in FGFR1 amplified sqNSCLC. Clinical trial information', ' NCT01004224']",
        "Doc_id":"ASCO_189173-199",
        "Doc_title":" Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study",
        "_version_":1606188991070076928},
      {
        "Meeting_name":" CT-based radiomic analysis of hepatocellular carcinoma patients to predict key genomic information.",
        "Background":"['Background', ' The utilization of computed tomography (CT) has virtually replaced the need for tissue diagnosis in hepatocellular carcinoma (HCC). Imaging features (e.g. size, shape and vascularity) have been associated with patient survival. However, the full potential of CT in HCC diagnosis may not be reached, as high-throughput computing allows for extraction of quantitative features that are not part of radiologists lexicon. The purpose of this study was to investigate the ability of radiomic analysis to successfully identify specific doxorubicin chemoresistant genes on CT images of treatment-nave hepatocellular carcinoma (HCC). Methods', ' We identified 27 treatment-nave patients with a single HCC tumor from The Cancer Genome Atlas (TCGA) whom had gene expression profiles. Baseline CT images were obtained from The Cancer Imaging Archive (TCIA). 3D Slicer software was used for manual tumor segmentation and final segmented images were reviewed by a board-certified radiologist. Following tumor segmentation, texture analysis was performed on MATLAB environment. A total of 310 rotation invariant texture features, which measure tumor heterogeneity, were obtained (first-order histogram and grey level co-occurrence matrix). The mRMR method was used to select the most relevant radiomic features. ROC analysis and LOOCV were used to assess the performance of five specific genes known to confer doxorubicin chemoresistance (TP53, TOP2A, CTNNB1, CDKN2A and AKT1). Results', ' Radiomic analysis identified TP53 (AUC = 86.61%, Specificity = 92.31%, Sensitivity = 92.9%), TOP2A (AUC = 78.0%, Specificity = 69%, Sensitivity = 85.7%), CTNNB1 (AUC = 86.8%, Specificity = 92.3%, Sensitivity = 85.7%), CDKN2A (AUC = 76.9%, Specificity = 76.9%, Sensitivity = 78.6%) and AKT1 (AUC = 72.5%, Specificity = 69.2%, Sensitivity = 85.7%) in treatment-nave HCC CT studies. Conclusions', ' The identification of specific genes that confer chemoresistance to doxorubicin can be reliably ascertained via the use of radiomic analysis. This study may help tailor future treatment paradigms via the ability to categorize HCC tumors on genetic level and identify tumors which may not have a favorable response to doxorubicin based therapies.']",
        "Doc_id":"ASCO_189713-199",
        "Doc_title":" CT-based radiomic analysis of hepatocellular carcinoma patients to predict key genomic information.",
        "_version_":1606189017508872192},
      {
        "Meeting_name":" Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.",
        "Background":"['Background', ' The genetic mechanisms associated with progression of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have not been described. We conducted next-generation sequencing (NGS) of HR-NMIBC and compared the genomic profiles of cancers that responded to intravesical therapy and those that progressed to muscle-invasive or advanced disease. Methods', ' DNA was extracted from formalin-fixed paraffin-embedded sections of tumor from 25 patients with HR-NMIBC (23 with T1HG; 3 with TaHG and carcinoma in situ). Ten patients with HR-NMIBC developed progression (pT2+ or N+) (progressors). Fifteen patients had no progression (non-progressors). Tissue from 11 patients with metastatic bladder cancer (BC) were analyzed for comparison. Results', ' We identified no difference in the frequency of mutations of TP53, PIK3CA, or KMT2D between the primary tumors of progressors compared to non-progressors and metastatic tumors. An increased frequency of mutations and deletions causing loss of function of CDKN2A and CDKN2B was identified in tumors at progression (37%) compared to non-progressors (6%) (p=0.10). We found a significant decrease in total mutational burden (TMB) comparing non-progressors, progressors and metastatic tumors at 15, 10.1 and 5.1 mutations/MB respectively (p=0.02). This association suggests more advanced tumors have decreased neoantigen burden and may potentially explain the mechanism of BCG response in non-progressors. Conclusions', ' TMB was significantly greater in non-progressors compared to progressors. We found no novel genetic drivers in tumors that progressed and HR-NMIBC had many genetic features similar to metastatic BC. The loss of CDKN2A appears to occur late in the process of invasion of BC and may represent an important step in progression. Further research is necessary to evaluate loss of CDKN2A as a biomarker for progression of NMIBC.']",
        "Doc_id":"ASCO_177429-197",
        "Doc_title":" Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.",
        "_version_":1606189004352389121},
      {
        "Meeting_name":" Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary",
        "Background":"['Background', ' Patients with advanced carcinoma of unknown primary (CUP) have limited effective therapeutic options given the challenges of phenotypic and genotypic diversity. To identify future novel therapeutic strategies we conduct an ongoing exploratory analysis of next-generation sequencing (NGS) of relapsed, refractory CUP.Methods', ' We identified CUP patients referred to our phase I clinic with adequate FFPE sections from archival tissue for a targeted CLIA-certified NGS assay (Foundation One, MA). Over 2000 exons of 186 cancer-related genes plus over 30 introns from 14 genes often rearranged in cancer were fully sequenced for point mutations, insertions/deletions, copy number alterations (CNAs) and select gene fusions.Results', ' Of 19 patients seen (10 male, 9 female; median age at diagnosis 49 years), 17 demonstrated genomic alterations (median 3 aberrations/tumor, range 0 - 10); two patients had no reportable genomic alterations. Of the 71 detected aberrations, 17 (24%) have been implicated in impaired cell cycle regulation and arrest; specifically in genes which encode the cyclin-dependent kinases (CDK12 Q570*, CDKN2A/B loss, CDKN2A p16INK4a loss and p14ARF exon 2-3 loss) or their associated proteins including amplification of CCND1 and CCNE1 (n = 3). Of these 8 patients with impaired cell cycle regulation, 5 (63%) demonstrated concurrent mutations associated with epigenetic deregulation and impaired DNA methylation, most commonly ARID1A Y1211fs*5 and S1929fs*25, which encodes the AT-rich interactive domain-containing protein 1A, Arid1a, a member of the SWI/SNF chromatin remodeling complex); other mutations observed are CREBBP S893L (encoding a ubiquitously expressed transcriptional coregulatory protein controlling chromatin remodeling via its histone acetyltransferase activity); MLL2 R4904* (encoding an H3K4-specific histone methyltransferase) and KDM6A S466* (encoding the histone H3 lysine 27 demethylase UTX). Overall 5 of 19 (26%) patients with advanced relapsed CUP demonstrated a profile of aberrations that concurrently impact cell cycle arrest and epigenetic regulation.Conclusion', ' Through NGS-based molecular profiling, we can a subset of patients with advanced carcinoma of unknown primary with coexisting mutations leading to impaired cell cycle arrest and epigenetic deregulation, highlighting a therapeutic combination with a cell cycle inhibitor (such as Cdk4/6 inhibitors currently in clinical trial) and histone deacetylase inhibitors.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-604",
        "Doc_title":" Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary",
        "_version_":1606188999208075265},
      {
        "Meeting_name":" Somatic mutations and copy number variations in cancer-associated genes in 695 ovarian cancer patients",
        "Background":"['Background', ' Recent genomic studies have improved molecular understanding of ovarian cancer but have had limited impact on therapeutic improvements. We sought to review somatic mutations and copy-number variations (CNVs) in cancer-associated genes in the tumors of 695 patients with ovarian, peritoneal, or fallopian tube cancer (ovarian cancer) at Dana-Farber Cancer Institute, with associated pathologic and clinical data.Methods', ' Testing was performed on formalin-fixed tumor tissue without germline analysis, with IRB approval and patient consent. 310 patients underwent genotyping for 471 mutations in 41 cancer-related genes (OncoMap test). 388 patients underwent next-generation sequencing (NGS) of 300 cancer-associated genes (OncoPanel test). Most samples were primary tumors, with a small subset recurrent. The majority of tumors were adenocarcinoma/carcinoma histology.Results', ' Of 310 patients tested by OncoMap, 102 had at least one variant. Among tumors with adenocarcinoma/carcinoma histology, mutations were most frequent in TP53, KRAS, PIK3CA, JAK3, MET, and CTNNB1. Gene alterations varied by subtype and supported previously reported associations including BRAF in borderline, KRAS in mucinous, PIK3CA in clear cell, and PIK3CA/CTNNB1/AKT1 in endometrioid tumors. From 388 patients tested by OncoPanel, 3903 single nucleotide variants were detected. Variants were classified by clinical pathologists according to evidence-based potential clinical relevance. 27 variants were Tier 1 (evidence confirming clinical utility in ovarian cancer) and 127 variants were Tier 2 (possible clinical utility in specific contexts). Tier 1 variants were most frequent in BRCA1 and BRCA2. Common Tier 2 variants included alterations in TP53, PIK3CA, KRAS, PTEN, BRCA1, BRCA2, ARID1A, and BRAF. Several alterations may be considered actionable in terms of eligibility for clinical trials. Finally, 227 patients tested by OncoPanel had CNV data for the panel of cancer-associated genes. CNVs were numerous with 12368 CNVs reported. CNVs were classified as 1-copy deletion (n = 6033), 2-copy deletion (n = 108), high amplification (n = 114), and low amplification (n = 6103). Among adenocarcinoma/carcinoma tumors, 2-copy deletions were frequent in RB1, PTEN, CDKN2A, and MAP2K4, and common highly amplified genes were CCNE1, KRAS, AKT2, ERBB2, and MECOM.Conclusions', ' Genotyping and/or NGS of cancer-associated genes in formalin-fixed tissue from ovarian tumors is feasible and can identify potentially clinically actionable alterations. Preliminary correlations with survival and treatment response are being explored.']",
        "Doc_id":"AACR_2016-95",
        "Doc_title":" Somatic mutations and copy number variations in cancer-associated genes in 695 ovarian cancer patients",
        "_version_":1606189039487025153},
      {
        "Meeting_name":" Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal frequency of druggable targets.",
        "Background":"['Background', '    Salivary gland adenocarcinomas (SAC) are a distinct group of frequently aggressive epithelial tumors. We queried whether the genomic alterations (GA) identified by comprehensive genomic profiling (CGP) in refractory and metastatic SAC could lead to potential targeted therapy selection.  Methods', '    DNA was extracted from 40 microns of FFPE sections from 92 clinically advanced SAC. Comprehensive genomic profiling was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 682X for 3,230 exons of 236 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. The results were evaluated from each sample for all classes of genomic alterations.  Results', '    There were 2 grade 1, 27 grade 2 and 63 grade 3 relapsed/refractory SAC in 30 (33%) female and 62 (67%) male patients with a median age of 59.6 years (range 25 to 84 years). There were 27 Stage III and 65 Stage IV cases. The majority (88%) of SAC harbored at least 1 clinically relevant alteration (mean 1.9 per patient) with a mean of 3.7 GA per tumor. GA occurred in 49 different genes including', ' PIK3CA (25%); HRAS (20%); CDKN2A (17%); ERBB2 (15%); and PTEN and NF1 (9%), NOTCH1 and MCL1 (8%), EGFR (5%), KRAS (4%) and RICTOR, HGF, FBXW7 and CDK4 (3%). The greater frequency of ERBB2 alterations (15%) observed in SAC was significantly higher than observed in 110 similarly studied specialized salivary carcinomas including acinic cell, adenoid cystic and mucoepidermoid carcinomas (1%)  (p = 0.0001). A similar increase in HRAS alterations of 18/92 (20%) SAC vs 4/110 (4%) in the specialized tumor group was also observed (p = 0.008). PIK3CAwas altered in 25% of SAC vs. 5% in 110 specialized tumors (p = 0.001).   Conclusions', '    SAC are a clinically aggressive and pathologically distinctive subset of salivary gland carcinomas. These tumors also differ significantly from the specialized salivary gland tumors in their genomic landscape. The high frequency of clinically relevant alterations in SAC including the 15% ERBB2 alteration frequency suggests that continued molecular analysis of this tumor type has the potential to lead patients to clinical trials employing both established and novel targeted therapies.']",
        "Doc_id":"ASCO_147111-156",
        "Doc_title":" Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal frequency of druggable targets.",
        "_version_":1606189026099855360},
      {
        "Meeting_name":" Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting.",
        "Background":"['Background', '  The management challenges of advanced gynecologic malignant neoplasms are often intensified in a community setting. We utilized comprehensive genomic profiling (CGP) of advanced gynecologic malignancies to identify routes of possible benefit from targeted therapy.  Methods', ' DNA was extracted from 40 microns of FFPE sections of advanced gynecologic malignancies. CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of > 500x for 3,769 exons of 236 cancer-related genes plus 47 introns from 19 genes frequently rearranged in cancer. All classes of genomic alterations (GA) were evaluated, and clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials.  Results', '  The 30 female patients had a median age of 62 years (range 32-88). There were 16 (56%) ovarian carcinoma, 9 (30%) endometrial carcinoma, and 1 (3.3%) case each of uterine sarcoma, uterine carcinosarcoma, leiomyosarcoma, vaginal melanoma, and peritoneal carcinoma. CGP revealed 80.00% (24/30) of cases harbored at least 1 CRGA, for  an average of 1.83 CRGA per case, and 100% of cases harbored at least one GA, for a total of 137 GA, for an average of 4.56 GA/case. The most frequently detected GA was in TP53 (52%), and the most common CRGA were in PTEN 36% (11/30), PIK3R1 28%(9/30), CDKN2A 12%(4/30), KRAS 12% (4/30) and PIK3CA 12% (4/30), respectively. There were 8 evaluable ovarian carcinoma patients that received therapy based on assay results, and 3/8 cases had complete responses and another 4/8 had partial responses with median duration of response of 31 weeks (range 2-43 weeks) and ongoing. The remaining evaluable patient had PD as a result of noncompliance.  Conclusions', '  In this group of patients with advanced gynecologic malignancies, CGP uncovered a high frequency of CRGA that lead to preliminary successes in multiple ovarian carcinoma patients. Further application of CGP in gynecologic cancers as a route to precision treatment for these patients appears warranted.']",
        "Doc_id":"ASCO_150967-156",
        "Doc_title":" Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting.",
        "_version_":1606188998370263041},
      {
        "Meeting_name":" Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).",
        "Background":"['Background', ' ATC is the most aggressive type of thyroid cancer with a median survival of 5 months from diagnosis. ATC patients with genomic alterations (GA) in TSC2, ALK, BRAF show occasional, limited benefit with targeted therapies. Methods', ' 90 ATC were studied by CGP to define the frequency of GA and opportunities for targeted therapy approaches in this devastating disease. DNA was extracted from 40 microns of FFPE sections, and CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 579X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. GA included base substitutions, indels, amplifications, copy number alterations and fusions/rearrangements. R software used for all statistical analyses. Fishers exact test used for mutation frequency comparisons among age groups. Results', ' Median patient age was 65 (range 33-86), 50 patients were male. There was a mean of 4.2 Known Likely Variant (KLV) genomic alterations per case, range 1-11. Adding Variants of Undetermined Significance (VUS) mean was 12.9, range 5-27. The most common KLV-GA were p53 (66%), BRAF (34%), TERT (32%), CDKN2A (32%), NRAS (26%), CDKN2B (20%), NF2 (14.4%), PTEN (13.3%), PIK3CA (12.2%). There were 2 EGFR; 5 JAK2 and 29 GAin the promoter region of TERT. BRAF V600E and NRAS/HRAS alteration were entirely mutually exclusive, and one case demonstrated both BRAF V600E and KRAS. Co-occuring mutations were CDKN2A with p53 (p=0.04). Some GA were more frequent in patients greater than 70 yrs of age such as BRAF, CDKN2A, PIK3CA, JAK2; while others were more common in 50 yrs patients like PTEN, NRAS. VUS of possible interest were MLL2 (n=15), ARID1A (11), TSC2 (5), ALK(2). Conclusions', ' A number of identified alterations in ATC patients may be amenable to molecularly targeted therapies, guiding future clinical trial development. Further assessment will be performed to the relationship of GA in ATC with patient demographics and disease evolution from differentiated thyroid carcinoma. SELECT KLV-GA (%)50 yrs n=15>50 to 70 yrs n=49>70 yrs n=25p5366.767.360BRAF2034.744CDKN2A13.332.744TERT26.732.736CDKN2B020.432NRAS33.328.616PIK3CA014.316RET6.728PTEN2016.34']",
        "Doc_id":"ASCO_162292-176",
        "Doc_title":" Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).",
        "_version_":1606189024667500544},
      {
        "Meeting_name":" Comprehensive integrative characterization of hepatocellular carcinoma",
        "Background":"['Background', ' Hepatocellular carcinomas (HCCs) are heterogenous primary liver cancers with pleomorphic histologic features. We present a comprehensive genetic, genomic, transcriptomic and proteomic analysis of 203 HCCs in The Cancer Genome Atlas Program (TCGA) on behalf of the TCGA Liver analysis working group to provide a deeper understanding of the molecular features of HCCs, to classify them in a clinically-relevant manner, and to provide a public resource that identifies potential targets for emerging therapies.Results', ' Mutation analyses confirmed the presence of TERT promoter mutations in 40% of HCCs. The analysis also revealed the first reported germline mutation in the TERT promoter in a 30 year old male, possibly reflecting an inherited predisposition to HCC. TERT promoter mutations were enriched in hepatitis C virus infected subjects. Analyses of hepatitis B virus (HBV)-induced HCCs demonstrated recurrent integrations of HBV in the TERT locus. Thus, HBV integration may substitute for TERT promoter mutations as an alternate mechanism of telomerase activation. Other tumor suppressor genes inactivated by mutation included the cell cycle genes TP53 (32% of cases), RB1 (8%), and PTEN (3%), the Wnt/beta catenin pathway gene AXIN1 (4%), and the chromatin remodeling genes ARID1A (9%), BAP1 (6%), ARID1B (4%), ARID2 (4%), and PBRM1 (3%). The oncogene CTNNB1 was mutated in 27% of HCCs. Mutations were also found in the MTOR pathway genes, MTOR (4%), TSC2 (4%) and TSC1 (3%). The patterns of mutational signatures observed included signatures characteristic of the known carcinogens aristolochic acid and aflatoxin B1. Clustering of mRNA, miRNA, or protein expression, DNA hypermethylation and DNA copy number profiles identified five, four, two, five and three clusters, respectively. Analysis of mRNA expression data identified five groups. In particular, Group 1 was associated with Asian race, higher histologic grade, and micro- and macrovascular invasion. Integrated clustering showed a grouping of HCCs into three superclusters', ' iCluster 1 had a low frequency of CDKN2A silencing, lack of CTNNB1 mutation, a normal-like methylation pattern, and overexpression of proliferation marker genes; iClusters 2 and 3 had a high frequency of CDKN2A silencing, CTNNB1 mutation, and overexpression of oxidative response genes; iCluster 3 tumors had a higher degree of chromosomal instability, high frequency of 17p loss, and a highly altered methylation profile. Copy number aberrations included gains in the MYC, VEGFA, CCND1, TERT, and MET loci and losses in the TP53, RB1, ERFFI1, CDKN2A, ARID1A and PTEN loci. Discussion', ' Based on integrated analysis of genome, transcriptome, methylome and proteome we showed that HCCs naturally separate into three to five distinct groups with associated molecular and clinical characteristics. Importantly, we identified a novel germline mutation in the TERT promoter that may be associated with an inherited risk for HCC.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-3745",
        "Doc_title":" Comprehensive integrative characterization of hepatocellular carcinoma",
        "_version_":1606189006454784000},
      {
        "Meeting_name":" A novel mechanism of hypoxia mediated cell cycle dysregulation",
        "Background":"['Background', ' Among the various factors in the tumor microenvironment influencing tumor growth and progression, hypoxia plays a key role in promoting tumor growth and resistance to therapeutics. However, a mechanistic understanding of the complicated biological interplay between the stromal framework (hypoxia context) and malignant regions of the same tumor remains an unmet need. In this study, we examined the molecular networks of interplay between hypoxia and miRNA deregulation. Study methods and results', ' In this study, we profiled the expression of miRNAs in ovarian cancer cells upon exposure to hypoxia (1% O2) using microRNA microarray (Agilent v14). We found that significant numbers of miRNAs are dysregulated. In A2780 and Skov3 ovarian cancer cells, using a statistical cutoff (p<0.05 and fold change >1.5), normoxia v/s short term (48hrs) and long term (6 days) hypoxia exposure, we found that 23 MicroRNAs were down regulated whereas 11 were upregulated. Among these, miR-134 validated to be overexpressed under hypoxia by 3 - 4 fold in A2780 and SKOV3 ovarian cancer cells consistently across the short and long term time points. Upon bioinformatics analyses for target sites of commonly up regulated miRNAs, we found that miR-134 was predicted to target CDKN2A (Miranda, microT, PITA, RNA22, TargetScan). CDKN2A is a protein involved in cell cycle control, precisely regulating cell cycle G1 control through complexing with CDK4. Considering the fact that CDKN2A expression is lost in several cancer types and its correlation with the aggressive tumor growth, we checked expression of CDKN2A under hypoxic conditions. CDKN2A was down-regulated under hypoxia by 55% and was inversely correlated with miR-134 expression in cell lines tested. Upon transfection of A2780 ovarian cancer cells with miR-134 microRNA mimics, we observed consistent down regulation of CDKN2A by >40%, compared to scrambled control transfected cells. This further proves the role of miR-134 in deregulating CDKN2A expression in ovarian cancer. Discussion', \" This study provides new insights into miRNA-134's role in regulating cell cycle in the context of hypoxia mediated signaling. These findings may have implications for new approaches targeted at curbing the deleterious effects of hypoxia on tumor growth.\"]",
        "Doc_id":"AACR_2012-178",
        "Doc_title":" A novel mechanism of hypoxia mediated cell cycle dysregulation",
        "_version_":1606189021517578240},
      {
        "Meeting_name":" Myxofibrosarcoma",
        "Background":"[\"BackgroundSoft tissue sarcomas are rare malignant tumors that account for approximately 1% of all malignancies. Myxofibrosarcoma (MFS) is one of the most common sarcomas in elderly patients. Because of their highly complex Karyotypes with extensive intratumoral heterogeneity, no specific recurrent aberration has emerged. In our Precision Cancer Medicine Program, we enroll patients with rare malignancies, metastatic or treatment-resistant disease in order to analyze the individual patient's disease and identify druggable targets. We sequenced two macroscopically different appearing tumor areas from a patient with a primary high-grade MFS using a Whole Exome Sequencing (WES) clinical test called EXaCT-1.DesignThe patient was enrolled prospectively through our Precision Medicine Clinic under an IRB approved protocol. Genomic DNA from fresh OCT (TissueTek) - frozen tissue from a myxoid hypocellular tumor area, from a more pleomorphic hypercellular tumor area and from benign tissue were extracted using the Promega Maxwell 16 MDx. Sequencing was performed using Illumina HiSeq 2500 (2100bp). A total of 21,522 genes were analyzed using Agilent HaloPlex Exome. Reads were aligned to GRC37/hg19 reference using BWA and processed accordingly to IPM-Exome-pipeline v0.9. Sequencing results were confirmed and further analyzed using CLONET (CLONality Estimate in Tumors) and fluorescence in situ hybridization (FISH). CDK4/6 inhibitors (PD0332991, LY2835219) were tested in a MFS monolayer cell line (OH931) and an engineered 3D mini-MFS system.ResultsWhole exome sequencing and CLONET analysis revealed a hemizygous deletion in the myxoid hypocellular tumor area and a homozygous deletion in the pleomorphic hypercellular tumor area of the tumor suppressor cyclin-dependent kinase inhibitor CDKN2A (p16/Ink4a). Looking through the genomic data published by Barretina et al. (Nat Genet. 2010), we recognized a homozygous deletion of CDKN2A in 15% of the MFS analyzed. Screening full sections of 30 MFS with FISH for CDKN2A deletion shows intratumoral heterogeneity with hemizygous deletion, homozygous deletion and amplification of CDKN2A. CDKN2A loss may be associated with increased sensitivity to CDK4/6 inhibitors. Treatment of CDKN2A null MFS cell line OH931 (kindly provided by Dr. Julia Bridge) with CDK4/6 inhibitors (PD0332991, LY2835219) showed decreased cell proliferation compared to a CDKN2A wild-type sarcoma cell line RD (ATCC CCL-136) in monolayer culture and in our newly developed 3D system.ConclusionTumor suppressor cyclin-dependent kinase inhibitor CDKN2A (p16/Ink4a) deletion or methylation has been reported in multiple cancer types and is correlated with worse patient outcome. Patients suffering from a CDKN2A (p16/Ink4a) null high-grade MFS may benefit from CDK4/6 inhibition as shown in a monolayer and 3D cell culture model of a MFS cell line. This study also provides proof of principle for the benefit enrolling sarcoma patients in Precision Cancer Medicine Programs.\"]",
        "Doc_id":"AACR_2015-5269",
        "Doc_title":" Myxofibrosarcoma",
        "_version_":1606189027619241984},
      {
        "Meeting_name":" Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.",
        "Background":"['Cancer is a genetic disease with frequent somatic alterations in DNA. Study of recurrent copy number aberrations (CNAs) in human cancers would enable the elucidation of disease mechanisms and the identification of key oncogenic drivers with causal roles in oncogenesis. We have comprehensively and systematically characterized CNAs and accompanied gene expression changes in the tumors and their matched non-tumor liver tissues from 286 hepatocellular carcinoma (HCC) patients. Our analysis identified 29 recurrently amplified regions and 22 deleted regions with a high level of copy number changes, harboring established oncogenes and tumor suppressors, including CCND1, MET, CDKN2A and CDKN2B, as well as many other genes not previously reported to be involved in liver carcinogenesis. Pathway analysis of cis-acting genes in the amplification and deletion peaks suggests the alterations of core cancer pathways, including cell cycle, p53, PI3K, MAPK, Wnt and TGF signaling, in large proportions of HCC patients. We further credentialed two candidate driver genes, BCL9 and MTDH, from the recurrent focal amplification peaks and showed that they play a significant role in HCC growth and survival. In summary, we have demonstrated that characterizing the CNA landscape in HCC will facilitate the understanding of disease mechanisms and the identification of oncogenic drivers that may serve as potential therapeutic targets for the treatment of this devastating disease.']",
        "Doc_id":"AACR_2013-2002",
        "Doc_title":" Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.",
        "_version_":1606189018076151808},
      {
        "Meeting_name":" Novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate regioisomers target folate receptor alpha positive ovarian cancer cells via inhibition of de novo purine nucleotide biosynthesis.",
        "Background":"['Epithelial ovarian cancers (EOC) represent a unique treatment challenge as over 50% of patients are diagnosed with advanced stage disease when surgical and chemotherapeutic interventions prove futile. Approximately 90% of EOC are folate receptor (FR)  positive and FR levels correlate with stage and grade. FR-targeted therapies represent a rational treatment option for patients with advanced EOC whose treatments fail. There are three primary mechanisms of folate transport in mammalian cells, the reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT) and FRs. RFC is the major transporter for folates and is expressed ubiquitously in normal tissues and tumors. Hence, developing novel antifolates that bypass cellular accumulation by RFC should reduce dose-limiting toxicities. PCFT is expressed in many solid tumors including ovarian cancer and is active at acidic pH. Previous studies established that a novel 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine antifolate with an isosteric thienoyl substitution and a three carbon bridge (AG94) showed selective cellular uptake by FR and PCFT over RFC. [1,3]Thienoyl regioisomers (AG150 and AG154) of AG94 showed subnanomolar potencies toward both KB nasopharyngeal carcinoma (IC50s = 0.1 and 0.09 nM, respectively) and IGROV1 ovarian carcinoma (IC50s of 0.64 and 0.1nM, respectively). While AG150 and AG154 were substrates for both PCFT and FRs, like AG94, their inhibitory effects at low drug concentrations were mediated primarily via FR, as indicated by their capacities to bind with high affinities to FR and protection by excess folic acid. Nucleoside protection assays with adenosine and 5-amino-4-imidazole carboxamide established that the first folate-dependent enzyme in the de novo purine biosynthesis pathway, glycinamide ribonucleotide (GAR) formyltransferase (GARFT), was the primary intracellular target for AG150 and AG154. GARFT targeting was confirmed by in situ metabolic labeling with [14C]glycine and measurement of accumulated [14C]formyl GAR in KB cells, for which IC50s were 1.35 and 1.46 nM, respectively. The purine salvage enzyme methylthioadenosine phosphorylase (MTAP) is frequently co-deleted with CDKN2a in solid tumors including ovarian cancer. Growth inhibitory effects of AG150 and AG154 were reversed in the presence of methylthioadenosine in MTAP-deficient IGROV1 cells transfected with MTAP cDNA. Our results demonstrate potent anti-tumor activities of the 6-pyrrolo[2,3-d]pyrimidine thienoyl regioisomers of AG94, AG150 and AG154, associated with their FR-mediated cellular uptake and inhibition of GARFT in de novo purine biosynthesis. Preservation of purine salvage including MTAP is likely an important cellular determinant of antitumor efficacy for this class of novel tumor-targeted agents.']",
        "Doc_id":"AACR_2013-5494",
        "Doc_title":" Novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate regioisomers target folate receptor alpha positive ovarian cancer cells via inhibition of de novo purine nucleotide biosynthesis.",
        "_version_":1606189030734561280},
      {
        "Meeting_name":" A novel mechanism of hypoxia-mediated cell cycle dysregulation",
        "Background":"['Background', ' Mechanistic understanding of the biological interplay between the stromal framework and malignant regions of the tumor remain an unmet need. In this study, we examined the molecular networks of interplay between hypoxia and miRNA deregulation. Study methods and results', ' We profiled the expression of miRNAs in high-grade ovarian cancer cells upon exposure to hypoxia (1% O2) using a microRNA microarray (Agilent v14). In A2780 and Skov3 cell lines, using a statistical cutoff p<0.05 and fold change >1.5, normoxia vs. short term (48 hrs) and long-term (6 days) hypoxia exposure, we found that 23 MicroRNAs were commonly down regulated, whereas 11 were upregulated. Among these, miR-134 was validated to be overexpressed under hypoxic conditions by 3-4 fold for both time-points. Upon extensive bioinformatic analyses, miR-134 was predicted to target CDKN2A (Miranda, microT, PITA, RNA22, TargetScan). CDKN2A is a protein involved in cell cycle control, precisely regulating cell cycle G1 control through complexing with CDK4. CDKN2A was down-regulated under hypoxia by 55% and was inversely correlated with miR-134 expression in the cell lines tested. Quantitative PCR analysis of pri-miR-134 under hypoxia exposure showed a more than 100-fold increase in expression compared to normoxia, suggesting a transcriptional regulatory event leading to high miR-134 across the panel of cell lines tested. Upon transfection of A2780 cells with miR-134 mimics, we observed consistent down-regulation of CDKN2A by >40%. To understand its functional relevance, migration, invasion, proliferation and viability assays were performed. We observed increases in cell proliferation (from 12% to 41%) in miR-134 transfected cells compared to control in the cell lines tested (p<0.05). Orthotopic mouse ovarian tumors treated with an anti-VEGF antibody were found to be substantially hypoxic and showed an inverse correlation between CDKN2A and miR-134. In tumor samples from patients with ovarian cancer, we observed strong negative correlation (r = -0.63, p<0.01) between CDKN2A and miR-134, validating the study at a human level. Discussion', ' This study provides new insights into the role of miRNA-134 in regulating cell cycle in the context of hypoxia mediated signaling. These findings may have implications for new approaches targeted at curbing the deleterious effects of hypoxia on tumor growth.']",
        "Doc_id":"AACR_2013-3091",
        "Doc_title":" A novel mechanism of hypoxia-mediated cell cycle dysregulation",
        "_version_":1606188988558737408},
      {
        "Meeting_name":" Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven by HRAS hotspot mutations.",
        "Background":"['Adenomyoepithelioma (AME) is a rare biphasic proliferative breast lesion, which may resemble salivary gland epithelial-myoepithelial carcinomas (EMCs). Most AMEs have an indolent clinical course, but malignant transformation and local and distant recurrences have been reported. We sought to define the mutational landscape of AMEs and investigate the functional impact of recurrent likely pathogenic mutations identified in these tumors. Nineteen AMEs were subjected to whole-exome massively parallel sequencing (MPS, n=7) or targeted capture MPS using MSK-IMPACT assay (n=12). Somatic genetic alterations and the cancer cell fraction of mutations were defined using state-of-the-art bioinformatics algorithms. Selected genes (i.e. HRAS and PIK3CA) were subjected to Sanger sequencing in a series of 17 additional AMEs (total n=36). Non-tumorigenic mammary epithelial cells (i.e. MCF10A, MCF10A with the PIK3CAH1047R mutation and MCF12A), which are estrogen receptor (ER)-negative, were utilized for 2D and 3D functional studies. Of 36 cases, 22 were ER-positive and 14 were ER-negative. MPS analysis revealed a low mutation burden and HRASQ61 and PIK3CA hotspot mutations in 6/19 (32%) and 11/19 (58%) AMEs, respectively. All HRASQ61 and all but one PIK3CA mutations were clonal. ER-positive and ER-negative AMEs were fundamentally histologically and genetically distinct. Whilst ER-positive AMEs displayed recurrent PIK3CA mutations (50%, 11/22) but lacked HRAS mutations, ER-negative AMEs displayed, in addition to PIK3CA mutations (57%, 8/14), recurrent HRASQ61 mutations (57%, 8/14). HRASQ61 mutations co-occurred with PIK3CA mutations (50%, 4/8), PIK3R1 deletions (12.5%, 1/8) and/or CDKN2A homozygous deletions (25%, 2/8). HRASQ61 mutations, but not PIK3CA mutations, were significantly associated with ER-negativity (100% vs 21%), concurrent carcinoma (50% vs 7%), axillary metastases (38% vs 0%), high proliferation (63% vs 4%), necrosis (63% vs 11%) and nuclear pleomorphism (75% vs 29%). In vitro forced HRASQ61R expression in MCF10A and MCF12A cells resulted in increased proliferation and transformation. In 3D organotypic cell cultures, forced HRASQ61R resulted in a highly disorganized growth pattern, a partial loss of epithelial phenotype and acquisition of aberrant myoepithelial differentiation, which was more overt in PIK3CA-mutant MCF10A cells. In conclusion, AMEs are phenotypically and genetically heterogeneous. Whilst PIK3CA hotspot mutations occur across the spectrum of lesions, HRASQ61 hotspot mutations are restricted to ER-negative AMEs, which should arguably be classified as breast EMCs. Our genomic and functional analyses are consistent with the notion that HRASQ61 mutations are driver events in the pathogenesis of ER-negative AMEs and may be sufficient for the acquisition of myoepithelial differentiation in breast cells.']",
        "Doc_id":"AACR_2017-3379",
        "Doc_title":" Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven by HRAS hotspot mutations.",
        "_version_":1606189034181230592},
      {
        "Meeting_name":" Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.",
        "Background":"['Activation of CDK4 by amplification, increased expression of Cyclin D1 (CCND1) or reduced expression of the CDK inhibitor p16 (CDKN2A) can contribute to melanocyte transformation, indicating that CDK4 can act as an oncogene in melanoma. We have analyzed the frequency of gene copy number variations (CNV) in the CDK4 pathway and looked for associations of these alterations with patient survival to assess if CDK4 is a viable target for the treatment of human melanoma. In addition, we screened a panel of melanoma cells with a highly selective CDK4/6 inhibitor PD-0332991 (PD-991) and performed gene expression and mutation analysis on these cells to explore possible genomic predictors of sensitivity.Genomic analysis revealed that 75% of primary melanomas had at least one CNV in the CDK4 pathway, with 55% showing a loss of CDKN2A. 28% of melanomas had two or more CNVs and melanomas with two or more CNVs involving CCND1 had worse overall survival (HR 5.56, P=0.02). From the cell line studies low CDKN2A mRNA expression, mutation or loss predicted sensitivity to PD-991 with 23 out of 27 mutant/loss cell lines being sensitive compared to only 3/7 wild type lines (p<0.03). Expression of CDK4, CCND1 or other cyclins or CDK-inhibitors did not predict sensitivity to PD-991. PD-991 induced an increase in both cell size and SA--galactosidase activity that is indicative of a senescent phenotype, and this was associated with cells having wild type p53. In summary, genomic alterations in the CDK4 pathway are frequent in melanoma and are associated with worse survival, particularly when melanomas harbor two or more CNVs involving CCND1. CDK4 inhibition induces a senescent phenotype in melanoma cells that is associated with loss of CDKN2A and wild type TP53. Taken together these data support evaluation of CDK4 inhibitors in melanoma and suggest that CDKN2A and TP53 maybe genomic predictors of sensitivity.']",
        "Doc_id":"AACR_2013-3416",
        "Doc_title":" Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.",
        "_version_":1606189013606072320},
      {
        "Meeting_name":" Alterations in the cell cycle checkpoint pathway in breast cancer.",
        "Background":"['Background', '    Breast cancer is a molecularly diverse disease with molecular subtypes defined by ER, PR and HER2 status. Dysregulation of the cell cycle pathway through activation of cyclin D1 and/or inactivation of CDKN2A is a mechanism of tumor progression in breast cancer and drugs targeting CDK4/6 is undergoing investigation in this disease with promising preliminary results. We investigated several key genetic alterations in cell cycle regulatory proteins in advanced breast cancer patient samples to identify potential targets for cell cycle related treatment options.  Methods', '    A comprehensive genomic profiling was performed on 37 breast cancer samples with the majority being metastatic. Testing included targeted exome sequencing of 562 genes in tumor and paired normal DNA.  Results', '    Patients ages ranged from 27-66 years. Analysis of cell cycle regulatory genes revealed focal amplification of cyclin D1/D2 or CDKN2A loss in 9/37 (24%) of  cases, of which, 45% were hormone receptor (HR) positive, HER2 negative,  33%  were HR positive, HER2 positive and 22% were triple negative (TNBC) subtype. Loss of RB1 was analyzed since it negatively regulates response to CDK4/6 inhibitors. Loss of RB1 was noted in 4/37 (10.8%) of cases, all of which were TNBCs. Only a single TNBC with RB1 loss had concurrent CDK4 amplification and loss of CDKN2A. No evidence of CCNE1 amplification was found in any samples. Incidence of CDK4 and CDK6 amplification was found in samples with cyclin D1 amplification or CDKN2A loss. Our cohort included a single male TNBC patient who harbored cyclin D1 amplification as well as CDKN2A loss. Overall, amplification of cyclin D1, cyclin D2, CDK4 and CDK6 was found in 16%, 5.4%, 2.7% and 2.7% respectively. Loss of CDKN2A was noted in 5.4% of tumors profiled.  Conclusions', '    Exome sequencing identified subsets of patients with mutated cell cycle associated genes that may benefit from CDK 4/6 inhibitors. Our data suggests loss of RB1 is more frequent in TNBC subtype which may confer resistance to CDK4/6 inhibitors. Our analysis suggests that in addition to HR positive, HER2 negative patients, a subset of HR positive, HER2 positive patients could be sensitive to CDK4/6 inhibitors due to activation of the cell cycle pathway as evidenced by mutations in key genes.']",
        "Doc_id":"ASCO_154996-163",
        "Doc_title":" Alterations in the cell cycle checkpoint pathway in breast cancer.",
        "_version_":1606189018056228864},
      {
        "Meeting_name":" Transcriptome characterization of high grade serous and endometrioid epithelial ovarian cancer tumors",
        "Background":"['Background', ' Little transcriptomic research has compared epithelial ovarian cancer (EOC) histological subtypes. We set out to characterize the transcriptomes of high-grade serous carcinomas (HGSC) and endometrioid carcinomas (EC), which make up around 70% and 20% of EOC tumors, respectively, and have some histopathological similarities.Methods', ' Fresh frozen tumors from EOC patients seen at the Mayo Clinic (30 EC and 62 HGSC) were used. 1ug RNA riboZero was used for library preparation using the Illumina TruSeq kit and sequenced on a HiSeq 2000 machine. Reads were aligned using TopHat2 followed by quantification of abundances using RSEM and differential expression analysis with edgeR. We analyzed transcriptomes, conducted pathway analyses, and summarized key candidate gene sets. Expressed SNVs (eSNVs) from the RNA-seq data were determined using GATK and RVboost.Results', ' The analysis found 699 genes with FDR < 110-5 for differential expression between HGSC and EC, with most genes being up-regulated in EC. The top most associated genes were TPH1, MAP2K6, KLK2, ADAM23, TESC and TRAF3IP2 (p<10-22). Pathway analysis of the genes up-regulated in EC revealed enrichment of the basal cell carcinoma signaling pathway (p = 1.210-5). Within 1 Mb of the 25 known EOC risk loci, we observed higher expression in HGSC for RSPO1 and HPSE (p <510-7). For genes functionally related to EOC, we observed in HGSC up-regulation (*p < 10-5, p<0.003) for FOXM1, CDKN2A, CCNE1*, CCND2, PIK3CA*, BRCA2, BIRC5, MMP9, FANCD2, and MAML2. In contrast, we found up-regulation in EC for MDM2*, KLK4*, BCL2, CCND1*, ANXA4*, CDH1, MMP7, and MAML3. We also identified 204 eSNVs (44 non-synonymous) associated with EC v HGSC subtype (p<10-4); this included an exonic TRAF3IP2 eSNV (66% EC, 13% HGSC, p = 410-7, chr6', '111877117).Discussion', ' Using one of the largest sets of identically processed fresh-frozen EOC tumors, some patterns emerged among the numerous EC v HGSC transcriptomic differences. TPH1, up-expressed in EC, is regulated by SOX4 which was also up-regulated in EC. Two sets of genes related to Kallikreins serine proteases were differentially expressed, including KLK2 which is known to regulate EGFR and pro-inflammatory cytokines and is regulated by MYC. Lastly, TRAF3IP2 encodes for a protein involved in regulating cytokines through members of the NFKB pathway.Conclusions', ' These findings suggest important biological insights into one of the rarer EOC histologies and may aid in the development of targeted treatment options. Research is on-going to incorporate additional features (e.g., DNA methylation, copy number) into a systems biology framework to better understand the molecular differences between EOC histologies.']",
        "Doc_id":"AACR_2016-1833",
        "Doc_title":" Transcriptome characterization of high grade serous and endometrioid epithelial ovarian cancer tumors",
        "_version_":1606189009715855361},
      {
        "Meeting_name":" Use of liquid biopsy for detection of renal cell carcinoma.",
        "Background":"['Background', ' Circulating tumor DNA (ctDNA) displays characteristics of an ideal serum biomarker. We sought to develop whole-exome sequencing of ctDNA to interrogate commonly mutated genes in renal cell carcinoma (RCC) for early tumor detection through a single blood sample. Methods', ' Patients with solid renal tumors and healthy controls provided 40 mL blood from which purified plasma cell-free DNA was prepared. A multiplex bar-coded polymerase chain reaction amplification using the Fluidigm Access Array was performed to prepare sequencing libraries for the Illumina HiSeq platform. Galaxy workflow was then utilized to identify mutations within the plasma cell-free DNA samples and results were compared to buffy coat sequencing containing control DNA for each individuals sample. The following genes were queried', ' VHL, PBRM1, SETD2, BAP1, KDM5C, KIT, NFE2L2, MET, TP53, CDKN2A, FGFR3, PIK3CA, BRAF, and MUC4. Criteria for calling mutations included adequate frequency by overall count and percentage of reads, identification in all overlapping sequences and presence of buffy coat-derived control DNA for comparison with <0.5% containing the mutation. Results', ' Of the preoperative RCC patients, 20/30 (67%) had detectable somatic mutations compared to 2/48 (4.2%) controls. These included nonsynonymous, frameshift, stop-gain, and splice site mutations. Mutations were detected in RCC patients with both early and advanced stage disease, including a patient with a 1.1 x 0.7 x 0.5 cm tumor. Mutations were seen in all genes assayed. Conclusions', ' The majority of RCC patients of various stages and histology had ctDNA detected in a single preoperative blood sample. Comparatively, only two of the control patients sampled were ctDNA positive. Controls will be followed to identify the possible sources of ctDNA. Developing such non-invasive methods for RCC detection has the potential to enhance both diagnosis and surveillance of renal malignancy, even in the setting of small renal masses.']",
        "Doc_id":"ASCO_179515-197",
        "Doc_title":" Use of liquid biopsy for detection of renal cell carcinoma.",
        "_version_":1606188979646889984},
      {
        "Meeting_name":" CDKN2A-deletion to predict relapse in adult B-cell acute lymphoblastic leukemia (B-ALL).",
        "Background":"['Background', '  CDKN2A locus on chromosome 9p21 is implicated in altered molecular pathways leading to leukemogenesis as a tumor suppressor by inhibiting the proliferative kinases CDK4/CDK6 and blocking the cell-cycle division during G1/S phase. Deletion of CDKN2A locus is frequently seen in ALL, although prognostic significance remains unclear.  Methods', '  Retrospective chart review at Mayo Clinic between 8/2005-11/2011 was performed on adult B-ALL patients (pts) who underwent fluorescent in situ hybridization (FISH) studies at diagnosis. Survival estimate was calculated using Kaplan-Meier statistics. Event-free survival (EFS) was defined as time between diagnosis and induction failure, relapse, or death, while overall survival (OS) as time between diagnosis and death  Results', '  Out of 27 pts who had FISH studies for CDKN2A, 15 (56%) pts had CDKN2A deletions (8 homozygous/7 hemizygous), while 12 (44%) pts had diploid cytogenetics (none had abnormalities of MLL, bcr/abl fusion or CDKN2A deletion on FISH). There was no significant difference in median age, gender, WBC, hemoglobin, platelet count, LDH or complete remission (CR) rate (p=0.924) between the two groups. CDKN2A-deleted pts had higher circulating blasts (34% vs 16%, p=0.017). Of 13 CDKN2A-deleted pts, chromosome 9p was intact in 9 (69%) pts using routine cytogenetics. In the CDKN2A-deleted group, allogeneic stem cell transplant (ASCT) was performed in 7 (47%) pts at first CR and 1 at second CR. Four of 15 (27%) CDKN2A-deleted pts also had bcr/abl fusion. Five-year EFS was poorer in CDKN2A-deleted pts compared to normal FISH group (22% vs 60%, p=0.042), while 5-year OS was 72% vs 60% (p=0.308), respectively. Excluding the 4 bcr/abl fusion pts, 5-year EFS was still statistically significant (p=0.008). In the CDKN2A deleted group, both 5-yr EFS (80% vs 0%, p=0.006) and OS (100% vs 42%, p=0.016) were significantly superior in pts who received ASCT.  Conclusions', '  CDKN2A deletions predict earlier relapse in pts with B-ALL. Majority of 9p abnormalities were only found by FISH testing and missed by conventional cytogenetics. In CDKN2A deleted pts, ASCT gave overall survival advantage. Further investigation through larger cohorts of pts is needed to validate these findings.']",
        "Doc_id":"ASCO_101518-114",
        "Doc_title":" CDKN2A-deletion to predict relapse in adult B-cell acute lymphoblastic leukemia (B-ALL).",
        "_version_":1606189040474783744},
      {
        "Meeting_name":" Targeted sequencing of upper tract urothelial carcinoma.",
        "Background":"['Background', '    Regardless of the anatomic location (renal pelvis or ureter (upper tract), bladder or urethra) urothelial carcinoma is considered a single entity.  Outcomes differ depending on site of initial diagnosis.  Moreover, little is known about the comparative biology across primary sites. To define the genomic profile of urothelial carcinoma arising from the upper tract, we used a next generation sequencing technology to analyze 26 sporadic high-grade urothelial tumors of the renal pelvis.  Methods', '    Frozen tumor samples and matched germline blood or normal kidney DNA from 26 nephroureterectomy specimens were obtained under an IRB-approved protocol.  DNA was analyzed using a next generation, targeted sequencing assay.  We compared these tumors to a set of 108 bladder tumors.  Fishers exact test analyzed associations with pathological stage and Cox regression with log-rank p-values examined associations with bladder recurrence and disease-free survival. Fishers exact test was used to compare mutation frequencies between upper tract and bladder tumors. P-values were adjusted for multiple comparisons using the Benjamini-Hochberg method. Results', '    Surgical pathology was Ta, T1, T2 and T3 in 7 (26.9%), 5 (19.2%), 4 (15.4%) and 10 (38.5%) patients, respectively.  High-grade disease was found in 24 (92.3%) patients with 6 (27.3%) patients having node positive disease.  The most frequently altered genes included FGFR3 (42.3%), KDM6A (38.5%), MLL2 (26.9%), TSC1 (26.9%), CREBBP (23.1%), CDKN2A (19.2%) and HRAS (19.2%).  No significant differences in tumor and patient characteristics were found between the bladder and upper tract cohorts.  A significant difference in the frequency of alterations between the upper tract and bladder cohorts was found in HRAS (19.2% vs 2.8%, p=0.032), TP53 (7.7% vs 57.4%, p<0.001) and TSC1(26.9% vs 5.6%, p=0.024).  Conclusions', '    We identified unique patterns of genomic alterations within upper tract urothelial carcinoma compared to bladder cancers.  Upper tract tumors are characterized by a higher frequency of activating FGFR3 and HRAS mutations, TSC1 nonsense mutations, and a lower frequency of TP53 alterations.  These findings may have future implications on the utility of targeted therapies in this disease subtype.']",
        "Doc_id":"ASCO_124397-142",
        "Doc_title":" Targeted sequencing of upper tract urothelial carcinoma.",
        "_version_":1606189008311812096},
      {
        "Meeting_name":" A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations.",
        "Background":"['Background', '  A variety of targetable driver mutations other than EGFR mutations and ALKfusions occur in 1%-2% of NSCLCs. Efficient screening systems for these rare mutations are necessary for the successful development of targeted therapies.  Methods', '  In February 2013, a new nationwide genomic screening system (LC-SCRUM-Japan) was established in Japan to screen advanced non-squamous NSCLCs without EGFR mutations for primarily ALK/RET/ROS1fusions. In November 2013, this system was amended to further screen for other driver mutations in fusion-negative cancers after the primary screening. Ten nanograms of genomic DNA extracted from biopsy or cytology specimens were subjected to the Ion Torrent AmpliSeq Cancer Hotspot Panel, version 2, and Ion Torrent next-generation sequencing, enabling the simultaneous analysis of 2800 hotspot mutations in 50 cancer-related genes.  Results', '  As of January 31, 2014, a total of 158 institutions were participating and 507 patients were enrolled in LC-SCRUM-Japan. Among the 148 cases that were enrolled after the protocol amendment, ALK/RET/ROS1 fusions were detected in 1 (1%)/7 (5%)/8 (5%) cases, respectively, and 107 cases without fusions were transferred to the multiplex mutation screening. In the mutation screening, a total of 121 mutations were detected in 79 cases (74%), including 46 mutations in driver oncogenes in a mutually exclusive manner (23 KRAS mutations [21%], 7 BRAF mutations [7%], 5 ERBB2 mutations [5%], 2 PIK3CA mutations [2%] and 1 NRAS mutation [1%]). In addition, 43 TP53 mutations, 5 CDKN2A mutations, 4 MLH1 mutations, 2 PTEN mutations, 1 IDH1 mutation, 1 IDH2 mutation, 1 FBWX7 mutation, 1 SMAD4 mutation and 1 STK11 mutation were detected. Among them, a case with a BRAF V600E mutation was enrolled in a global phase II study of a BRAF inhibitor, dabrafenib (NCT01336634).  Conclusions', '  This screening system enabled rare fusions and mutations in driver oncogenes, especially RET, ROS1, KRAS, BRAF and ERBB2, to be detected precisely and more frequently in limited amounts of samples from advanced NSCLCs, thereby contributing to the enrollment of patients in clinical trials for targeted therapies.']",
        "Doc_id":"ASCO_130137-144",
        "Doc_title":" A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations.",
        "_version_":1606188971634720768},
      {
        "Meeting_name":" Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).",
        "Background":"['Background', '  ASCOP represents a rare subtype (1-4%) of exocrine pancreatic cancer for which the clinical and molecular features are not well defined. We reviewed clinical characteristics and performed comprehensive molecular profiling in a cohort of patients with ASCOP treated at MSKCC. Methods', '  Patients (pts) with ASCOP diagnosed from January 2000-July 2015 were identified from a prospectively maintained database, following IRB approval. Clinicopathological data including time to progression (TTP), recurrence-free interval (RFI) and overall survival (OS) were recorded. Samples were reviewed by a pancreas pathologist to optimally select the squamous component for molecular profiling using MSK-IMPACT platform. This is a hybridization capture based next generation sequencing assay for targeted deep sequencing of all exons and selected introns of 410 key cancer genes. Tumor and matched normal libraries (where available; n=9) were sequenced on an Illumina HiSeq 2500. Sequencing output was processed using a custom analysis pipeline to detect single nucleotide variants, short indels, copy number aberrations and structural rearrangements.  Results', '  We identified 84 pts with ASCOP of whom 15 had sufficient tissue/consent for analysis. Median OS for resected pts was 17 months (mo) and 6 mo respectively. Median PFS on 1st line therapy (FLT) for stage IV disease was 3 mo. 53 pts underwent surgical resection, of whom 11 remain disease free at median follow up of 24 mo. 15/15 (100%) had KRAS mutations (mut). 11/15 (73%) had TP53 mut. 6/15 (40%) had SMAD4 mut [4 point mutations (PM), 2 frameshift deletions]. 6/15 (40%) had CDKN2A mut (4 deletions, 2 PM). Mut were also found in FAT 1 (3/15), JAK3 3 (3/15), TBX 3 (2/15) and FGFR amplification was found in 1 pt sample.   Conclusions', '  ASCOP like conventional ductal adenocarcinoma has a poor prognosis with a comparable molecular signature in the most common alterations.  Potential targets e.g., FGFR1 may allow novel agents in select pts.   Demographics.ASCOP n=84Median age (yrs)65 (21-88)Gender_Male51 (61%)Female33 (39%)Location_Head47 (56%)Body/Tail37 (44%)Smoker_Never39 (46%)Ever45 (54%)Stage_I4II48III7IV25RFI post-surgery months4 (1-53)FLT_Gemcitabine-based285FU-based16']",
        "Doc_id":"ASCO_159883-173",
        "Doc_title":" Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).",
        "_version_":1606188986974339072},
      {
        "Meeting_name":" A comprehensive system of congenic mouse melanoma models for evaluation of immune therapies",
        "Background":"['There has been longstanding interest in the relationship between the immune system and malignant melanoma, the deadliest form of skin cancer. Melanoma has been the tumor of choice for the evaluation of a wide variety of therapeutic approaches that rely on stimulation of the immune system to combat cancer. The striking responses to immune checkpoint inhibitors noted in some melanoma patients have now been observed in several other malignancies, including renal cell carcinoma, lung cancer, and prostate cancer. These findings are very encouraging, however the specific mechanisms of response and reasons why only a subset of patients respond to therapy are not known. The extraordinary potential of immune therapies in cancer suggests that human-relevant mouse models of cancer are required to understand mechanisms of response and to optimize therapy so that a larger proportion of patients respond.We have generated and evaluated a series of genetically engineered mouse models driven by alterations in Braf, Pten, Cdkn2a, beta catenin, p53, and Nras that reflect the genetic diversity of the vast majority of human melanoma. We have backcrossed 6 of these models to C57Bl/6, generated tumors, and isolated a series of over 20 congenic mouse melanoma cell lines. Several independent lines have been isolated for each melanoma genotype generated. Injection of these lines into C57Bl/6J mice results in reproducible tumor formation in the absence of co-injection of Matrigel. We are in the process of characterizing the tumor microenvironment in each of the models using flow cytometry and a novel quantitative imaging approach of histological sections, which produces flow cytometry-like data, but retains spatial and morphologic information that can be utilized to characterize much smaller tumors. This series of congenic lines represents an ideal set of models for the study of cancer immunology and responses to immune therapies.']",
        "Doc_id":"AACR_2015-5141",
        "Doc_title":" A comprehensive system of congenic mouse melanoma models for evaluation of immune therapies",
        "_version_":1606188976206512128},
      {
        "Meeting_name":" Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.",
        "Background":"['Background', ' To date, only limited data are available on genomic alterations present in metastatic lesions of patients with metastatic urothelial carcinoma (mUC). The constant release of cell free DNA (cfDNA) from tumor cells into the peripheral blood stream may provide a valuable source for detection of cancer associated somatic copy number variations and mutations. The aim of this project was to evaluate the feasibility of detecting clinically relevant genomic alterations in mUC by next-generation sequencing (NGS) of circulating cfDNA. Methods', ' Peripheral blood (20ml) was collected from 15 patients with mUC before chemotherapy. Plasma cfDNA was isolated using the QIAAmp Circulating Nucleic Acid Kit. Germline control DNA was extracted from peripheral blood mononuclear cells (PBMCs) using the DNEasy Kit (Qiagen). We performed deep (>500X) targeted DNA sequencing on cfDNA and germline DNA using a custom NimbleGen SeqCap EZ Choice Library and Illumina sequencers. Our custom panel included 50 bladder cancer-relevant genes, including key tumor suppressors (e.g. TP53, RB1, CDKN2A), cell cycle drivers (e.g. CCND1, CCNE1), DNA repair genes (e.g. ATM, BAP1, ERCC2), PI3K pathway genes (e.g. PIK3CA, PTEN, AKT1), and other oncogenic pathways (e.g. RAS/RAF, EGFR, ERBB2, PPARG, FGFR3). Results', ' Somatic mutations and/or copy number changes were detected in 14/15 samples, with a median variant allele frequency >5%. The overall mutational landscape was highly consistent with bladder cancer, including mutations in TP53 and ARID1A (and other chromatin modifiers), as well as hotspot activating mutations in PIK3CA. Typical copy number changes, including focal amplifications of ERBB2, KRAS, and CCNE1 were detected. We identified complex gene rearrangements, including an activating FGFR3 fusion in one case. Extended analyses with a larger patient population are currently pending. Conclusions', ' Non-invasive characterization of genomic changes in peripheral blood of patients with mUC using NGS of plasma cfDNA is feasible in a high proportion of patients. Analysis of cfDNA might therefore provide an improved understanding of genomic changes in mUC and could be developed as a biomarker to help guide the use of targeted therapies.']",
        "Doc_id":"ASCO_179431-197",
        "Doc_title":" Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.",
        "_version_":1606188988563980288},
      {
        "Meeting_name":" Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets",
        "Background":"['Lung neuroendocrine tumors (LNETs) comprise small-cell lung cancer (SCLC), large-cell neuroendocrine tumors (LCNEC), and pulmonary carcinoids (PCA), and account for 25% of all lung cancer cases. The low 5-year survival rate of the highly aggressive LNETs (SCLC and LCNEC) combined with the lack of an effective treatment, suggest that understanding how these tumors arise and identifying therapeutic targets are unmet needs. We performed genome/exome, and transcriptome sequencing of 29 SCLC (Ref.1), 60 LCNEC, and 45 PCA to better understand their molecular origin and identify altered genes that may offer therapeutic opportunities.In contrast to SCLC and LCNEC, we found that RB1 and TP53 mutations were rare events in PCA suggesting that PCA are not early progenitor lesions of SCLC or LCNEC, but arise through independent mechanisms. Moreover, GSEA analysis showed that genes of the RB1 pathway were downregulated in SCLC but not in PCA. Our data also show that inactivation of chromatin-remodeling genes, specifically genes involved in histone methylation and subunits of the SWI/SNF complex, is sufficient to drive transformation in PCA.In a preliminary analysis of 15 LCNEC (Ref.2) we observed a predominance of mutations typical of SCLC, such as RB1, TP53, and CREBBP/EP300. In this larger series, we additionally found samples with mutations frequent in adenocarcinoma (AD) or squamous (SQ) lung cancer. We could then distinguish two well-defined groups of LCNEC', ' a SCLC-like group, carrying MYCL1 amplifications and mutations in both RB1 and TP53 genes; and an AD/SQ-like group, harbouring CDKN2A deletions, TTF1 amplifications, and frequent mutations in KEAP1 and STK11. Interestingly, RB1, STK11, and KEAP1 mutations happened in an almost mutually exclusive way. These data suggest that LCNEC might represent an evolutionary trunk that can branch to SCLC or AD/SQ, and also that LNETs and non-LNETs are not completely different entities. This is already suggested by the fact that one of the resistance mechanisms of EGFR-mutant adenocarcinomas to tyrosine-kinase inhibitors is through trans-differentiation to SCLC (Ref.3).Finally, we also identified new targetable driver genes in SCLC and LCNEC', ' FGFR1 amplifications were observed in 6% and 18% of the cases respectively; PTEN mutations were identified in 10% of the SCLC cases; and interestingly, one of the LCNEC samples (belonging to the SCLC-like group) harboured an activating RFWD2-NTRK1 fusion gene suggesting that fusions affecting NTRK1 may not only be a targetable opportunity for AD (Ref.4) but also for LCNEC and, based on the molecular similarities, also SCLC.(1) Peifer and Fernandez-Cuesta et al. Nat Genetics 2012(2) The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) Sci Transl Med 2013(3) Sequist et al., Sci Transl Med 2011(4) Vaishnavi et al. Nat Medicine 2013']",
        "Doc_id":"AACR_2014-1531",
        "Doc_title":" Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets",
        "_version_":1606189010835734528},
      {
        "Meeting_name":" Next generation sequencing for discovery of somatic mutations and clonal relationships in platinum-resistant metastatic urothelial cancer",
        "Background":"['Background', ' Beyond first-line platinum based chemotherapy, there are currently no FDA-approved therapies for advanced platinum-resistant urothelial carcinoma (PRUC). Our objective was to generate the first detailed genomic profile of metastatic PRUC to identify molecular changes critical to the development of platinum-resistance and metastasis. Methods', ' Following informed consent, we collected 50 urothelial tumor samples, from 23 patients consented through our precision medicine protocol. Metastatic tumor samples were obtained from metastatic biopsies or surgical metastatectomy. Germline samples were prospectively collected for every patient and matched archival formalin-fixed paraffin-embedded primary tumors from the same patients were retrieved. Our cohort comprises 23 metastatic samples, 37 platinum resistant urothelial samples and 18 trios of matched primary, metastatic and germline samples including two rapid autopsy cases that yielded tumor samples from multiple primary and metastatic sites. We performed whole exome sequencing of all tumor and germline samples and RNA sequencing on 18 advanced PRUC tumors. We utilized our in-house computational pipeline for integrated analysis of somatic single nucleotide variants and somatic copy-number alterations and to analyze the clonal evolution of the primary and metastatic in each patient. We utilized the DAVID bioinformatic tool for pathway analysis. Results', ' Advanced PRUC samples were enriched for several molecular alterations, we identified 414 recurrently mutated genes (defined as genes mutated in 2 or more samples and having the highest number of mutations per nucleotide) including common genes such as TP53(45%) as well as actionable alterations in PIK3CA(11%) and TSC1(19%). Frequent copy number alterations included CDKN2A deletions (33%), E2F3(10%) and ERBB2(7%) amplifications. Pathway analysis showed an enrichment of mutations in genes involved in controlling apoptosis (p = 1.0E-7, FDR 1.7E-4) and cell cycle regulation (P = 1.6E-2, FDR 2.3E1) compared to the TCGA dataset of untreated urothelial carcinoma primary tumors.We reconstructed phylogenetic trees from matched primary, metastatic and germline trios revealing evidence of divergent clonal evolution between primary tumors, lymph node and visceral metastases. In some cases, shared mutations occurred with gradually increasing variant allele frequencies across primary tumors, lymph node metastasis and visceral metastases respectively, indicating clonal selection of mutations that were present in the primary tumor. We also identified unique acquired mutations in metastatic lesions that were not present in primary tumors. Conclusions', ' This study generates a detailed molecular profile of the genomic landscape of PRUC revealing evidence of extensive heterogeneity and clonal selection underlying platinum-resistance and metastatic spread.']",
        "Doc_id":"AACR_2015-3880",
        "Doc_title":" Next generation sequencing for discovery of somatic mutations and clonal relationships in platinum-resistant metastatic urothelial cancer",
        "_version_":1606189015817519104},
      {
        "Meeting_name":" Antitumor activity of CDK4/6 inhibition in combination with radiation therapy on glioblastoma stem cells",
        "Background":"['Almost 80% of glioblastoma tumors have alterations in the CNKN2A-CDK-Rb pathway. Cyclin dependent kinases 4 and 6 (CDK4/6) act as cell cycle regulators and have been recognized as therapeutic targets for glioblastoma (GBM). In the current study, we determined the antitumor activity of CDK4/6 inhibition (palbociclib and abemaciclib) alone and in combination with radiation on a panel of glioblastoma stem cells (GSCs). The GSCs were molecularly characterized using multiple omimcs techniques and Western blots identified specific phospho- and total protein levels. Approximately 50% of cell lines have homozygous deletion of CDKN2A although CDK4 and CDK6 protein expression was significantly elevated in most of the GSCs. RB protein was constitutively phosphorylated in only a subset (45%)', ' GSC11, GSC262, GSC231, GSC304 and GSC7-2. In our panel of GSCs, there were total of three cell lines with CDKN2A loss, RB phosphorylation and CDK4/6 overexpression (GSC262, GSC11 and GSC231). Our data showed that GSC262, GSC11, GSC231 (CDKN2A deletion, RB intact), GSC7-2 and GSC300 (CDKN2A WT, RB intact) were sensitive to CDK4/6 treatment (IC50  1M). CDK4/6 inhibitor treated GSCs showed G1 cell cycle arrest and decreased phospho-RB levels in GSC262 and GSC7-2 cells. We next determined whether CDK4/6 inhibition combined with radiation has additive or synergistic antitumor effect. A clonogenic assay demonstrated that neurosphere formation was significantly decreased by CDK4/6 inhibition in combination with radiation compared to either treatment in GSC262 (resistant to radiation treatment) or GSC7-2 (sensitive to radiation treatment) cell lines. The radiation resistant GSC (GSC262) treated with radiation and CDK4/6 inhibitor became sensitive to radiation therapy whereas radiation sensitive GSC (GSC7-2) had a significant decrease in colony formation compared to radiation alone. CDK4/6 combined with radiation increased -H2AX protein expression levels and decreased cyclin D1 protein expression in a time dependent manner compared to single drug treatment. These data indicate synergistic antitumor effects of CDK4/6 inhibition combined with radiation therapy in GSCs in vitro. Further investigation is ongoing to evaluate this combination therapy.']",
        "Doc_id":"AACR_2016-2815",
        "Doc_title":" Antitumor activity of CDK4/6 inhibition in combination with radiation therapy on glioblastoma stem cells",
        "_version_":1606188975430565888},
      {
        "Meeting_name":" Development of a noninvasive and sensitive urine screening test for liver cancer targeting circulation-derived cancer DNA biomarkers",
        "Background":"['Hepatocellular carcinoma (HCC), or liver cancer, is an aggressive disease and is regarded as one of the fastest growing cancers in the United States in incidence. The 5-year survival rate of HCC patients drops dramatically from a poor 26%, in early-stage cancer, to a mere 2% in late stages of this disease. The only available early detection biomarker is serum alpha-fetoprotein, which can detect only 40-60% of cases. Our goal is to develop a screening test for early detection of liver cancer, in order to meet this urgent need for new and better biomarkers for HCC. Cancer is a disease of the genome and epigenome, and if we can detect these underlying genetic mutations and epigenetic modifications in the periphery, we can effectively detect cancer early. Hence, we chose a panel of both HCC-associated genetic and DNA methylation biomarkers. We have previously shown that urine contains fragmented cell-free DNA derived from the circulation and that we can detect cancer-related DNA, both mutated and methylated DNA, in the urine of such patients. We have also demonstrated that the concentration of tumor-derived DNA in plasma and in urine is similar in patients with tumors. In order to demonstrate the feasibility of detecting HCC DNA biomarkers in the circulation derived urine DNA, we have developed short amplicon (50 bp) PCR-based assays targeting HCC-specific mutations in TP53 and CTNNB1 genes and HCC-specific methylation in GSTP1, RASSF1A and CDKN2A genes. Urine DNA isolated from samples of hepatitis, cirrhosis, and HCC patients were tested in each of the assays and analyzed for individual marker and panel performance. The performance of the markers and our approach towards the development of a targeted next generation urine DNA based HCC screening test is discussed.']",
        "Doc_id":"AACR_2015-1569",
        "Doc_title":" Development of a noninvasive and sensitive urine screening test for liver cancer targeting circulation-derived cancer DNA biomarkers",
        "_version_":1606189005956710400},
      {
        "Meeting_name":" Development of a urine DNA based marker panel for early detection of liver cancer",
        "Background":"['Hepatocellular carcinoma (HCC) or liver cancer is an aggressive disease and one of the fastest growing cancers in incidence in the United States. The 5 year survival rate drops dramatically from a poor 26% in early stages to a mere 2% in later stages of the disease. Currently, the only available biomarker for early detection is serum alpha-fetoprotein which can identify only 40-60% of cases. We aim to improve the poor disease prognosis by developing a screening test capable of detecting liver cancer in its earlier stages. Since cancer is a disease of the genome and epigenome, if we can detect these underlying genetic mutations and epigenetic modifications in the periphery, we should be able to effectively detect cancer early. We have previously shown that urine contains fragmented, cell-free, cancer related DNA, both mutated and methylated, derived from the circulation of cancer patients. We have also demonstrated that the concentration of tumor-derived DNA in plasma and in urine is similar in patients with tumors. Hence, we propose the use of a panel of HCC-associated genetic and epigenetic methylation DNA biomarkers to develop a sensitive, noninvasive urine screening test for HCC. In order to detect these markers in the circulation derived urine DNA, we developed short amplicon (50 bp) PCR based assays targeting HCC-associated mutations in TP53, CTNNB1, hTERT genes and HCC associated methylation in GSTP1, RASSF1A and CDKN2A. Urine DNA isolated from hepatitis, cirrhosis and HCC patients were tested in each of the assays and analyzed. Panel performance parameters such as sensitivity, specificity and area under the receiver operating curve were calculated for individual markers and then as a group in order to evaluate their ability to distinguish HCC patients from hepatitis and cirrhosis subjects. The potential of this urine test in the early detection of HCC is discussed.']",
        "Doc_id":"AACR_2014-888",
        "Doc_title":" Development of a urine DNA based marker panel for early detection of liver cancer",
        "_version_":1606189008568713216},
      {
        "Meeting_name":" Identification of inactivating mutations in stepwise hepatocarcinogenesis using next generation sequencer",
        "Background":"['Early hepatocellular carcinoma (HCC) is histologically diagnosed as the existence of intratumoral portal tracts with stromal invasion. It consists of small hepatocytes with little cellular atypia but with structural atypia. This type of very well-differentiated cancerous tissue is usually characterized by indistinct margins and many portal tracts within the tumor, and develops into classical HCC. To identify sequential genomic changes in stepwise hepatocarcinogenesis, we analyzed fusion genes and mutations using next generation sequencer about 43 early and 105 advanced HCCs. First, exome sequence showed that base sequence aberrations (non-silent) were more frequent in advanced HCC than early HCC (70.9  29.0 vs 53.7  23.8 genes per tumor, P = 0.0002). Mutations in p53/RB pathway including TP53, ATM, RB1, CDKN2A, and CDKN1A were observed in 27.9% and 38.1% in early and advanced HCCs, respectively (P = 0.161) and those of WNT/b-catenin pathways consisting of CTNNB1, AXIN1, and APC were recurrently observed in both early and advanced HCCs (27.9% vs 41.0%, P = 0.095). On the other hand, mutations in SWI/SNF complex genes were more frequently observed in advanced HCC (35.2%) than early HCC (16.3%, P = 0.016). Especially, inactivating mutation of ARID was found in 16 advanced HCCs (15.2%) while only 1 case in early HCC (2.3%, P = 0.018). Consistent with our previous report homozygous deletions near CSMD1 and CDKN2A were also found in 8 and 5 cases, respectively, only in advanced HCC. Next, we detected 4 types of fusion gene, including interchromosomal (translocation), intrachromosomal (deletion), intrachromosomal (translocation), and inversion by RNA sequencing. We also found that every HCC harbored 2 to 5 fusion genes, which were more frequent in advanced than earlyHCC, although there were no recurrent rearrangements in neither advanced nor early HCCs. Especially chromathripsis, in which 10 to 100 rearrangements were localized in the specific genomic regions and genomic features imply chromosome breaks occur in one-off crisis, was the event observed only in advanced HCC. Taken together, genomic changes were more frequent in advanced HCC, and inactivating mutations of p53/RB and WNT/b-catenin signaling pathways are the driver mutation in the initiation of hepatocarcinogenesis and that of ARID2 may play pivotal roles in the progression from early to advanced HCC.']",
        "Doc_id":"AACR_2014-5167",
        "Doc_title":" Identification of inactivating mutations in stepwise hepatocarcinogenesis using next generation sequencer",
        "_version_":1606189034059595776},
      {
        "Meeting_name":" Impact of human papillomavirus (HPV) E6/E7 gene silencing on the expression of biomarkers that distinguish HPV+ versus HPV16- head and neck squamous cell carcinomas (HNSCC).",
        "Background":"['Background', ' Three studies (Pyeon et al, Slebos et al, and Schlecht et al) have identified biomarkers that distinguish HPV+ versus HPV- HNSCC using cDNA microarrays. We sought to determine whether the identified biomarker differences are a direct consequence of HPV16 E6 andE7 oncogene expression. Methods', ' We selected genes that were found to have altered expression in HPV16+ HNSCC compared to HPV16-. Short hairpin RNAs targeting HPV type 16 E6 and E7 genes were delivered by retrovirus infection to HPV16+ oropharyngeal cancer cell lines 147T and 090. cDNA microarray analysis was performed (slides represented approximately 35000 genes) to determine the transcriptional profile before and after E6/E7 silencing. Results', ' E6/E7 gene silencing affected the expression of the following genes', ' RFC4, CDKN2A, MCM6, NASP, EP300, E2F2, PCNA, KLK6, ANGPT1, DNAJCI, PRKCG (Table). Conclusions', ' Expression of several biomarkers that distinguish HPV16+ from HPV16- HNSCC is regulated by E6/E7 gene expression. Targeting E6/E7 will be an effective therapeutic strategy in HPV16+ HNSCC since alteration of key molecules that increase the malignant potential of these tumors is controlled by E6/E7 expression. HUGO ID DescriptionFold Change 147TFold Change 090 RFC4Replication factor C (activator 1)-1.36-2.51 CDKN2ACyclin-dependent kinase inhibitor 2A (p16INK4A)-1.3-1.25 MCM6Minichromosome maintenance deficient 6-1.32-1.23 NASPNuclear autoantigenic sperm protein (histone-binding)-1.24-1.31 EP300E1A binding protein p300-1.32-1.25 E2F2E2F transcription factor 2-1.69-1.97 PCNAProliferating cell nuclear antigen-1.42-1.47 KLK6Kallikrein 6 (neurosin, zyme); human protease M+1.66+1.4 ANGPT1Angiopoietin 1+1.37+1.42 DNAJC1DnaJ (Hsp40) homologue, subfamily C, member 1+1.69+1.46 PRKCGProtein kinase C, gamma+1.3+1.35']",
        "Doc_id":"ASCO_32701-65",
        "Doc_title":" Impact of human papillomavirus (HPV) E6/E7 gene silencing on the expression of biomarkers that distinguish HPV+ versus HPV16- head and neck squamous cell carcinomas (HNSCC).",
        "_version_":1606188997018648576},
      {
        "Meeting_name":" Comparison of pathology versus IHC-based ovarian carcinoma histology assignment using gene expression, DNA methylation, and clinical outcome data",
        "Background":"['Background', ' Epithelial ovarian cancer (EOC) is composed of five major histologic types', ' 1) high-grade serous carcinoma (HGSC), accounting for most cases (70%); and the rarer 2) clear cell, 3) endometrioid, 4) mucinous, and 5) low- grade serous carcinoma (LGSC). As EOC risk factors are histology specific, as are the site of precursor lesions, accurate subtyping is critical to understanding EOC prognostic factors and etiology. Our aim was to compare two currently employed histology assignment strategies using gene expression, DNA methylation, and clinical outcome data Methods', ' Histology assignment based on', \" a) pathologist, and b) an integrated pathologist and IHC prediction algorithm (pathIHC) (using ARID1A, CDKN2A, DKK1, HNF1B, MDM2, PGR, TP53, TFF3, VIM, and WT1 staining patterns), was compared for tumors of all histologies at the Mayo Clinic, Rochester. The 500 most variable probes from Illumina Methylation450 BeadChips (N = 259) and Agilent 444K expression arrays (N = 245) were used to perform unsupervised hierarchical clustering. Fisher's Exact test was used to test the association of clusters with histology. Cox proportional hazards regression analysis was used to test the association of clusters and histology with time to progression (TTP) and time to death (TTD).Results\", ' Eighty-two percent of tumors were concordant between histology assignment strategies. Clustering based on methylation data produced two distinct clusters. PathIHC produced more homogenous clusters (p-value = 2.810-16) than pathology alone (p = 1.310-9). Cluster M1, characterized by high levels of methylation across almost all probes, was enriched for the rarer EOC subtypes; cluster M2, characterized by moderate levels of methylation across 50%-75% of probes, was predominantly HGSC. These patterns were observed irrespective of histology assignment strategy; however, when using histology by pathologist, cluster M2 had more endometrioid and LGSC tumors interspersed with HGSC tumors. Clustering based on expression data also produced two clusters. PathIHC produced slightly more homogenous clusters (p = 9.010-11, pathology alone, p = 2.310-10). Cluster E1 was enriched for the rarer EOC subtypes; cluster E2 was primarily serous lineage tumours (HGSC and LGSC), particularly when using histology by pathIHC. Considering only clinical outcomes, histologies by pathology were more significantly different in terms of TTP (p = 1.110-6) and TTD (p = 1.710-3) than histologies by pathIHC (TTP, p = 5.410-6; TTD, p = 5.710-3).Conclusions', ' Histology by pathIHC produced more homogeneous clusters in both the methylation and expression data; thus, molecular data supports this strategy. Differences in clinical outcomes (TTP and TTD) between histology groups were more pronounced when using assignment by pathologist; thus, clinical data supports this strategy.']",
        "Doc_id":"AACR_2015-4246",
        "Doc_title":" Comparison of pathology versus IHC-based ovarian carcinoma histology assignment using gene expression, DNA methylation, and clinical outcome data",
        "_version_":1606188978874089472},
      {
        "Meeting_name":" Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load.",
        "Background":"['Background', ' Upper tract urothelial carcinoma (UTUC) is generally thought to have a more aggressive clinical phenotype as compared to urothelial carcinoma of the bladder (UCB). We interrogated genomic differences between these entities. Methods', ' DNA was extracted from 40 microns of FFPE sections from 295 and 195 consecutive patients with UCB and UTUC, respectively. Comprehensive genomic profiling (CGP) was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 627X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. The CGP assay included base substitutions (SUB), INDELs, copy number alterations (CNA) and fusions/rearrangements. Genomic alterations (GAs) linked to drugs on the market or under evaluation in mechanism driven clinical trials were considered clinically relevant GAs (CRGAs). A 2-sided Z-test for comparison of population proportions was used to juxtapose the frequency of GAs and CRGAs in UTUC and UCB. Results', ' There were 70% male and 30% female patients with a mean age of 66 years. Although both UCB and UTUC harbored a similar number of GAs/sample (6.4 for both), CRGAs were slightly more common with UCB (2.6 vs 2.0). The most frequent GA was in TP53, and this was more common in UCB (56% vs 46%, P = 0.03). In contrast, the next most frequent GA (CDKN2A) was more common in UTUC (43% vs 34%, P = 0.047). Amongst CRGAs, differences in FGFR3 alteration approached statistical significance, with a higher frequency in UTUC (28% vs 21%, P = 0.08). A borderline increase in frequency of ERBB2 alterations in UCB was also seen (17% vs 11%, P = 0.07). Mutational load was higher in UCB as compared to UTUC (6.6 GAs/MB vs 5.5 GAs/MB). Conclusions', ' These results highlight key differences in the frequency of GAs present in UTUC and UCB. In addition to explaining the clinical phenotype of these disease, they may inform ongoing and future trials of targeted therapy in this population.']",
        "Doc_id":"ASCO_165623-176",
        "Doc_title":" Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load.",
        "_version_":1606188999586611200},
      {
        "Meeting_name":" Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.",
        "Background":"['Background', ' Large scale genomic sequencing studies in RCC (e.g., TCGA) have classically focused on localized disease, which is often curable. Advanced RCC represents a unique disease setting in which novel therapeutic targets may have a clinical impact.  Methods', '  CGP for genomic alterations (GAs) was performed prospectively in 443 consecutive patients with advanced RCC (relapsed RCC or metastatic RCC at presentation).  DNA was extracted from 40 microns of FFPE sections. CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 646X for 3,230 exons of 182 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer (Frampton et al, Nat Biotechnol 2013). The CGP assay included base substitutions, INDELs, copy number alterations and fusions/rearrangements. Clinically relevant genomic alterations (CRGAs) were defined as alterations for which a selective inhibitor of the target or pathway is available.  Results', '  There were 73% male and 27% female patients with a mean age of 56 years. 198 (44.6%) of the sequenced RCC cases were derived from metastatic sites. 400 patients (89%) had at least 1 GA with a mean 3.1 GA/case. Of the 400 RCC harboring GA, 396 (99%) had at least 1 CRGA involving 111 individual genes with a mean of 1.32 CRGAs/RCC case. The most common CRGA in order of frequency were', ' ATM (11%), PTEN (8.5%), TSC1(8.3%), mTOR (7%), MET (6.5%), AR (5.3%), DNMT3A (5%) and TSC2 (5%). Other GAs such the ones with prognostic value in RCC included CDKN2A (21%) and BAP1 (12%). Collecting duct carcinomas (CDCs) harbored an enrichment of NF2 truncating alterations (>40%), distinct from renal medullary carcinoma (RMC). Multiple CDC cases harbored SMARCB1 alterations suggesting these cases could be construed as RMC if a genomic criterion of SMARCB1loss of function is used for diagnosis.   Conclusions', '  CGP can uncover a wide variety of CRGAs in advanced RCC with the potential to direct use of targeted therapies based on the tumor genotype. CGP can also refine the diagnosis of renal epithelial neoplasms.']",
        "Doc_id":"ASCO_149585-156",
        "Doc_title":" Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.",
        "_version_":1606188980695465984},
      {
        "Meeting_name":" Genome-wide analysis of stepwise hepatocarcinogenesis using next generation sequencer.",
        "Background":"['Early hepatocellular carcinoma (HCC) originates from the hepatocytes of chronic liver disease and develops into classical HCC. To identify sequential genomic changes in multistep hepatocarcinogenesis, we analyzed fusion genes and mutations using next generation sequencer about 40 early and 80 advanced HCCs. First, exome sequence showed that base sequence aberrations were more frequent in advanced HCC than early HCC, and mutations including TP53 (24%), CTNNB1 (24%), and ARID1A (16%) were recurrently observed in both early and advanced HCCs. Consistent with our previous report homozygous deletions near CSMD1 and CDKN2A were also found in 8 and 5 cases, respectively, only in advanced HCC. Next, we detected 4 types of fusion gene, including interchromosomal (translocation), intrachromosomal (deletion), intrachromosomal (translocation), and inversion by RNA sequencing. We also found that every HCC harbored 2 to 5 fusion genes, which were more frequent in advanced than early HCC, although there were no recurrent rearrangements in neither advanced nor early HCCs. Especially chromathripsis, in which 10 to 100 rearrangements were localized in the specific genomic regions and genomic features imply chromosome breaks occur in one-off crisis, was the event observed only in advanced HCC. Taken together, genomic changes were more frequent in advanced HCC, suggesting early HCC originates in the chronic liver disease and progresses into advanced HCC with genomic aberrations.']",
        "Doc_id":"AACR_2013-4020",
        "Doc_title":" Genome-wide analysis of stepwise hepatocarcinogenesis using next generation sequencer.",
        "_version_":1606189031688765440},
      {
        "Meeting_name":" CDKN2B loss promotes progression from benign melanocytic nevus to melanoma",
        "Background":"['The CDKN2A locus on chromosome 9p21 encodes two tumor suppressors', ' the cyclin dependent kinase inhibitor p16INK4a and the MDM2 regulator p14ARF. Homozygous deletion of this locus is among the most common genetic events in human cancer across tissues, with the resultant selective advantage to cancer cells generally attributed to the loss of CDKN2A proteins, which help maintain functional Rb and p53. However, in greater than 90% of cancer tissues harboring CDKN2A deletion, the adjacent CDKN2B gene encoding the p15 cyclin dependent kinase inhibitor, is also deleted. The degree to which CDKN2B-encoded p15 loss contributes to human tumorigenesis is unclear. Here we show that CDKN2B is highly upregulated in common, benign melanocytic nevi (moles) expressing the constitutively active BRAF(V600E) oncogene. A large percentage of melanomas develop in continuity with these pre-existing nevi, suggesting that nevus melanocytes are not permanently senescent, and can serve as tumor-initiating cells upon acquisition of additional genetic changes. By examining primary melanocytes isolated directly from freshly excised benign human nevi, as well as normal primary melanocytes engineered to inducibly express BRAF(V600E), we link BRAF activation to a TGF-dependent p15 induction that arrests nevi in their pre-malignant state. We also use the primary nevus cells to establish a new genetically-defined, human in vivo melanoma xenograft model, which maximizes medical relevance by utilizing the naturally occurring melanoma precursor cells in a native 3-dimensional environment. With this approach, we show that p15 depletion in benign nevi promotes progression to melanoma, establishing the reversibility of nevus melanocyte growth arrest, and the functional importance of CDKN2B loss in human cancer.']",
        "Doc_id":"AACR_2015-1239",
        "Doc_title":" CDKN2B loss promotes progression from benign melanocytic nevus to melanoma",
        "_version_":1606189020591685632},
      {
        "Meeting_name":" The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma",
        "Background":"['Few data are available on the role of CHK inhibitors in Diffuse Large B cell Lymphoma (DLBCL). The checkpoint kinases 1 (CHK1) and 2 (CHK2) are serine-threonine kinases involved in the DNA damage response pathway. CHK inhibition enhances the efficacy of DNA damaging agents in a variety of tumors, including p53 deficient cells, that rely on the G2/M checkpoint, having a dysfunctional G1 checkpoint. DLBCL with dysfunctional p53 axis (harboring p53 mutations and/or CDKN2A loss) have been recently shown to have a dismal outcome. In this study we report the activity profile of the CHK1/2 inhibitor PF-0477736 (Pfizer) in a panel of B cell lymphoma cell lines and primary cells, and explore its mechanisms of action. Three Germinal center B cell (GCB) DLBCL derived cell lines (SUDHL-4, SHDHL-6, BJAB), 3 Activated B cell (ABC) DLBCL (HBL-1, U2932, TMD8), 2 mantle cell lymphoma (Mino, SP-53), and the Hodgkin Lymphoma cell line KM-H2 were first screened for p53 and CDKN2A mutations and deletions. P53 mutations were detected in the following cell lines', ' HBL-1, U2932, SUDHL-6, BJAB, Mino, SP-53. TMD8 was p53 wild-type but with an homozygous deletion of CDKN2A. Of note SUDHL-4 and KM-H2 were p53 wild type, with no deletion of CDKN2A. To assess the effect of PF-0477736 on cell proliferation, cells were incubated with increasing concentrations of PF-0477736 (from 5 to 2000 nM) for 24, 48 and 72 hours (hrs), and cell viability assessed by WST-1 assay (Roche). A significant growth inhibition was evident after 48 hrs, in all cell lines, excluding SUDHL-4 and KM-H2 that were resistant (IC50 8300 and 6800 nM at 48 hrs, respectively). The BJAB cell line showed the highest sensitivity (IC50 10 nM at 24 hrs). The IC50 ranged from 140 to 230 nM at 48 hrs in the other sensitive cell lines. Using Annexin V- propidium iodide staining, we found that PF-0477736 25-500 nM induced cell death by apoptosis in a time and dose dependent manner. Of note PF-0477736 100-1000 nM demonstrated activity also in primary DLBCL cells. We found no correlations between baseline levels of CHK1/2 activation and outcome. In the sensitive cell lines inhibition of the downstream target CDC25c ser216 phosphorylation coupled with a marked increase in levels of the DNA damage marker H2AX was observed by western blot as soon as after 24 hrs of incubation with concentrations equal to the IC50 (25 - 250 nM). PF-0477736 at the dose of 50-100 nM synergistically enhanced the efficacy of Doxorubicin (0.1 to 1 M) at 24 hrs. These data suggest that PF-0477736 has single agent activity and synergizes with chemotherapy in DLBCL. The drug shows high single agent activity in the subset of DLBCL with genomic lesions of the p53 pathway, that are resistant to conventional chemotherapy and associated with dismal outcome, providing the rationale for further clinical investigation of PF-0477736 in DLBCL alone or in combination with chemotherapy. PF-0477736 was provided by Pfizer.']",
        "Doc_id":"AACR_2012-4694",
        "Doc_title":" The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma",
        "_version_":1606189041447862273}]
  }}
